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Introduction
1 Introduction
Bluetongue virus (BTV) is the type species of the genus Orbivirus in the family 
Reoviridae (Van Regenmortel, 2003; Mertens et al., 2004b). Currently, there are 
24 recognized serotypes (BTV-1 to -24) and an unconfirmed 25th, “Toggenburg 
orbivirus” (TOV) (Hofmann et al., 2008). BTV is almost exclusively spread by 
Culicoides spp. biting midges (Diptera) and occurs worldwide. All 24 serotypes 
can cause bluetongue disease (BT), a non-contagious hemorrhagic disease of 
domestic and wild ruminants and camelids with no known zoonotic potential 
(Verwoerd and Erasmus, 2004).
BT primarily affects sheep, but clinical disease in cattle and deer does occur. It 
can have considerable economic impact, both directly by deaths and decreased 
productivity and indirectly by trade losses through animal movement restrictions 
(Verwoerd and Erasmus, 2004). BT is notifiable to the World Organisation for 
Animal  Health  (OIE,  2006)  and  to  veterinary  authorities  in  many countries, 
including Germany (TierSeuchAnzV, 2009; BlauzungenV, 2009). 
While  bluetongue  had  long  been  considered  exotic  to  Europe,  repeated 
incursions and extensive circulation of several serotypes in the Mediterranean 
and, recently,  in Central  Europe have arguably made it  an European  disease 
(Wilson and Mellor,  2008). The introduction of BTV-8 to Central Europe in 
2006 marked the begin of an unprecedented epizootic with severe disease in 
livestock  and  financial  losses  in  the  hundreds  of  millions.  The  EU  and 
Switzerland  launched  a  mass  vaccination  campaign  as  soon  as  inactivated 
vaccines became available in 2008, the largest such campaign since the end of 
foot-and-mouth vaccination in the 1990s. These vaccines, however, had not yet 
obtained EU marketing authorization. German authorities considered the data 
provided  by  the  manufacturers  insufficient  for  a  compulsory  vaccination 
campaign  and  commissioned  independent  studies  to  evaluate  the  safety  and 
efficacy of the vaccines. 
This  work  reproduces  the  results  of  the  efficacy  study  and  a  follow-up 
investigation of protection one year after vaccination. The possible implications 
of inactivated vaccines for BTV diagnosis by real-time RT-PCR were examined 
in an animal experiment, whose results are included here as well. 
While the BTV-8 epizootic was still ongoing, BTV-6 appeared in northwestern 
Europe in late 2008. The results of a field survey to investigate its prevalence in 
Germany and related animal experiments are presented, together with serotype-
specific real-time RT-PCR assays that were used in the field survey and are now 
deployed in BTV routine diagnostics.
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2 Literature review
2.1 Taxonomy, virion properties and structure
Bluetongue  virus,  together  with  the  closely  related  species  African  Horse  
Sickness  virus (AHSV)  and  Epizootic  Hemorrhagic  Disease  virus  (EHDV) 
belongs to the genus  Orbivirus (comprising at least 20 species overall) in the 
family Reoviridae. The reovirus family includes vertebrate, arthropod and plant 
pathogens (Mertens et al., 2004b). Unique among reoviruses, all orbiviruses are 
arthropod-borne  viruses  (arboviruses),  maintained  in  nature  through 
transmission between susceptible vertebrate hosts by blood-feeding arthropods. 
The term “arbovirus” itself has no taxonomic significance, merely describing 
the mode of transmission of  viruses of many families  and genera.  With few 
exceptions  (such  as  African  Swine  Fever  virus),  most  arboviruses  are  RNA 
viruses (Hart, 2001).
The non-enveloped, three-layered icosahedral BTV capsids have a diameter of 
86 nm and a relative molar mass of about 10.8 x 107, 12% of which is genomic 
RNA (cores: 6.7 x 107 and 19.5%, respectively). In the presence of protein, the 
virus is stable at a temperature of 4 °C, or even 20 °C. Generally, infectivity 
remains constant between pH 6.5 and 8, but decreases markedly outside of that 
range (Erasmus, 1990). For low pH, this is probably related to the loss of outer 
capsid proteins, a phenomenon that is also relevant in the replication cycle. Due 
to the lack of a lipid envelope, orbiviruses are relatively resistant to solvents and 
detergents, but readily inactivated by acidic disinfectants, sodium hypochlorite 
(bleach) and iodophors (Howell and Verwoerd, 1971). Infectivity is abolished at 
a pH of less than 3 and temperatures exceeding 60 °C. While freezing reduces 
infectivity by about 90%, it  then remains stable at -70 °C, but not at -20 °C 
(Mertens et al., 2004b).
Like all reoviruses, BTV has a segmented, linear double-stranded RNA genome. 
Orbivirus genomes have ten segments, with exactly one copy of each segment 
per  particle  (Mertens et  al.,  2004b).  Owing  to  the  segmented  genome, 
simultaneous infection of cultured cells, vertebrate hosts or arthropod vectors 
with different BTV strains can lead to the exchange of genetic information and 
the creation  of reassortant  viruses  (Oberst et  al.,  1987; Samal et  al.,  1987a; 
Samal et al., 1987b; Stott et al., 1987; Ramig et al., 1989). The combined length 
of all segments is approximately 19,200 base pairs, but varies with serotype. 
Their  complete  nucleotide  sequence  had  first  been  determined  for  BTV-10 
(Fukusho et  al.,  1989).  All  segments  of  all  known  serotypes  share  short 
conserved  ends  (5’-GUUAAA…UUAC-3')  (Mertens  and  Sangar,  1985; 
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reviewed by Alpar et al., 2009). The genome encodes seven structural and four 
non-structural proteins (see table 1). Each segment contains one open reading 
frame flanked by non-coding regions. The open reading frame on segment 10 
encodes two proteins by alternate translation initiation (Lee and Roy, 1987). In 
many strains of BTV this is also the case for segment 9 (Wade-Evans et al., 
1992; Maan et al., 2010).
Seg-
ment
Size 
(nt)
Encoded 
protein
Location (number of copies per virion), 
proposed function
Protein size
(weight)
1 3954 VP1 Within the core (12), RNA-dependent RNA polymerase
1302 aa
(150 kDa)
2 2926 VP2 Outer capsid (180), type-specific structural protein 
961 aa
(111 kDa)
3 2772 VP3 Inner (sub-core) capsid (120), scaffold for VP7 layer
901 aa
(103 kDa)
4 2011 VP4 Within the core (24), RNA capping enzyme
644 aa
(75 kDa)
5 1770 NS1 Non-structural protein (0), forms tubules of unknown function in host cells
552 aa
(64 kDa)
6 1639 VP5 Outer capsid (360), structural protein, co-determinant of virus serotype
526 aa
(59 kDa)
7 1156 VP7 Core capsid (780), group-specific structural protein
349 aa
(39 kDa)
8 1123 NS2 Non-structural phosphoprotein (0), forms viral inclusion bodies in host cells
354 aa
(41 kDa)
9 1046 VP6 Within the core (72), RNA helicase 329 aa(36 kDa)
10 822 NS3 Non-structural glycoprotein (0), membrane protein, aids virus release from host cells
229 aa
(26 kDa)
NS3A Expressed by alternate translation initiation
216 aa
(24 kDa)
Table 1: Bluetongue virus genome segments and proteins. Size (amino acids, aa) 
and weight (Dalton, Da) data are for the European reference isolate of BTV-8 
(Roy, 1992; Grimes et al., 1998; Stuart et al., 1998; Mertens et al., 2004b; Maan 
et al., 2008; Noad and Roy, 2009)
The outer  layer  of  BTV particles  consists  of  180 copies  of  virion protein  2 
(VP2) arranged in sixty triskelia  (three-fold interlocked  spirals),  interspersed 
with 120 globular trimers of virion protein 5 (VP5) (Hewat et al., 1992; Nason 
et  al.,  2004).  VP2 shows the  greatest  variability  of  all  BTV proteins  (Roy, 
1992).  It  mediates  hemagglutination  as  well  as  receptor  binding  during  the 
initiation of infection (Hübschle,  1980; Hassan and Roy, 1999) and contains 
most of the epitopes that  interact  with neutralizing antibodies,  making it  the 
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main determinant of virus serotype (Huismans and Erasmus, 1981; Appleton 
and Letchworth, 1983; Kahlon et al., 1983; Mertens et al., 1989). 
VP5 is thought to influence the highly conformation-dependent VP2 protein by 
their close interaction in the outer capsid layer (White and Eaton, 1990), but 
may also harbor some neutralization sites itself (DeMaula et al.,  2000).  It  is 
involved in membrane penetration leading to the release of viral particles from 
endosomes into the cytoplasm, and can also act as a membrane fusion protein in 
vitro (Hassan et al., 2001; Forzan et al., 2004). Before the virus particle actually 
enters the cytoplasm of an infected cell, the outer capsid layer is lost (Mertens  et  
al., 2004a) (see figure 1).
The  remaining  core  capsid  consists  of  260  virion  protein  7  (VP7)  trimers 
supported by an inner sub-core layer made up of 12 decamers of VP3 (Stuart et  
al., 1998). The VP7 trimers are easily visible by electron microscopy, and had 
been described as capsomers arranged in ring-like structures (Els and Verwoerd, 
1969), a feature alluded to in the genus name (Latin  orbis,  -is m.: a circle or 
ring)  (Roy,  2007).  Together,  VP7  and  VP3  form  the  core  particle  with  a 
diameter of 73 nm (Grimes et al., 1998). The protein sequences of VP3, and to a 
lesser extent VP7, are highly conserved across the BTV serogroup (Huismans 
and Erasmus, 1981) and VP7 is the immunodominant group-specific antigen. 
BTV shares some 60% of VP7 amino acids with EHDV, and 45% with AHSV 
(Iwata et al., 1992). 
Along the five-fold symmetrical axes of the particle, the VP3 decamers leave 
twelve small pores in their centers. At the pores, the minor structural proteins 
VP1, VP4 and VP6 form transcription complexes that  are closely associated 
with the genetic material in the central space of the core (Gouet  et al., 1999; 
reviewed by Mertens et al., 2009b). Each complex is made up of one copy of 
VP1,  a  VP4 dimer  and  a  VP6 hexamer  (Stuart et  al.,  1998).  The available 
structural  and biochemical  data are consistent  with the assumption that  each 
genome segment is associated with a transcription complex to allow for their 
independent simultaneous transcription (Nason et al., 2004).
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Figure 1: Overview of key structural features of BTV1.
2.2 History, global distribution and economic impact
Historically, BTV was thought to be confined to southern Africa, where it has 
probably  been  endemic  in  wild  ruminants  from  antiquity.  The  disease  was 
recognized  in  the  late  18th century,  when  fine-wooled  sheep  breeds  were 
introduced  to  the  Cape  Colony  (Verwoerd  and  Erasmus,  2004).  The  first 
detailed scientific studies date from the beginning of the 20 th century. Initially, 
they referred to the disease as “malarial catarrhal fever”, since Hutcheon (1902) 
had assumed its agent to be an insect-transmitted plasmodium. Spreull (1905) 
1 Source: ViralZone, http://www.expasy.org/viralzone, Swiss Institute of 
Bioinformatics. Used with permission.
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credited  Robertson and Theiler  with the discovery  of  the viral  nature  of  the 
disease, and suggested that the common name “bluetongue” (from the Afrikaans 
“bloutong”, used by Boer farmers to describe the distinctive cyanotic tongue of 
severely affected sheep) should be used instead (Gorman, 1990).
The plurality of antigenetically different strains of variable virulence and the 
implications for immunization against BTV were first described in the 1940s 
(Neitz,  1948).  Eventually,  the  BTV serogroup  was  classified  into  serotypes 
based on neutralization. While Howell  (1960) had defined 16 serotypes,  this 
number  subsequently increased  to  24 (see  review by Gorman,  1990,  for  the 
corresponding reference strains). By definition, serotypes are distinct antigenic 
groups of bluetongue viruses, but there is a varying degree of cross-reactivity in 
in vitro tests as well as cross-protection in vivo (Erasmus, 1990) (see figure 2). 
BTV  types  that  cross-react  serologically  were  also  found  to  have  greater 
similarity in deduced VP2 amino acid sequences (Maan et al., 2007).
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Figure 2: Map of serological relationships between BTV serotypes (Erasmus, 
1990), showing BTV-4 as a hypothetical “ancestral serotype”.
An  outbreak  in  Cyprus  in  1943  (Gambles,  1949)  was  the  first  confirmed 
occurrence  of  BTV outside  of  Africa,  followed by reports  from the  Eastern 
Mediterranean  region  (Komarov  and  Goldsmit,  1951)  and  the  Indian 
subcontinent (Sarwar, 1962; Sapre, 1964). In the 1950s BTV was confirmed in 
sheep  in  California  (Hardy  and Price,  1952;  McKercher et  al.,  1953).  Later 
genetic analyses, however,  indicated that several BTV serotypes share a long 
evolutionary history in North America (Heidner et al., 1991). In Canada, BTV 
(serotype  11)  has  only  been  detected  in  the  Okanagan  Valley  of  British 
Columbia  (Dulac et  al.,  1992).  Recent  warming  trends  have  a  favorable 
influence on indigenous vectors,  however,  and may allow incursions and the 
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eventual establishment of BTV in other parts of Canada (Weaver and Reisen, 
2010). 
BTV has been isolated from both arthropods and vertebrates on all continents 
except Antarctica.  It  regularly occurs throughout much of the world between 
latitudes  of  approximately  40°  to  50°  N and  35°  S,  where  it  is  considered 
enzootic. Recently, however, BTV has spread far beyond the upper limits of this 
traditional range into areas of Europe where it had never been reported. Similar 
detections  of  previously  exotic  serotypes  have  been  reported  from  the 
southeastern  United  States,  Israel  and  northern  Australia  (reviewed  by 
MacLachlan, 2010).
Strains of BTV in different regions of the world are distinct and often exist in 
stable ecosystems (Gould and Pritchard, 1990). Isolates of the same serotype 
with different geographical origins (so-called topotypes) can be distinguished by 
sequence variations in genome segment 2 coding for the outer capsid protein 
VP2 (Maan et al., 2004; Mertens et al., 2007). Geographic separation allows the 
acquisition of unique point mutations (Maan et al., 2009). An analysis of full-
length  segment  2  sequences  of  all  24  serotypes  found  nine  evolutionary 
branching  points,  which  correlate  with  ten  nucleotypes  defined  by  <35% 
difference in nucleotide sequences (Maan et al., 2007). Globally, a distinction is 
made  between  virus  isolates  belonging  to  the  “western”  (Africa  and  the 
Americas) or “eastern” (Eurasia and Oceania) lineages, respectively (Balasuriya 
et  al.,  2008;  reviewed  by  Mertens et  al.,  2009a).  The  level  of  divergence 
between those lineages indicates long physical separation (Maan et al., 2009). 
Not all gene segments of BTV can be used to clearly topotype strains of BTV, 
however (Bonneau et al., 2000). Segments 7 and 10 show variations that do not 
simply reflect  the geographic origins of the virus isolate (Pierce et al., 1998; 
Maan et al., 2008).  Individual genes evolve independently, in response to the 
selective pressures encountered within their respective insect  and mammalian 
hosts.  Genetic  drift  during  alternating  passages  in  insects  and  mammals 
generates quasispecies populations and novel genotypes are fixed by founder 
effects  when unique viral  variants  are  randomly ingested  by feeding  vectors 
(Bonneau et al., 2001; reviewed by Bonneau and MacLachlan, 2004).
A major epizootic  on the Iberian  Peninsula caused by BTV-10 was the first 
documented occurrence of BTV in Europe outside of Cyprus, starting in 1956 
(Manso-Ribeiro et  al.,  1957; Lopez and Botija,  1958).  Within four years,  its 
eradication was achieved by a massive campaign of quarantine, slaughter and 
vaccination (Gorman, 1990). Bluetongue was then generally considered exotic 
to Europe until 1998, when BTV-9 was detected on several Greek islands close 
to  the  Turkish  mainland.  This  and  other  serotypes  subsequently  spread 
northwards and westwards on the Aegean islands. Meanwhile, BTV-1 had been 
introduced from Northern Africa to the Iberian Peninsula and Italy. While the 
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northern  movement  of  BTV-2,  -4,  -9  and -16,  present  in  the  Mediterranean 
Basin,  is  apparently  restricted,  the  area  affected  by  BTV-1  has  recently 
expanded across the Iberian peninsula and France (reviewed by MacLachlan, 
2010). Bluetongue, originally a tropical and subtropical disease, has regularly 
occurred in Europe during the last decade (Wilson et al., 2008) (see table 2).
In August 2006, BTV-8 was first detected in the Netherlands (Enserink, 2006). 
Retrospective  studies  suggest  that  the  original  introduction  of  BTV-8  had 
probably occurred during the spring of 2006 near a nature reserve in Eastern 
Belgium where large numbers of migratory birds congregate (Saegerman et al., 
2010b),  but  many  other  possible  routes  of  introduction  have  been  proposed 
(Mintiens et  al.,  2008).  By the  end  of  2006,  cases  had  also  been  found  in 
Belgium, France, Luxembourg and Germany (Saegerman et al., 2008), where 
the  first  case  had  been  confirmed  on August  21,  2006 (Anonymous,  2006). 
Reports of new cases ceased by January 2007. The virus did not die out at the 
end  of  the  vector  season,  however,  and  reemerged  only  a  short  time  later 
(Hoffmann et al., 2008).
Possible explanations for its successful overwintering are listed by Wilson et al. 
(2008), persistence in the vector or host populations being the most prominent. 
Most species of  Culicoides at northern latitudes survive the winter as larvae. 
Experiments designed to look for vertical (transovarial) transmission of BTV in 
Culicoides have consistently reported negative results (reviewed by Wilson et  
al., 2008). In mild winters, however, it is possible that a small fraction of the 
infected adult  Culicoides population might survive long enough to bridge the 
gap between transmission seasons. If adult midges enter buildings when outdoor 
temperatures  begin  to  drop,  they  might  experience  conditions  that  are 
sufficiently warm for blood-feeding year-round (Wilson et al., 2008; Zimmer et  
al., 2010). This could explain the very early reemergence of BTV-8 in Germany 
in February 2008 (Hoffmann et al., 2008).
BTV could also covertly persist in the ruminant population. Transmission across 
the placenta to the fetus has been repeatedly demonstrated for European BTV-8 
(De Clercq et al., 2008; Menzies et al., 2008; Backx et al., 2009; Darpel et al., 
2009b; Worwa et al., 2009), while evidence for latent infection of ruminants is 
inconsistent (reviewed by Wilson et al., 2008). BTV does not cause persistent 
infections, but prolonged viremia in excess of two months has been reported in 
cattle  (Singer et  al.,  2001).  This  could  permit  the  virus  to  overcome  short 
periods of vector absence. Rather than a single overwintering mechanism, there 
likely is a toolbox of possible mechanisms that interact with and complement 
one another (Wilson et al., 2008). 
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Sero-
type
First 
isolate*
Affected regions or 
countries Immediate origin Status
1 2001 Greece Turkey (suspected) (eastern 
lineage)
Ongoing 
(Islands)
2007 Iberian Peninsula, 
France, Sardinia
Algeria, Morocco (western 
lineage)
Ongoing
2 2001 Corsica, Italy, 
Balearic Islands
Tunisia Ongoing 
(Italy)
2003 Italy South African (SA) vaccine 
strain from 2002 campaign
4 1999 Greece and the 
Balkans
Related to earlier isolates from 
Cyprus (1969) and Turkey 
(1978)
Probably 
resolved
2003 Balearic Islands, 
Italy, Iberian 
Peninsula
Tunisia (suspected), distinct 
from strains in the eastern 
Mediterranean
Ongoing 
(Italy)
6 2008 Netherlands, 
Germany (Lower 
Saxony)
Unknown (SA vaccine strain) Probably 
resolved
8 (2006) Bulgaria Unknown Probably 
resolved
2006 Europe Unknown (western lineage) Ongoing
9 1998 Greece and the 
Balkans, Bulgaria, 
Italy
Unknown (eastern lineage) Ongoing
2003 Italy SA vaccine strain from 2002 
campaign (western lineage)
11 (2008) Belgium Unknown (South African 
vaccine strain)
Probably 
resolved
16 1999 Greece, Cyprus Unknown (eastern lineage) Ongoing
2002 Italy SA vaccine strain reassortant 
from Israel (suspected)
2004 Croatia, Sardinia SA vaccine strain from Italian 
campaign
TOV (2008) Switzerland, Italy, 
Germany
Unknown Unknown
Table 2: Bluetongue viruses recently occurring in Europe and their suspected 
origins. *Parentheses indicate that no isolate was made, but the virus was 
detected by other means. (Maan et al., 2004; Ferrari et al., 2005; Mertens and 
Attoui, 2007; Batten et al., 2008b; Hofmann et al., 2008; Saegerman et al., 
2008; Anonymous, 2009d; e; h; Listes et al., 2009; Hofmann et al., 2010)
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From 2007 onwards, BTV-8 has spread as far as Spain, Norway and Hungary. 
From  August  2006  to  October  2009,  veterinary  authorities  in  Germany 
registered  BTV-8 in 26,950 animal  holdings (Gethmann et  al.,  2010).  After 
vaccination was introduced in 2008, the number of new cases fell dramatically 
(data for Germany are presented by Conraths et al., 2009), but the virus has not 
been eradicated (Gethmann et al., 2010).
In early  2008, “Toggenburg  orbivirus” (TOV),  a novel  orbivirus  isolate  that 
might  prove  to  be  a  25th BTV serotype,  was  found in  goats  in  Switzerland 
(Hofmann et al., 2008). Later that year, BTV-6 and -11 were detected in the 
Netherlands, Germany and Belgium, respectively. They did not spread to any 
meaningful  extent,  and  the  strains  were  found to  be  very  closely  related  to 
modified-live virus (MLV) vaccines regularly used in South Africa (De Clercq 
et  al.,  2009;  Eschbaumer et  al.,  2009b;  reviewed  by Hateley,  2009).  As for 
BTV-8, the method of introduction of those strains is still unclear (MacLachlan 
and  Guthrie,  2010).  The  increasing  global  trade  not  only  in  livestock  has 
probably  increased  the  frequency  of  introduction  of  exotic  viruses  to  new 
ecosystems,  while  climate  change  in  Europe  may  explain  the  increasing 
tendency of those strains to persist and spread there (Wilson et al., 2008).
Bluetongue has repeatedly caused heavy losses particularly in naïve populations 
of susceptible breeds in non-endemic areas (reviewed by Alpar et al.,  2009). 
The number of sheep that died or were culled during the repeated incursions of 
several  serotypes  into  the  Mediterranean  Basin  between  1998  and  2005  is 
estimated at  over one million (Purse et al.,  2005), a death toll never seen in 
areas where BTV is enzootic. In the 1990s, annual losses to BT were estimated 
at US$3 billion worldwide (Tabachnick et al., 1996).
The BTV-8 epizootic in Europe is believed to have caused greater economic 
damage than any previous outbreak involving a single serotype (Wilson and 
Mellor,  2008).  For  2006 and  2007,  the  total  costs  for  the  Netherlands  were 
estimated at €200 million (Velthuis et al., 2010). In 2007, over €20 million were 
paid in direct compensation for bluetongue-related animal deaths in Germany 
(Gethmann et al., 2010), a figure that does not include losses due to decreased 
production, trade restrictions or costs for treatment and diagnostics.  Figure 3 
gives an overview of zones in the EU where movement restrictions due to BTV 
currently apply. These zones can only be lifted after two years of confirmed 
absence of BTV circulation in an area (European Commission, 2007).
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Figure 3: Map of BTV restricted zones in the EU 
(European Commission, 2010).
2.3 Vectors and transmission
The global distribution of BTV coincides with its main vector,  Culicoides spp. 
midges (Diptera,  Ceratopogonidae) (Mellor, 1990), which are associated with 
the transmission of several viruses, protozoa and filarial nematodes (Meiswinkel 
et  al.,  2004).  Their  role  in  BTV transmission  had  first  been  shown for  C. 
imicola Kieffer (Du Toit, 1944). Since then, only about thirty of more than one 
thousand  species  in  the  Culicoides genus  have  been  found  to  be  potential 
vectors of BTV. But even for innately competent vectors, there are important 
behavioral  aspects  to  consider,  such  as  host  preference  and  seasonal  and 
circadian  activity  (Kampen,  2009).  What  is  more,  within  a  competent 
Culicoides species, not all female midges are susceptible to BTV infection or 
capable  of  transmitting the virus when infected.  The proportion of  these  so-
called refractory midges in a population is variable (Mellor, 1990). 
Other  arthropods  can  possibly  spread  the  virus  by  purely  mechanical 
transmission (Luedke et al., 1965), and European BTV-8 was shown to infect 
ticks (Bouwknegt et al., 2010). Modes of transmission without the involvement 
of  arthropods  have  been  suggested,  including  iatrogenic  transmission  by 
humans. Their epidemiological  relevance,  however,  is mostly negligible.  The 
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geographical distribution and seasonal incidence of BTV is largely determined 
by the presence of suitable vectors (Venter et al.,  2009), with the  Culicoides 
species or species complex predominantly responsible for the transmission of 
BTV differing  between  regions  of  the  world  (MacLachlan et  al.,  2009).  C. 
imicola is not involved in the BTV-8 epizootic in Central Europe (Meiswinkel 
et  al.,  2008),  and  the  C.  obsoletus species  complex  is  assumed  to  be 
predominantly responsible for BTV transmission in Germany (Mehlhorn et al., 
2007; Hoffmann et al., 2009a).
BTV seasonality is influenced by ecological factors such as rainfall, temperature 
and humidity (Erasmus, 1990). During their active period, adult female midges 
feed  on  blood  to  obtain  protein  for  the  production  of  eggs.  If  their  host  is 
infected with BTV, virus particles from the blood meal replicate in cells of the 
mid-gut epithelium of the midge. Progeny virus is released into the hemolymph 
and infects secondary target organs. Transmission during subsequent feedings 
on vertebrate hosts can take place only after  virus replication in the salivary 
glands of  the  midge.  At  an ambient  temperature  of  25 °C,  this  takes  ten to 
fifteen days after initial infection of the midge. Once infected with BTV, midges 
remain so for life, with no apparent disadvantage to the insect (Mellor, 1990). 
There is molecular evidence for vertical transmission in midges (White et al., 
2005), but so far virus has never been isolated from larvae.
In any case, there are means of BTV spread that do no rely on arthropod vectors 
at  all.  Semen from infected bulls collected during the viremic phase may be 
infective, and cows reportedly have been infected by such semen (Bowen  et al., 
1985). There is limited evidence for horizontal transmission between infected 
and  not  infected  animals  in  close-contact  conditions  (Jochim et  al.,  1965; 
López-Olvera et  al.,  2010),  and  calves  can  be  experimentally  infected  by 
contaminated colostrum (Backx et al., 2009).  Vertical transmission along with 
teratogenic  potential  has  been  described  for  modified-live  virus  vaccines  for 
bluetongue, but is highly unusual for field strains of BTV. The passage of BTV 
strains in heterologous culture systems can confer undesirable properties: The 
most prominent feature of laboratory-adapted virus is the ability to cross the 
placenta, which can lead to fetal malformation and abortion. Teratogenic effects 
of vaccination with modified-live virus vaccines were first described more than 
fifty years ago (Shultz and Delay, 1955). These effects are now well recognized 
and vaccination of pregnant ewes with live vaccines is discouraged (reviewed 
by Osburn, 1994).
On the other hand, fetal infection following natural exposure of ruminants to 
wild-type viruses is rare. There have been reports of abortion after infection of 
sheep with pathogenic strains, but this was considered a consequence of high 
fever in the ewe. In regions where live vaccines have never been used (such as 
Australia), there was no evidence of virus crossing the placenta (Kirkland and 
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Hawkes, 2004). The recently discovered TOV reportedly caused transplacental 
infection in goats (Chaignat et al., 2009). 
For the European  strain of  BTV-8, however,  transplacental  transmission and 
infection  of  cattle  by  direct  contact  with  infected  placental  tissue  was  first 
reported  in  February  2008 (Menzies et  al.,  2008).  Zoo carnivores  had  been 
fatally  infected  by  the ingestion  of  aborted  fetal  ruminants  (Jauniaux  et  al., 
2008).  Evidence  for  transplacental  transmission  in  cattle  and  sheep  was 
collected  in  field  studies  (Darpel et  al.,  2009b;  Saegerman et  al.,  2010a; 
Santman-Berends et al., 2010), corroborating experimental findings (Backx et  
al., 2009; Worwa et al., 2009). This suggests that the European field strain of 
BTV-8 might have picked up properties of in vitro passaged bluetongue viruses 
at some point in the past (MacLachlan and Osburn, 2008; MacLachlan, 2009). 
Even if vertical  transmission is only secondary in BTV epidemiology, it  can 
become increasingly important in periods or areas with little or no  Culicoides 
activity (Gibbs et  al.,  1979; Santman-Berends et  al.,  2010).  Up to now, live 
virus has been successfully isolated only from transplacentally infected calves 
that received either no maternal colostrum or only pooled colostrum (reviewed 
by Darpel et al., 2009b). The failure to reisolate virus  in vitro, however, does 
not necessarily preclude infection of midges feeding off these calves (Santman-
Berends et al., 2010). In any case, the combined serological and real-time RT-
PCR results of pregnant dams give no clear indication of the infection status of 
the unborn except  in  the case  of  a  double negative  result  (De Clercq et  al., 
2008), which is an important consideration for animal trade.
2.4 Host range 
The host  range of BTV is very broad,  from sheep,  cattle and goats to deer, 
mouflon, antelopes and various other even-toed ungulates, including camelids. 
The outcome of infection ranges from fatal to subclinical, with the latter being 
predominant. Since BTV infection of cattle usually goes unnoticed and results 
in  prolonged  viremia,  they  are  considered  important  reservoir  hosts. 
Historically,  the  primary  vertebrate  host  species  probably  were  African 
antelopes (Erasmus, 1990). 
Although ruminants and camelids are the most important hosts of BTV, other 
species can be affected.  In the 1990s, there were several fatalities in pregnant 
dogs that had been accidentally infected by a canine vaccine contaminated with 
BTV-11 (Evermann et  al.,  1994).  This was later  confirmed by corroborative 
experiments (Brown et  al.,  1996).  Following this incident,  an extensive field 
survey detected antibodies to BTV in African carnivores,  but only in species 
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that prey on wild ruminants (Alexander et al., 1994). The European strain of 
BTV-8 was reported to have killed European lynx that had been infected by the 
ingestion  of  aborted  fetal  ruminants  (Jauniaux et  al.,  2008).  African  Horse 
Sickness virus (AHSV), a closely related orbivirus species, reportedly infected 
carnivores that were fed horse meat (Van Rensberg et al., 1981). 
Intracranial  infection  of  newborn  mice  has  been  used  in  BTV research  and 
vaccine production for over fifty years (Van Den Ende et al.,  1954; Svehag, 
1962; Franchi et al.,  2008).  More recently,  interferon receptor-deficient  adult 
mice  were  experimentally  shown  to  be  susceptible  to  fatal  BTV  infection 
(Calvo-Pinilla et al., 2009a).
2.5 Virus replication
In  nature,  BTV  is  maintained  by  an  endless  series  of  alternating  cycles  of 
replication  in  Culicoides midges  and  various  mammalian  species  (Mellor, 
1990).  Accordingly,  the  virus  has  evolved  to  optimize  its  transmission 
efficiency  within  the  context  of  the  vector/host  relationship.  Its  replication 
mechanisms and strategies within the mammalian host have consequences for 
transmission to the insect vector and vice versa (Darpel et al., 2009a). 
A single bite from a transmission-competent infected midge will reliably infect 
susceptible sheep, while experimental infection by needle inoculation requires 
much higher amounts of virus. It is presently unclear why transmission from the 
vector  to  the  host  is  more  efficient,  but  it  has  been  suggested  that 
immunomodulatory proteins in the saliva of the vector may play an important 
role (reviewed by Darpel et al., 2009a). Relatedly, bites by Culicoides spp. can 
lead to hypersensitivity reactions in many species, including sheep (Connan and 
Lloyd, 1988) and are the cause of so-called “sweet itch” in horses (Mellor and 
McCraig, 1974).
After inoculation by the midge, BTV is transported to regional lymph nodes by 
migrating dendritic cells (Hemati et al.,  2009). After initial replication in the 
lymph node (Pini, 1976; Barratt-Boyes et al., 1995), virus progeny is released 
into the blood stream and large amounts of virus are then produced in peripheral 
blood  mononuclear  cells  (PBMC)  and  endothelia  (Pini,  1976;  Mahrt  and 
Osburn, 1986; Barratt-Boyes and MacLachlan, 1994) (see also figure 4). High 
levels of early replication have recently also been reported in skin. Historically, 
this might have been underestimated, because virus isolation is hindered by the 
fibrous and compact nature of skin tissue. The skin may be both an important 
site for replication and a source of virus for blood-feeding vectors (reviewed by 
Darpel et al., 2009a).
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On a cellular  level,  replication occurs principally in mononuclear  phagocytic 
cells, endothelial cells  and lymphocytes undergoing blastogenesis (Mahrt and 
Osburn, 1986; MacLachlan et al., 1990; Barratt-Boyes et al., 1992; Ellis et al., 
1993;  reviewed  by  MacLachlan et  al.,  2009),  whereas  the  interaction  with 
erythrocytes and unstimulated lymphocytes does not proceed beyond attachment 
of the virus to the cell membrane (Brewer and MacLachlan, 1994).
Viremia  in  ruminants  can  persist  for  extended  periods  of  time,  even  in  the 
presence of high titers of neutralizing antibody (Luedke, 1969; Luedke et al., 
1969; reviewed by Singer et al.,  2001). It  has been shown that this apparent 
immune  evasion  is  not  due  to  antigenic  drift  (Heidner et  al.,  1988).  While 
infectious  virus  has  been  recovered  from blood as  late  as  two months after 
experimental  infection of  cattle,  circulating  viral  RNA can  be detected  even 
longer  (Katz et  al.,  1994).  This  is  achieved  by  passive  association  with red 
blood cells (MacLachlan et  al.,  1994; Brodie et  al.,  1998).  Accordingly,  the 
duration of detection correlates with the lifespan of erythrocytes (Brewer and 
MacLachlan, 1994). Bluetongue virions bind to glycophorins on the surface of 
ruminant  erythrocytes  and  escape  neutralization  in  invaginations  of  their 
membrane,  thus  extending  the  period  of  possible  infection  of  blood-sucking 
midges  (Eaton  and  Crameri,  1989).  Although viremia  is  prolonged in BTV-
infected  cattle,  it  is  not  persistent  and  recovered  animals  are  immune  to 
reinfection with the homologous serotype of BTV (MacLachlan et al., 1990). 
One  in vitro experiment suggested a potential for persistent BTV infection of 
lymphocytes  (Takamatsu et  al.,  2003),  but  this  could  not  be  confirmed  in 
naturally infected animals (Melville et al., 2004).
In vitro,  BTV can  also replicate  in  a  wide  range of  cells,  from mammalian 
epithelia and endothelia to insect cells originating from midges, mosquitoes and 
flies (Ross-Smith et al., 2009). In cultured cells, field isolates often replicate 
poorly at first, but adapt readily (Roy, 2007). BTV core particles, which have 
been stripped of their outer capsid layer, have a much reduced infectivity for 
mammalian  cells,  but  can  still  infect  insect  cells  (Mertens et  al.,  1996), 
indicating a distinct cell attachment and penetration capability of VP7 (Xu  et al., 
1997).
Insect-derived cell lines (including C. sonorensis [= C. variipennis] embryonic 
cells) can be productively infected without an increase  in cell  death.  On the 
other hand, BTV was shown to induce apoptosis and cytopathic effect (necrosis) 
in  several  mammalian  cell  lines  (Mortola et  al.,  2004),  with  possible 
implications  for  pathogenesis  in  the  vertebrate  host  (DeMaula et  al.,  2001; 
DeMaula et  al.,  2002a).  In  baby  hamster  kidney  (BHK)  cells,  host  cell 
translation is reportedly shut off within 10 hours of infection (Mertens  et al., 
1984). BSR cells (a BHK clone) were shown to remain fully viable for the first  
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day after infection, but viability decreased more than 10-fold within the next 
two days, even at low initial multiplicities of infection (Li et al., 2009). 
On a cellular level, the outcome of infection is influenced by the mechanism of 
virus  release  (reviewed  by  Ross-Smith et  al.,  2009).  Unlike  the  budding  of 
progeny virions from insect cells, virus release from mammalian cells causes 
damage to the cell membrane, possibly culminating in cell death (Owens  et al., 
2004).  The extent  of  damage,  however,  varies  in  the course  of  infection.  A 
considerable  number  of  infectious  progeny  is  released  before  the  onset  of 
cytopathic effect  (Noad and Roy, 2009),  suggesting a different,  less harmful 
mode of virus egress in the early stages (Hyatt et al., 1989; Eaton et al., 1990). 
Production  of  mature  particles  is  exponential  between  8  and  24  hours  post 
infection (reviewed by Schwartz-Cornil et al., 2008).
In order to infect host cells, viruses must transport their genomic material across 
a  lipid  bilayer.  For  mammalian  cells,  the  BTV  outer  capsid  protein  VP2 
mediates cell attachment and endocytosis in clathrin-coated vesicles (Forzan  et  
al., 2007). The cellular receptor for BTV is assumed to be a glycoprotein (Eaton 
and  Crameri,  1989),  and  purified  VP2 has  also  been  shown to  have  strong 
affinity  for  glycophorin  A  (CD235a),  a  sialoglycoprotein  component  of 
erythrocytes (Hassan and Roy, 1999) that has also been identified as a cellular 
receptor  for  several  other  viruses  (see  for  example  Wybenga et  al.,  1996; 
Thacker and Johnson, 1998; Sanchez et al., 2004). A sialic-acid binding domain 
on BTV VP2 has recently been identified by cryo-electron microscopy (Zhang 
et al., 2010). 
Within the endosome, VP2 dissociates from the outer capsid layer, and the low 
pH activates VP5-mediated membrane fusion and permeabilization (Hassan et  
al.,  2001;  Forzan et  al.,  2004).  Zhang  et  al. (2010)  recently  proposed  a 
perforation mechanism involving 12 amphipathic helical regions on the external 
surface of VP5.
After the outer capsid layer is lost, virus cores are released into the cytoplasm. 
The  core  particle  does  not  disassemble  further.  In  the  cytoplasm,  it  is 
transcriptionally  active,  synthesizing  and  extruding  multiple  capped  but  not 
polyadenylated  message-sense  RNA  copies  of  each  double-stranded  RNA 
segment of the viral genome (Verwoerd and Huismans, 1972; Mertens et al., 
2004a).  This viral mRNA is produced by transcription complexes formed by 
VP1, VP4 and VP6 at the core particle pores (Gouet et al., 1999; Noad and Roy, 
2009).  Individually,  VP4 has  been shown to be the mRNA capping enzyme 
(Martinez-Costas et  al.,  1998),  while  VP1  is  the  RNA-dependent  RNA 
polymerase  (Urakawa et  al.,  1989).  The  third  minor  core  protein,  VP6,  has 
helicase activity (Stäuber et al., 1997). Together, they unwind double-stranded 
viral RNA, synthesize single-stranded RNA of both polarities and modify the 5’ 
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termini of newly synthesized viral mRNA molecules for efficient translation by 
the host cell (Roy, 2007).
In cell culture, the first BTV-specific proteins (NS1 in particular) are detectable 
within two to four hours after infection (Huismans and Van Dijk, 1990). Core 
structural  proteins  produced  by  the  host-cell  translation  machinery  are 
assembled  in  viral  inclusion  bodies  (virus  assembly  factories)  (Roy,  2007) 
whose  major  component  is  the  NS2  phosphoprotein  (Eaton et  al.,  1990). 
Inclusion bodies in infected cells are aggregated with BTV RNA, and NS2 also 
appears  to  be  involved  in  the  selective  packaging  of  genome segments  into 
progeny particles  (Lymperopoulos et al., 2006), while the polymerase enzyme 
VP1 is not substrate-specific (Lymperopoulos et al., 2003). Once formed, new 
cores are transcriptionally active until the outer capsid proteins VP2 and VP5 
are added to the virus particle.
The subsequent release of progeny virions varies between host cell types. Virus 
progeny are released both as enveloped particles by budding through the plasma 
membrane (although the envelope  is  only short-lived) and as  non-enveloped 
particles by extrusion through the membrane (Hyatt et al., 1989), processes that 
involve NS1 and NS3 (Beaton et al., 2002; Owens et al., 2004). While NS1 and 
NS2 are always synthesized abundantly (the former makes up 25% of total BTV 
proteins in an infected cell) (Roy, 2007), the expression levels of the membrane 
proteins NS3 and NS3A (which lacks the 13 N-terminal amino acids of NS3) 
depend on the host cell species. They are generally high in insect cells, and low 
in cells of vertebrate origin (French et al., 1989; Guirakhoo et al., 1995). The 
extent of their production appears to be positively correlated with the efficiency 
of virus release. NS3 interacts with TSG101, a cellular protein implicated in the 
trafficking  and  release  of  enveloped  viruses,  whose  knockdown  with  small 
interfering  RNA  was  shown  to  inhibit  BTV  release  from  mammalian  cells 
(Wirblich et  al.,  2006).  The precise  function  of  the  perinuclear  cytoplasmic 
tubules formed by NS1 multimers, a striking feature of BTV infection, presently 
remains unclear,  while  experiments  in  vitro and  in  vivo have  implicated  the 
protein as a major determinant of pathogenicity in the vertebrate host (reviewed 
by  Kirkland  and  Hawkes,  2004;  Owens et  al.,  2004).  Throughout  the  viral 
replication process, the core shell serves as a physical barrier between the cell  
cytoplasm and the double-stranded viral RNA (Mertens et al., 2004a), hiding 
the latter from the defense mechanisms of the host cell (Jacobs and Langland, 
1996). Accordingly, progeny virus double-stranded RNA is synthesized to viral 
mRNA templates within newly formed cores and only the 5’ terminus of the 
coding strand of each segment is capped (Roy, 2007).
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2.6 Pathogenesis and clinical disease
The  clinical  manifestation  of  BTV  infection  varies  considerably  between 
species,  breeds  and  virus  strains  (reviewed  by  MacLachlan et  al.,  2009). 
Serotype does not determine virulence, there are both highly virulent and benign 
strains within the same serotype (Kirkland and Hawkes, 2004; MacLachlan et  
al., 2009). Although BTV can infect many species of ruminants, clinical signs 
of disease are generally associated with sheep (Erasmus, 1990). Still, indigenous 
breeds from regions where BTV is endemic are rarely affected. Some European 
breeds,  on the other hand, appear to be particularly susceptible (Jeggo et al., 
1987;  Veronesi et  al.,  2005;  Darpel et  al.,  2007;  Worwa et  al.,  2010). 
Environmental conditions, particularly exposure to sunlight, reportedly have a 
marked  influence  on  disease  severity  (Eisa et  al.,  1980),  with  possible 
implications for animal experiments in high-containment animal housing with 
artificial  lighting  (Erasmus,  1990).  Immunodeficiency  due  to  concurrent 
infections  can  exacerbate  the  severity  of  bluetongue  disease  (Brodie et  al., 
1998).
Infected  cattle  usually  do not  develop overt  clinical  signs,  but  the European 
strain of BTV-8 caused disease in a larger percentage of infected bovines than 
ever  reported  before.  Field  observations  from  the  BTV-8  epizootic  found  a 
higher incidence of edema, coronitis, dyspnea and actual “blue tongue” in sheep 
than in cattle, while cattle more frequently presented crusts and lesions of the 
nasal  mucosa,  conjunctivitis  and teat  lesions  (Elbers et  al.,  2008).  The case 
fatality rate in sheep was found to be at least three-fold higher than in cattle 
(Conraths et  al.,  2009).  BTV infection  of  cattle  has  recently  been  reviewed 
extensively (Dal Pozzo et al., 2009), with particular regard to infections with 
European BTV-8.
In goats, bluetongue disease is rarely seen and when it does occur, it is mostly 
mild (Backx et al., 2007). Interestingly, the recent detection of TOV, a putative 
25th BTV serotype, was made in clinically healthy goats (Hofmann et al., 2008).
Infection of wild ruminants usually is asymptomatic (Rodriguez-Sánchez et al., 
2010), but fatalities in mouflon (Ovis orientalis musimon) have been reported 
(Fernández-Pacheco et  al.,  2008).  In  2007,  during  the  BTV-8  epizootic  in 
Europe,  seroprevalence  in hunted red deer  (Cervus elaphus) in Belgium was 
found  to  be  over  40%,  with  no  apparent  increase  in  spontaneous  mortality 
(Linden et al., 2008). Wild ruminants found dead in western Germany were also 
serologically examined.  In the 2007/2008 hunting season, antibodies to BTV 
were  detected  in  45% of  red  deer  (91  of  203 animals),  but  not  in  roe  deer 
(Capreolus  capreolus;  499  animals)  (Lutz,  2008).  In  the  following  season, 
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prevalence  in red deer  was lower (7 of  27, 26%),  but  BTV antibodies  were 
found in 2% of roe deer (3 of 129). In mouflon, prevalence was stable (6 of 45, 
13% and 2 of 11, 18%, respectively) (Lutz, 2009). 
Experimental infection of red deer with BTV-1 and -8 led to prolonged presence 
of viral RNA in blood and seroconversion, but no clinical disease was recorded 
(López-Olvera et  al.,  2010).  Interestingly,  North  American  white-tailed  deer 
(Odocoileus virginianus) are highly susceptible to BT (Vosdingh et al., 1968). 
Expression  levels  of  the  Toll-like  receptor  3  gene  have  recently  been  put 
forward as a possible explanation for observed differences in disease severity 
(Vos et al., 2009).
Bluetongue clinical signs in infected mammals can vary widely, from apathy 
and weight loss to swollen heads, tender feet and death (Wilson et al., 2008), or 
fever,  oronasal  ulceration,  facial  edema,  coronitis,  muscle  necrosis,  and 
pulmonary  edema,  respectively  (MacLachlan et  al.,  2008).  Another  peculiar 
feature of BTV infection of sheep are focal intramural hemorrhages at the base 
of the pulmonary artery (Roy, 2007).
At the center  of BTV pathogenesis lies virus-mediated injury to small  blood 
vessels.  Virus replication in endothelial cells  causes  cell  injury and necrosis, 
potentially leading to hemorrhage, thrombosis and tissue infarction (Mahrt and 
Osburn,  1986).  BTV infection  was  shown to activate  pulmonary  endothelial 
cells and macrophages (DeMaula et al., 2001; DeMaula et al., 2002a; DeMaula 
et  al.,  2002b;  Drew et  al.,  2010).  Similar  to  the  pathogenesis  of  viral 
hemorrhagic  fevers  like  Ebola,  host-derived  cytokines  and  other  vasoactive 
substances  contribute  to  the  endothelial  dysfunction  and  increased  vascular 
permeability that characterizes fulminant BT (reviewed by MacLachlan et al., 
2009).
19
Literature review
Figure 4: The cycle of BTV infection 
(PBMC: peripheral blood mononuclear cells, RBC: red blood cells, 
EC: endothelial cells)
2.7 Immune response
The interaction of bluetongue virus with the immune system of the mammalian 
host has been studied extensively. BTV infection causes panleucopenia with a 
minimum at 7 to 8 days post infection (Ellis et al., 1990). BTV is also a potent 
inducer of type I interferon in sheep (Foster et al., 1991), cattle (MacLachlan 
and Thompson, 1985) and mice (Jameson et al., 1978).
After BTV infection, neutralizing antibodies appear within one or two weeks 
(Foster et  al.,  1991) and  play  a central  but  not  exclusive role  in  protection. 
Ruminants that have recovered from BTV infection are immune to reinfection 
with  the  same  serotype,  possibly  for  life  (Ward  and  Carpenter,  1997). 
Reconvalescent serum and monoclonal antibodies can passively protect against 
homotypic BTV infection, as can colostrum-derived maternal antibodies, even 
from vaccination with inactivated vaccines  (Jeggo et al.,  1984b; Oura et al., 
2010). Infection with a single serotype offers no lasting cross-protection against 
other serotypes (Jeggo et al., 1986). 
Animals experimentally infected with one BTV serotype produce neutralizing 
antibodies to only that serotype. Serial infections with different BTV serotypes, 
however,  elicit  a broad neutralizing antibody response  even  to serotypes not 
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encountered  previously  (Jeggo et  al.,  1983;  Jeggo et  al.,  1986).  After 
vaccination with outer capsid proteins alone, there is good correlation between 
neutralizing  antibody response  and  type-specific  protection  against  challenge 
(Huismans et al., 1987; Roy et al., 1990). 
Inactivated whole virus vaccines,  on the other hand, can also protect  against  
virulent  challenge  without  inducing  any  measurable  neutralizing  antibody 
response at all (Stott et al., 1985). Similarly, the degree of immunity after BTV 
infection is not correlated to the level of neutralizing antibodies, even against 
homologous  challenge  (Jeggo et  al.,  1984b),  suggesting  the  involvement  of 
other factors in the outcome of subsequent infections. 
BTV-specific  cytotoxic  (CD8+)  T-lymphocytes  (CTL) were  demonstrated  in 
mice, sheep and cattle (Jeggo and Wardley, 1982; Jeggo et al., 1984a; Ellis et  
al.,  1990).  In  transfer  experiments,  recipient  sheep  were  afforded  partial 
protection  by  B-cell  depleted  thoracic  duct  lymphocytes  from  their 
reconvalescent monozygotic twins. This partial immunity was not strictly type-
specific  (Jeggo et  al.,  1984a;  Jochim,  1985).  Relatedly,  in  a  vaccination 
experiment with bluetongue VP7, expressed by a heterologous virus vector, a 
certain  degree  of  protection  was  detected  in  the  complete  absence  of 
neutralizing antibodies (Wade-Evans et al., 1996).
BTV-specific CTL were found to be mostly serotype cross-reactive in  in vitro 
assays (Jeggo et al., 1984a; Takamatsu and Jeggo, 1989). This cross-reactivity, 
however,  seems  not  to  correlate  with  the  relationships  between  serotypes 
evident  in the cross-reaction  of  neutralizing antibodies,  which could indicate 
that the cellular and humoral immune responses involve different viral proteins 
(Takamatsu and Jeggo, 1989). Little is known about the location of antigenic 
sites for T cells, however. Important variations in the protein targets of CTL 
exist between individuals and host species (reviewed by Schwartz-Cornil et al., 
2008). In mice, CTL predominantly recognize non-structural proteins (Jones et  
al., 1996), while in sheep, VP2 and NS1 were found to be major immunogens 
for CTL (Takamatsu et al., 1990; Andrew et al., 1995). Not surprisingly, it was 
found  that  heterotypic  responses  are  directed  to  conserved  non-structural 
proteins rather than to the variable outer capsid.
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2.8 Diagnosis and control
Bluetongue is not contagious. Excretions and secretions from infected animals 
only contain minimal amounts of virus, and susceptible animals generally are 
refractory to oral infection. Products from infected animals such as meat, milk 
and wool, are harmless from an epidemiological point of view, even though this 
does not apply to semen and embryos (reviewed by Erasmus, 1990). 
BTV can be introduced into new areas by movement or migration of infected 
ruminants, and infected midges can be dispersed with livestock, vehicles, trade 
shipments or on the wind (reviewed by Mintiens et al., 2008). Prevailing winds 
can carry midges over long distances (Ducheyne et al., 2007; Hendrickx et al., 
2008).  Wind-borne spread of infected midges across the sea is the suspected 
mode of introduction of BTV-1 from Northern Africa to the Iberian peninsula 
and Italy (Wilson and Mellor, 2008). It has even been proposed that serotypes of 
BTV that  occur  in  Africa  can  be  spread  to  the  Americas  by  virus-infected 
insects  carried  on  the  trade  winds,  a  theory  that  is  consistent  with  genetic 
topotyping studies of global BTV strains (Gibbs and Greiner, 1994; MacLachlan 
and Guthrie, 2010).
Conventional control measures such as the destruction of infected animals or 
herds are not effective against BTV. Movement restrictions, however, can help 
in slowing down the spread of the virus, by preventing the shipment of infected 
animals over long distances (BVET, 2009). Once BTV has established itself in a 
region, it may be impossible to eradicate and difficult to control, on account of 
its wide host range and the probable existence of clinically inconspicuous carrier 
animals. Likewise, the eradication or even an effective reduction of the vector is  
currently not possible and ecologically undesirable (Erasmus, 1990). Methods 
for vector control include insecticides, larvicides and sterilization of males by 
irradiation  (Verwoerd  and  Erasmus,  2004).  Insect-proof  housing can  prevent 
vector  exposure,  but  this  is  not  feasible  for  many  sectors  of  the  livestock 
industry (Orrù et al., 2004). The exposure of sheep to C. imicola can reportedly 
be reduced by keeping cattle in close proximity, because this vector species has 
a preference for the latter (Nevill, 1978).
After BTV-8 had been introduced to northern Europe in 2006, initial attempts at 
disease  control  by  animal  movement  restrictions  and  insecticides  were  not 
successful  (Gethmann et  al.,  2010),  even  though  several  insecticides  were 
experimentally shown to be effective against Culicoides (reviewed by Schmahl 
et al., 2009). In the EU, vaccination is considered the principal, and possibly the 
only, effective veterinary measure in response to bluetongue, accompanied by 
ancillary  measures  such  as  movement  restrictions  and  surveillance  (Van 
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Goethem,  2008).  The  OIE  maintains  a  list  of  prescribed  BTV  tests  for 
international trade (OIE, 2009b).
The reliable, rapid detection and identification of newly introduced BTV strains 
is required for the implementation of appropriate vaccination strategies (Mertens 
et  al.,  2009a).  As  a  counter-example,  some  60,000  sheep  were  vaccinated 
against BTV-4 in Turkey in 1999, while it was later confirmed that the outbreak 
in question had been caused by BTV-9 (Maan et al., 2004). 
2.8.1 Diagnostic methods and considerations
For a positive diagnosis, BTV antigen, RNA or antibodies must be detected in a 
sample  by  virus  isolation,  molecular  or  serological  methods.  Clinical  and 
pathological  diagnosis  can  only  be  presumptive  and  requires  laboratory 
confirmation, but it can provide an early indication of infection, particularly in 
areas where BTV is exotic and not included in routine surveillance (Mertens et  
al., 2009a). To avoid false-negative results in laboratory diagnosis, serogroup-
specific assays for BTV must be able to detect all known BTV serotypes and 
strains. On the other hand, they must also be able to reliably distinguish these  
from other viruses, especially those that cause similar clinical signs. Based on 
clinical  symptoms, differential  diagnosis in cattle can include foot-and-mouth 
disease and other vesicular diseases, bovine viral diarrhea, infection with bovine 
herpesvirus  type  1,  malignant  catarrhal  fever,  epizootic  hemorrhagic  disease 
(caused  by  a  closely  related  orbivirus  not  occurring  in  Europe)  and  non-
infectious  conditions  like  photosensitization  or  intoxications  (Bexiga et  al., 
2007; Elbers et al., 2008). A wide range of infectious and non-infectious causes 
of  bluetongue-like  symptoms  in  sheep  is  given  by  Verwoerd  and  Erasmus 
(2004).
Acute BTV infection is characterized by viremia, and virus can be isolated from 
blood  (particularly  the  cellular  fraction)  and  other  tissues  by  intravascular 
injection of embryonated chicken eggs or inoculation of permissive cell cultures 
(Goldsmit and Barzilai, 1968; Bando, 1975; Sawyer and Osburn, 1977; Clavijo 
et al., 2000). Many mammalian cell lines support BTV replication, but cells of 
insect origin appear to have a higher sensitivity for native field strains (Mertens 
et al., 1996). BTV amplification in chicken eggs or cultured cells can then be 
verified  by  specific  assays.  Immune  staining  using  reconvalescent  sera  or 
monoclonal antibodies, as well as nucleic acid hybridization techniques, can be 
used to detect viral proteins in cell culture and tissues (Afshar, 1994).
BTV RNA extracted  from a sample  can be  selectively amplified  by reverse 
transcription polymerase chain reaction (RT-PCR) and detected by agarose gel 
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electrophoresis or real-time fluorogenic RT-PCR assays. This currently is the 
most sensitive method of BTV detection (Mertens et al., 2009a). Phylogenetic 
comparisons of the 24 BTV reference strains show a perfect correlation between 
sequence variation of the highly variable genome segment 2 (coding for VP2) 
and serotype (Maan et al., 2007). Conversely, segments 1, 3, 4 and 5 are highly 
conserved  across  serotypes.  Therefore,  depending  on  primer  and,  where 
applicable,  fluorogenic probe design, RT-PCR analysis can be used to detect 
any  bluetongue  virus,  or  only  certain  serotypes  or  strains  (reviewed  by 
Hoffmann et al., 2009b). Group-specific real-time RT-PCR assays targeted at 
conserved regions on segments 1 and 5 have been validated successfully and are 
in regular use at many laboratories (Shaw et al., 2007; Toussaint et al., 2007; 
Batten et al.,  2008a).  Positive RT-PCR results, however,  must be interpreted 
carefully, since BTV RNA can remain detectable in blood long after the last 
positive virus isolation (Bonneau et al., 2002; Hoffmann et al., 2009b) (see also 
figure 5).
Figure 5: Timeline of BTV diagnostic parameters, showing the long period of 
concurrent detection of viral RNA and antibodies, as well as the presence of 
detectable viral RNA long after the end of infectious viremia.
Typing of BTV isolates by molecular assays is considerably faster than virus 
neutralization  tests,  and  independent  of  reference  virus  stocks  or  sera.  PCR 
primers and probes are readily available from many commercial suppliers. RT-
PCR can easily identify and analyze multiple infections with different serotypes 
and  can  be used to  differentiate  between field and  vaccine  strains,  which  is 
difficult  or  impossible with traditional  methods.  Amplified  cDNA fragments 
obtained by RT-PCR can be sequenced and compared to published sequences 
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for confirmation of serotyping and molecular epidemiology studies (Mertens et  
al., 2009a)
Historically, antibody detection in serum samples relied on complement fixation 
and agar gel immunodiffusion. Both, however, proved inferior to enzyme-linked 
immunosorbent assays (ELISA) and were eventually replaced (Hamblin, 2004). 
Highly sensitive antibody ELISAs can recognize the humoral response to BTV 
as early as one week after infection (Batten et al., 2008a; Oura et al., 2009). 
Several  different  systems  are  commercially  available,  mostly  using 
recombinantly  produced  VP7  protein,  which  is  largely  conserved  across  all 
serotypes. Indirect ELISAs are available for milk testing (Kramps et al., 2008).
Cell culture-based neutralization tests, first described in the 1950s (Haig et al., 
1956), are used to detect serotype-specific antibodies in samples by measuring 
their  neutralizing  activity  on  reference  virus.  A  reverse  method,  the  virus 
neutralization  test,  can  be  used  to  type  virus  isolates  by  incubation  with 
reference sera. Neutralization tests are labor-intensive and require virus stocks 
and sera which are not commercially available. Therefore, they are not widely 
used for routine surveillance and typing, but are a useful research tool (Mertens 
et al., 2009a).
Both ELISA and real-time RT-PCR, on the other hand, are suitable for high-
throughput automation and screening  of large animal populations.  Generally, 
RT-PCR assays  can  detect  BTV infection  earlier  than serological  assays.  In 
reconvalescent animals, antibodies are detectable for long periods, possibly for 
life (Mertens et al., 2009a). This is where diagnostic and control strategies for 
BTV can  be  at  cross  purposes,  because  the  reliable  differentiation  between 
infected and vaccinated animals is difficult. Theoretically, inactivated vaccines 
should only elicit antibody responses to structural proteins. The discrimination 
potential  of  non-structural  protein-based  ELISAs  has  been  demonstrated 
(Anderson et al., 1993; Barros et al., 2009), but this is highly dependent on the 
purity of the vaccine. The carryover of non-structural proteins from the culture 
system used to produce the vaccine can result in antibodies to those proteins in 
vaccinated  animals  (Alpar et  al.,  2009).  In  any  case,  vaccination  campaigns 
using  inactivated  whole  virus  vaccines  inevitably  compromise  VP7-based 
serological surveillance (Mertens et al., 2009a). Since inactivated vaccines do 
not contain replicating virus, vaccinated animals usually remain negative in the 
RT-PCR. For highly sensitive real-time assays, however, this has been disputed 
(Steinrigl et al., 2009).
For live vaccines, the notable differences in segment 2 sequence even between 
strains of the same serotype often allow their discrimination from field strains 
(Mertens et  al.,  2007),  but  this is  only applicable during the viremic period. 
Serologically, animals vaccinated with live vaccines cannot be discerned from 
those that had been infected with field strains of the same serotype.
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2.8.2 Vaccination
Generally,  protection  against  a  viral  disease  can  be  accomplished  either  by 
immunization with live but attenuated viruses, inactivated virus particles or sub-
particle units. The latter can either be extracted directly from infectious material 
or produced in a heterologous system by genetic engineering of bacterial, yeast, 
or other cellular systems into which the gene is introduced. Certain viruses can 
also be used as vectors for gene expression either in culture or directly in the 
host (Roy et al., 1990).
Different strategies against bluetongue have been used in the past. At the turn of 
the 20th century, the viral nature of the etiological agent of BT was discovered in 
South Africa and first attempts at immunization were made soon after (Theiler, 
1908). Initially, lowly virulent BTV strains were utilized. For four decades, the 
original  Theiler  strain  was  maintained  solely  by  passage  in  sheep,  despite 
evidence that the vaccine was not entirely safe and that the resultant monotypic 
immunity  was  inadequate  (reviewed  by  Kirkland  and  Hawkes,  2004). 
Eventually,  strains  that  had  been  attenuated  by  repeated  passages  in 
embryonated chicken eggs were introduced (Alexander et al., 1947). 
When cell culture systems for BTV became available, these were used for virus 
propagation. This process offers the additional benefit of being able to refine the 
vaccine  strain  by  plaque  purification  (reviewed  by  Verwoerd  and  Erasmus, 
2004).
There  is  a  delicate  balance  between  achieving  an  acceptable  reduction  in 
virulence  while  at  the  same  time  maintaining  the  required  level  of 
immunogenicity.  Live  vaccines  have  been  shown  to  cause  disease  in  some 
breeds of sheep (Veronesi et al., 2005; Monaco et al.,  2006; Veronesi et al., 
2010), can be transmitted by vectors (Ferrari et al., 2005) and have an altered 
tissue tropism that can lead to teratogenic effects in pregnant animals (Kirkland 
and Hawkes, 2004) and virus excretion in semen (Kirkland et al., 2004). 
In general, replication of the vaccine virus results in the development of a strong 
immune response. There are numerous concerns over the use of live vaccines, 
however, especially in an epizootic situation. In general, the use of live vaccines 
should be restricted to periods of reduced or absent vector activity. Pregnant 
animals  must not  be vaccinated,  and movement restrictions after  vaccination 
should apply  (Alpar et  al.,  2009).  The OIE Terrestrial  Animal  Health  Code 
(OIE, 2009a) prescribes that animals must be vaccinated at least 60 days before 
shipment.
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With  modified-live  virus  vaccines  the  primary  aim  of  vaccination  is  the 
protection  against  disease  in  areas  where  BTV is  already  endemic,  not  the 
prevention of virus transmission. Conversely, in the face of a BTV epizootic in a 
previously unaffected region, the prevention of clinical disease is important, but 
secondary  to  the interruption of  further  spread  or  establishment  of  the  virus 
(Alpar et al., 2009).
Live vaccines, however, usually cause viremia in vaccinated animals (Veronesi 
et al., 2005; Veronesi et al., 2010), if only for a short period of time. This can 
result in the uptake and spread of vaccine strains by vectors when vaccination is 
carried out during periods of vector activity. Claims that vaccine strains only 
cause viremia at levels that are insufficient for vector infection are contentious 
(Kirkland and Hawkes, 2004). Recently, circulation of two vaccine strains in 
unvaccinated populations has been reported in Italy and Croatia (Ferrari et al., 
2005; Listes et al., 2009). 
The  commercially  available  live  vaccine  strains  have  been  attenuated  by 
passages in heterologous culture systems. It is therefore believed that repeated 
passages between insects and ruminants can restore the original virulence of the 
vaccine strain, but so far there is no experimental evidence (Alpar et al., 2009).
Viruses  with  segmented  genomes  can  exchange  genetic  information  during 
concurrent infection of the same cell with two or more distinct parental strains. 
Accordingly,  vaccination  with  replication-competent  BTV always  carries  the 
risk of reassortment of genome segments with other co-infecting BTV strains. 
This risk increases even further when vaccine strains are no longer confined to 
the animals that have actually been vaccinated, but are spread by vectors. There 
are  a  number  of  documented  examples  of  reassortment  occurring  between 
bluetongue viruses both within and across serotypes (Oberst et al., 1987; Samal 
et al., 1987a; Samal et al., 1987b; Stott et al., 1987; de Mattos et al., 1991). A 
2002 BTV-16 isolate from Italy was shown to carry segment 5 of the BTV-2 
vaccine strain. At this point, the BTV-2 vaccine had never been used in Italy, 
but BTV-2 and BTV-16 MLV vaccines were in regular use in Israel (Batten et  
al., 2008b). Since then, the use of MLV vaccines against BTV-2, -4, -9 and -16 
in Italy has further contributed to the diversity of the circulating viruses, instead 
of eradicating BTV from the region (Alpar et al., 2009).
When  two  distinct  parental  strains  reassort,  there  are  1,022  (210-2)  possible 
hybrids when all segments can recombine freely. Segments 2 and 6 cannot be 
exchanged  independently  in  all  cases  (Matsuo  and  Roy,  2009),  but  cross-
neutralizing reassortants have been reported (Cowley and Gorman, 1989). Either 
way,  if  one  single  reassortant  comes  to  dominate  an  entire  outbreak,  this 
suggests a considerable selective advantage (Batten et al., 2008b).
In vitro studies demonstrated that a second virus infecting Vero cells does not 
contribute genome segments to the progeny of the mixed infection when the 
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second infection occurs  more  than a few hours after  the first  (Ramig  et  al., 
1989).  After  experimental  infection  of  Culicoides midges,  however,  this 
interference takes several days to develop. Since fully engorged midges readily 
feed  on  another  blood meal,  their  high  permissiveness  for  mixed  infections 
might play an important role in BTV evolution (el Hussein et al., 1989).
Relatedly,  multivalent  vaccine  formulations  require  attention  to  possible 
interference  and  differences  in  replication  efficiency  and  immunogenicity 
between  the  viruses  involved  (Jeggo et  al.,  1986;  Alpar et  al.,  2009).  A 
quadrivalent vaccine (BTV-10, -11, -13 and -17) has been used in deer, mouflon 
and bighorn sheep in California (McConnell et al., 1985). The South African 
polyvalent  live-attenuated  vaccine  package2 (originally  developed  at  the 
Onderstepoort  Veterinary  Institute)  comes  in  three  bottles,  to  be  injected  at 
three-week intervals. Its bottle A contains serotypes 1, 4, 6, 12 and 14, bottle B 
serotypes 3, 8, 9, 10 and 11, and bottle C serotypes 2, 5, 7, 13 and 19 (Dungu et  
al., 2004). 
The origin and passage history of the strains in the South African product is 
diverse, ranging from the original BTV-4 strain isolated by Theiler around 1900, 
to isolates from Cyprus, Portugal and Pakistan (Alpar et al., 2009). Serotypes 15 
to 18 and 20 to 24 are not included in the standard formulation, but vaccine 
strains of some of these serotypes are available on demand, as are monovalent 
formulations of strains contained in the polyvalent product.
Individually,  the  modified-live  BTV-8  vaccine  strain  was  shown  to  protect 
sheep against challenge with European BTV-8 (Dungu et al., 2008). The use of 
bottle B of the South African vaccine in Bulgaria in 1999 and 2000 in response 
to  the  introduction  of  BTV-9,  however,  marks  the  only  official  use  of  the 
polyvalent  vaccine  package  in  Europe  (Savini et  al.,  2008).  Interestingly, 
serological evidence for BTV-8 infection of sentinel animals was obtained from 
Bulgaria  in  2006,  roughly  coinciding  with  its  introduction  to  northwestern 
Europe. No virus or RNA was found, therefore the relevance of these reports 
cannot be determined (Oura et al., 2006). The isolates of BTV-8 from elsewhere 
in Europe, however, do not match the modified-live vaccine strain (Maan et al., 
2008). 
In other recent campaigns in France, Italy and Spain, only custom monovalent 
or bivalent live vaccine formulations of South African origin, matched to the 
serotypes involved in the outbreaks, have been used. No inactivated vaccines 
were  commercially  available  before  2005 (Savini et  al.,  2008).  Table 3 lists 
BTV vaccines that have been used in Europe until 2006.
2 Onderstepoort Biological Products, Onderstepoort, South Africa; 
http://www.obpvaccines.co.za/prods/41.htm
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Country Monovalent modified-live virus vaccines
BTV-2 BTV-4 BTV-9 BTV-16*
France (Corsica) 2000-2002 2004
Italy 2002-2006 2004-2006 2004-2006 2004
Portugal 2005-2006
Spain 2000-2001 2004-2006
Country Bi- or polyvalent modified-live virus vaccines
BTV-2/4 BTV-2/9 Bottle B**
Bulgaria 1999-2000
France (Corsica) 2003-2004
Italy 2004-2006 2002-2006
Spain 2003
Country Inactivated vaccines
BTV-2 BTV-4 BTV-2/4
France (Corsica) 2005 2006
Italy 2005-2006
Portugal 2005-2006
Spain 2005-2006
Table 3: Bluetongue vaccines used in Europe until 2006 (Savini et al., 2008).
*Use of the BTV-16 MLV vaccine was discontinued over concerns about its 
attenuation. **Contains BTV-3, -8, -9, -10 and -11.
A  monovalent  modified-live  virus  vaccine  against  serotype  16  had  been 
included in a 2004 campaign in Italy, but its use has been discontinued due to 
insufficient attenuation of the strain (Monaco et al., 2006). In late 2004, BTV-
16 with 100% segment 5 homology to the vaccine strain was isolated in Croatia, 
where  the  vaccine  had  never  been  used.  There  was  no  record  of  relevant 
livestock movements, and based on meteorological data, a wind-borne dispersal 
of midges infected with the vaccine strain was suggested (Listes et al., 2009).
Interestingly, isolates from the BTV-16 outbreak that had prompted the use of 
the vaccine in the first place were found to be closely related to the vaccine 
strain as  well.  This suggests a recent  common origin,  possibly in a  BTV-16 
vaccination campaign in Israel a decade earlier (Mertens et al., 2007), where a 
custom pentavalent  vaccine  (serotypes  2,  4,  6,  10  and  16)  provided  by  the 
Onderstepoort  laboratory  was  used (Shimshony,  2004).  This  chain of  events 
exemplifies the inherent  problems of traditional  modified-live BTV vaccines. 
The recently developed reverse genetic systems (Boyce et al., 2008; Attoui et  
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al., 2009), however, might allow the development of safer alternatives based on 
directed genetic engineering of bluetongue viruses.  First strategies have been 
suggested very recently (Matsuo and Roy, 2009; Roy et al., 2009; Zhang et al., 
2010).
Recombinant  vaccines,  on  the  other  hand,  already  offer  the  good 
immunogenicity  of  a  replicating  virus  (the  non-BTV backbone)  without  the 
possibility of reassortment or vector-borne spread, provided the backbone does 
not  productively  infect  arthropods.  Several  prototype  vaccines  have  been 
developed and tested with promising results. The capsid proteins VP2, VP5 and 
VP7  of  BTV-1  were  used  in  vaccination  experiments  with  a  recombinant 
“Western  Reserve”  strain  vaccinia  virus,  eliciting  neutralizing  antibody 
responses  and  protection  against  challenge  infection  (Lobato et  al.,  1997). 
Capripox viruses individually expressing VP2, VP7, NS1 and NS3 of BTV-2 
completely prevented viremia in goats challenged with the homologous serotype 
three weeks after combined application, but their protective efficacy in sheep 
was much lower (Perrin et al., 2007). In another experiment with homologous 
virus, a canarypox virus vector (based on the commercial  ALVAC platform) 
expressing both outer capsid proteins of BTV-17 fully protected sheep against 
virulent  challenge (Boone et  al.,  2007).  A capripox virus expressing VP7 of 
BTV-1 even afforded partial protection against a highly virulent  heterologous 
BTV-3 challenge in sheep.  While all  controls died, most vaccinated animals 
recovered.  Viremia  was  not  examined,  but  all  animals  displayed  signs  of 
bluetongue disease (Wade-Evans et al.,  1996). A replication defective canine 
adenovirus  that  expressed  VP7  of  BTV-2,  on  the  other  hand,  induced  a 
measurable  non-neutralizing  humoral  response,  but  did  not  afford  clinical 
protection against homologous or heterologous challenge (Bouet-Cararo et al., 
2009).
As  far  as  BTV  reassortment  and  reversion  to  virulence  are  concerned,  all 
recombinant pox viruses are considered safe on account of their DNA genome 
(Alpar et al., 2009). Only the coding regions of BTV segments are transcribed, 
yielding mRNAs that lack the conserved termini of native BTV RNA. Their role 
in RNA packaging during bluetongue virion assembly, however, has not been 
verified (Lymperopoulos et al., 2003). Vaccinia virus is a very common vector 
for  recombinant  vaccines.  Its  wide  host  range,  however,  was  named  as  a 
potential  issue for  use in the field.  Recent studies  on recombinant  BTV and 
AHSV  vaccines  (Calvo-Pinilla et  al.,  2009b;  Chiam et  al.,  2009),  using  a 
modified  vaccinia  “Ankara”  strain  rather  than  the  “Western  Reserve”  strain, 
however, reported good immunogenicity for a safe backbone that has lost the 
ability to productively infect mammalian cells (Sutter and Moss, 1992).
In  any  case,  there  are  numerous  possibilities  for  BTV vaccines  that  do  not 
involve replicating virus at all. One inherently safe option is vaccination with 
30
Literature review
incomplete virions or individual virus proteins, an approach generally referred 
to  as  “sub-unit”  vaccination.  Vaccination  with  the  outer  capsid  protein  VP2 
alone  can  protect  sheep  against  challenge  with  virulent  virus  of  the  same 
serotype (Huismans et al., 1987). The neutralizing antibody titer, however, as 
well as the level of observed protection are greater when VP2 and VP5, isolated 
from  purified  virus  particles  or  heterologously  expressed  in  vitro,  are  used 
together – a finding that is possibly explained by their close interaction in the 
virion,  the  strong  conformational  dependence  of  VP2,  and  the  presence  of 
neutralizing epitopes not only in VP2 but also in VP5 (DeMaula et al., 2000; 
Alpar et al., 2009). Recombinant baculoviruses have long been used to express 
BTV proteins with good results (French et al., 1989). When expressed on its 
own, the sub-core protein VP3 can self-assemble, demonstrating that neither the 
BTV genome nor NS2 is required for virion assembly (Belyaev and Roy, 1993). 
Adding VP7 further increases strength and rigidity. The helicase protein VP6 is 
not readily incorporated into these core-like particles (CLP), however, and it is 
likely  that  VP6  needs  to  be  associated  with  BTV  RNA  in  order  to  be 
encapsidated  (Nason et  al.,  2004).  The  absence  of  the  genome  apparently 
reduces the outward pressure on the CLP (Gouet et al.,  1999), resulting in a 
reduced particle diameter.  This in turn can interfere with the addition of the 
outer capsid layer. But in general, virus-like particles (VLP) present structural 
proteins in the correct conformation and give a good immune response (Roy et  
al.,  1994).  There  are  stability  issues,  though,  and  the  efficiency  of  their 
production is low, resulting in high costs. In the livestock industry, cost is a 
major factor in vaccine choice. Accordingly, in spite of the technology being 
available  for  two decades,  there  has  never  been  a  commercial  BTV vaccine 
based on VLPs (Alpar et al., 2009). These issues are being addressed in ongoing 
research  efforts,  however,  and  new  candidate  vaccines  have  been  tested 
successfully (Stewart et al., 2010).
First experiments with inactivated whole virus vaccines, on the other hand, date 
back as far as 1975 for BTV (Parker et al., 1975), and even longer for AHSV 
(Mirchamsy  and  Taslimi,  1968).  Inactivated  vaccines  offer  significant 
advantages over attenuated vaccines  because  the absence of  replicating virus 
eliminates  concerns  about  viremia,  vector  transmission  and  reversion  to 
virulence and there is no danger of fetal infection or reassortment. Procedures 
for  inactivating  bluetongue  virus  using  formalin,  β-propiolactone,  binary 
ethylenimine or  gamma radiation (Campbell et  al.,  1985) and administration 
with  different  adjuvants  have  been  extensively  reported  (reviewed  by 
SCAHAW, 2000; Ramakrishnan et al., 2006), but rigorous quality control must 
be applied to ensure that every vaccine batch is adequately inactivated (Stewart 
et al., 2010).
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Experimental inactivated vaccines against serotypes 3, 4 (Parker et al., 1975), 
11 and 17 (Berry et al., 1982) had been shown to be immunogenic, but their 
protective efficacy was not evaluated. Good efficacy results have been reported 
for monovalent inactivated vaccines directed against serotypes 2, 4, 11 and 16 
and a bivalent vaccine directed against serotypes 2 and 4 (Stevens et al., 1985; 
reviewed by Savini et al., 2008; Hamers et al., 2009b; Savini et al., 2009). More 
than  25  years  after  the  study  by  Parker  et  al. (1975),  the  first  commercial 
inactivated vaccine became available (Alpar et al., 2009). This BTV-2 vaccine 
was also the first inactivated vaccine to be used in the field after the emergence 
of BTV in Europe (Savini et al., 2008). 
In 2008, on account of the rapid spread and high impact of BTV-8 in central  
Europe, the EU and Switzerland agreed on a large-scale vaccination campaign 
using monovalent inactivated vaccines  against  that  serotype.  Four companies 
offered vaccines based on Dutch and Belgian BTV-8 seed strains, inactivated 
with β-propiolactone and adjuvanted with aluminum hydroxide and saponin. For 
the first year, the potential demand across all member states had been estimated 
at around 250 million doses (Bartram, 2009), and the campaign is still ongoing 
(Gethmann et al., 2010). 
Inactivated  vaccines  had  been  selected  because  of  safety  concerns  with 
modified-live  virus  vaccines.  Since  inactivated  vaccines  do  not  contain 
replicating virus, larger amounts of antigen and suitable adjuvants are required 
for  effective  immunization.  Together  with  the  perceived  need  for  booster 
injections,  at  least  in  cattle,  this  leads  to  increased  costs  compared  to  live 
vaccines  (Savini et  al.,  2008).  Still,  for  the  same  amount  of  antigen  the 
production of inactivated whole virus vaccines is considerably cheaper than the 
production  of  VLPs.  Similar  to  VLPs,  they  can  be  used  in  strategies  to 
differentiate  infected  from vaccinated  animals  (DIVA)  (Savini et  al.,  2008). 
Depending  on the purity  of  the vaccine  formulation they elicit  no or  only a 
reduced immune response to non-structural  proteins (Alpar et al.,  2009). But 
despite  promising  experimental  results  (Barros et  al.,  2009),  no  commercial 
system  for  BTV  DIVA  diagnostics  is  currently  available.  Most  available 
ELISAs detect antibodies to VP7, which are induced by both BTV infection and 
vaccination with inactivated whole virus vaccines.
Finally,  even where  effective  vaccines  are  available  and being used,  time is 
needed  to  build  up  the  immune  response.  The  first  immunization  with  an 
inactivated vaccine in cattle requires two doses, and the development of stable 
immunity  therefore  takes  up  to  eight  weeks  (Gethmann et  al.,  2010).  This 
“immunity gap” could be filled by effective antiviral agents (Goris et al., 2008). 
Up  to  now,  no  antivirals  against  BTV  are  available,  but  high-throughput 
compound screening assays for drug discovery are being deployed (Li et al., 
2009).
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3 Objectives
When they  were  first  offered  in  2008,  no  independent  efficacy  data  for  the 
inactivated vaccines to be used in the German vaccination campaign had been 
available. Their short- and long-term efficacy was evaluated in vaccination and 
challenge experiments in sheep and cattle. In addition, the possible detection of 
BTV genome after vaccination with an inactivated vaccine was investigated.
No  serotype-specific  real-time  RT-PCR  assays  for  the  detection  of  BTV 
serotypes with relevance for Germany had been available. Appropriate assays 
were designed and validated.
The prevalence of BTV-6 infection in northwestern Germany was unknown, and 
limited  information  on  the  virulence  of  the  emerging  BTV-6  strain  was 
available.  This was investigated in a field survey and animal experiments  in 
cattle, sheep and mice.
The  use  of  blood  as  an  inoculum  in  BTV  animal  experiments  is  often 
impractical.  The suitability  of  culture-grown virus  for  challenge  experiments 
was  assessed  in  sheep,  and  the  recently  proposed  BTV model  in  interferon 
receptor-deficient adult mice was tested.
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4 Results
The manuscripts are presented in the form accepted for publication. 
Each  manuscript  has  its  own reference  section formatted  in  the style of  the 
respective journal;  references and abbreviations from the manuscripts are not 
included in the relevant sections at the end of this document. Figures and tables 
are numbered individually within each manuscript.
The poster “European Bluetongue virus serotypes 6 and 8: Studies on virulence 
and cross-protection” is reproduced as presented at the 4th European Congress of 
Virology. A relevant manuscript is in preparation.
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Efficacy of three inactivated vaccines against bluetongue virus serotype 8 
in sheep
Abstract
Bluetongue has become a major animal health issue in the European Union. The 
member states and Switzerland have agreed on a vaccination strategy.  Three 
different inactivated monovalent vaccines against bluetongue virus serotype 8 
were selected for the compulsory vaccination program carried out in Germany 
in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep 
immunised  under  field  conditions  by  clinical,  virological  and  serological 
examination before and after  experimental  challenge infection with a BTV-8 
field isolate. Antibody levels prior to challenge infection differed between the 
vaccinated groups, but all seroconverted animals were fully protected against 
clinical  disease  and  virus  replication.  Only  one  vaccinated  animal  was  very 
weakly positive in the real-time RT-PCR at day 10 after challenge infection, and 
one seronegative sheep in one of the vaccine groups was not protected.
Introduction
Bluetongue (BT) is a non-contagious, arthropod-borne disease of ruminants and 
camelids caused by bluetongue virus (BTV) of the genus Orbivirus in the family 
Reoviridae. BTV is transmitted by Culicoides spp. biting midges. It can cause 
severe  disease,  particularly  in  sheep,  and  can  have  considerable  economic 
impact.  BT is notifiable to the World Organisation for  Animal  Health (OIE, 
Office International des Epizooties). Presently there are twenty-four established 
serotypes (BTV-1 to -24) with only low levels of cross-protection [1]. A putative 
new  BTV  serotype,  Toggenburg  orbivirus,  was  recently  discovered  in 
Switzerland[2]. Bluetongue was first described in Africa at the beginning of the 
20th  century,  but  did  not  regularly  occur  in  Europe  (except  Cyprus)  before 
1998[3].  Since  then,  at  least  five serotypes  (BTV-1,  -2,  -4,  -9  and  -16)  have 
invaded Mediterranean Europe on different occasions. After its introduction in 
2006, BTV-8 has caused a severe epizootic in Western and Central Europe, in 
areas  where  BTV  had  never  been  reported  before  and  which  were  not 
considered  to be at  risk of  BTV introduction[4-8].  Smaller  incidents involving 
BTV-6 and -11 that were ascribed to the illegal use of modified live vaccines 
have been reported in Northern Europe[9]. The route of introduction of BTV-8 is 
still unclear[10], but it now represents a serious threat to the livestock population 
of Europe. Vaccination accompanied by ancillary measures such as movement 
restrictions and surveillance has been demonstrated to be an effective veterinary 
public health instrument to control the spread of BT[11-13]. The EU member states 
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and Switzerland agreed on a vaccination strategy to reduce clinical disease and 
losses  in  domestic  ruminants,  to  contain  the  spread  of  the  disease  and  to 
facilitate safe trade in live animals[14]. A number of imported modified-live virus 
(MLV) vaccines against serotypes 2, 4, 9 and 16 had been used in Southern 
Europe[12] when inactivated vaccines  had not  been commercially  available[15]. 
Due to  the risks  associated  with MLV vaccines,  e.g.  insufficient  attenuation 
leading  to  clinical  disease,  teratogenicity,  spread  by  vectors  with  possible 
reversion to virulence and reassortment of genes with field strains[4,12,16-18], the 
use  of  inactivated  vaccines  is  preferred[4,19-22].  Inactivated  vaccines  directed 
against serotypes 2, 4 and 16 have already been shown to be generally safe and 
effective[12,23]. Experimental inactivated vaccines against other serotypes are in 
development in India and China[13]. 
In 2008, Germany initiated a compulsory vaccination program against BTV-8 
using  inactivated  monovalent  vaccines.  Covered  by  fast-track  legislation, 
vaccinations were scheduled to begin as soon as the newly developed vaccines 
were  available,  i.e.  before  any  of  the  vaccines  had  obtained  EU  marketing 
authorisation[24]. While this procedure is acceptable in the face of serious disease 
events[25], there is an unequivocal preference for authorised vaccines [26]. When 
seeking  marketing  authorisation  for  veterinary  immunologicals  with  the 
European  Medicines  Agency (EMEA),  manufacturers  need  to  provide  safety 
and  efficacy  data.  While  the  EMEA  does  not  require  field  trials  for 
authorisations  of  bluetongue  vaccines  under  exceptional  circumstances[26], 
studies  to  evaluate  the  safety  and  efficacy  of  three  inactivated  monovalent 
vaccines (BLUEVAC® 8, CZ Veterinaria S.A., Porriño, Spain; Zulvac® 8, Fort 
Dodge  Animal  Health,  Naarden,  The  Netherlands  and  BTVPUR® AlSap  8, 
Merial  S.A.S.,  Lyon, France)  were  commissioned[27] as a  prerequisite  for the 
exceptional  authorisation in Germany under §17c Tierseuchengesetz  (Animal 
Diseases Act)[28]. After the safety of the vaccines had been assessed in a field 
study  in  the  German  federal  state  of  Mecklenburg-Western  Pomerania[28], 
animals  from  this  field  study  were  used  to  evaluate  vaccine  efficacy.  The 
purpose of the present study was to determine the level of protection conveyed 
by the three vaccines employed in Germany when applied under field conditions 
against an experimental challenge infection with BTV-8. In addition to a general 
evaluation of vaccine efficacy, differences in the degree of protection provided 
by  the  different  vaccines,  if  any,  were  to  be  assessed.  For  eventual  full  
authorisation, the manufacturers must combine safety and efficacy results from 
laboratory studies with supportive data from field studies[25].
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Materials and methods
Sheep
Twenty-three healthy female German black-headed mutton sheep were obtained 
from  a  farm  that  had  participated  in  the  vaccine  safety  field  study  in 
Mecklenburg-Western Pomerania[28]. The farm is situated in a region that had 
never  been  affected  by  BT.  All  animals  had  been  tested  negative  for  BTV 
antibodies in the early spring of 2008 before they were included in the vaccine 
safety  study.  The animals  were  randomly selected  from the  vaccine  groups, 
resulting in a broad age distribution. Seventeen animals were between six and 
fifteen months of age and six were older than fifteen months. This provides an 
adequate cross-section of an exposed population in the field. The animals were 
sequentially numbered and divided into three groups based on the vaccine they 
had received (table 1). 
Group label Vaccine Dosage Second dose Sheep
controls saline solution 1 ml after 3 weeks 1 - 6
C BLUEVAC® 8 2 ml no 7 - 12
F Zulvac® 8 Ovis 2 ml after 3 weeks 13 - 17
M BTVPUR® AlSap 8 1 ml no 18 - 23
Table 1. Vaccines and groups.
Groups C and M consisted of six animals each, group F comprised 5 animals. 
Six animals from the same farm and breed that had been mock-vaccinated with 
saline solution were used as controls. These animals were about six months old 
at the time of challenge. Animals in groups C and M had been vaccinated once 
three months before challenge infection, sheep in group F had been given the 
second dose of vaccine that is recommended by the manufacturer three weeks 
later,  i.e.  nine  weeks  before  challenge.  The  animals  were  subsequently 
transferred to the BSL-3 facility of the Friedrich-Loeffler-Institut (FLI). They 
were shown to be free of circulating BTV genome by real-time RT-PCR before 
challenge  infection.  During  the  entire  study,  rectal  body  temperatures  were 
measured  daily,  and  the  animals  were  examined  for  clinical  signs  by 
veterinarians.
Vaccines
In the preceding field study, the animals had been vaccinated with one of the 
three inactivated vaccines intended for the 2008 BT vaccination campaign in 
Germany[28].  The  vaccines  in  question  are  inactivated,  monovalent  BTV-8 
38
Short-term efficacy of inactivated BTV-8 vaccines in sheep
preparations in aqueous solution. Seed viruses were European BTV-8 isolates 
from  the  2006  outbreak.  Saponins  and  aluminium  hydroxide  were  used  as 
adjuvants,  and  vaccines  C  and  F  also  contain  thiomersal.  All  animals  were 
vaccinated following the instructions provided by the manufacturers (table 1). 
The vaccines were injected subcutaneously into the lateral thoracic wall. In the 
field study, vaccinations were carried out by veterinarians under the supervision 
of the Institute of Epidemiology of the Friedrich-Loeffler-Institute. 
Challenge virus
The  blood  used  for  challenge  infection  of  the  sheep  was  obtained  from  a 
Holstein  calf  that  had  been  intravenously  inoculated  with  a  blood specimen 
submitted by the veterinary authorities of the district of Aachen, Germany, to 
the  national  reference  laboratory  for  BT  in  August  2007  (submission  no. 
173/07). The specimen was from a BT outbreak in a sheep herd held close to the 
Belgian  border  south-west  of  Aachen.  In  accordance  with  OIE 
recommendations for BTV challenge experiments[22], the virus was not subjected 
to any passages in embryonated chicken eggs or cell culture. After inoculation 
with the specimen, the calf was monitored for viraemia by real-time RT-PCR. A 
half-litre of blood was taken by jugular venipuncture on day 7 after inoculation 
in a phase of high-level viraemia. The blood was collected in tubes containing 
potassium EDTA and stored at 4 °C. Virus was isolated from the blood by tissue 
culture inoculation and stored for reference. 
On the day of challenge infection of the sheep, a 150 ml aliquot of the blood 
was diluted with an equal volume of sterile phosphate-buffered saline (PBS) and 
centrifuged. The supernatant was discarded and packed blood cells were washed 
twice with PBS. Subsequently, blood cells were resuspended in PBS, sonically 
disrupted and the lysate was divided for injection. The blood preparation was 
confirmed to be free from bacterial contaminations. The unprocessed blood not 
used for challenge infection remained in storage for further experiments.
Challenge infection
On day 0 of the study, all sheep were inoculated with 4 ml of the bovine blood 
preparation at 1.25 x 103 50% tissue culture infective doses (TCID50) per ml and 
1.22 x 106 BTV genome copies per ml. Every animal received two subcutaneous 
injections of 2 ml in the bald axillar regions of both sides. The infective dosage 
was determined by end-point titration on baby hamster kidney (BHK)-21 C13 
cells  (RIE179,  Collection  of  Cell  Lines  in  Veterinary  Medicine,  FLI,  Insel 
Riems, Germany). BTV genome content was measured by real-time RT-PCR.
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Blood samples
Whole blood samples from all animals were taken on days 0, 3, 4, 5, 6, 7, 10,  
12, 14, 17 and 21, and serum samples on days 0, 7, 14 and 21 post challenge  
infection (dpi).  Blood was drawn by jugular puncture and collected in tubes 
containing potassium EDTA or clot activator, respectively (Monovette, Sarstedt, 
Nümbrecht, Germany). Samples were stored at 4 °C until analysis.
RNA detection and quantification
Total RNA from whole blood samples was extracted using a commercial  kit 
(NucleoSpin 96 RNA, Macherey-Nagel, Düren, Germany) in an extraction robot 
(Freedom EVO, Tecan,  Männedorf,  Switzerland).  The amount of  bluetongue 
viral genome in samples and the inoculum was determined using two real-time 
reverse transcriptase polymerase chain reaction (RT-PCR) assays, specific for 
BTV  or  BTV-8,  respectively.  The  BTV-8-specific  assay  (Hoffmann  et  al., 
unpublished) amplifies a fragment of the gene encoding the outer shell protein 
VP2,  which  is  highly  variable  between  serotypes.  The  BTV-specific  assay 
amplifies a highly conserved sequence at the 5’ end of BTV genome segment 
5[29]. One-step RT-PCR was performed for 10 minutes at 50 °C and 5 min at 95 
°C followed by 42 cycles of 15 seconds at 95 °C, 20 sec at 56 °C and 30 sec at  
72  °C  (iScript  One-Step  RT-PCR  Kit  for  Probes,  Bio-Rad  Laboratories, 
Hercules, CA, USA) in an Mx3005P QPCR system (Stratagene, La Jolla, CA, 
USA).  BTV  genome  copy  number  in  the  inoculum was  determined  with  a 
calibration curve obtained by concurrent amplification of serial  dilutions of a 
BTV genome standard with known copy numbers. Our implementation of the 
BTV-specific  assay  has  been  favourably  evaluated  in  an  inter-laboratory 
comparison  test[30].  Accordingly,  we  used  it  to  cross-validate  the  newly 
developed BTV-8 specific assay. Both assays show highly similar sensitivity.
Serology
Before challenge infection, serum samples were collected from all animals to 
determine  the  initial  level  of  BTV-specific  antibodies.  Changes  in  antibody 
levels were monitored by taking further samples at 7, 14 and 21 dpi. Undiluted 
sera and serial two-fold dilutions up to 1:512 in PBS were tested in the ELISA.  
Antibody levels against the BTV major core protein VP7  were determined with 
two  commercially  available  ELISA  kits.  A  competitive  assay  (ID  Screen 
Bluetongue Competition, ID VET, Montpellier,  France)  and a double-antigen 
sandwich  assay  (Ingezim  BTV  DR,  Inmunología  y  genética  aplicada,  S.A., 
Madrid, Spain) were used according to manufacturers’ instructions. 
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Neutralising  titres  against  BTV-8  in  serum  samples  were  determined  as 
described by Savini  et al.[31], testing serial two-fold dilutions starting with an 
initial dilution of 1:10. If by this method no neutralising antibodies could be 
detected  in  a  sample  while  the  undiluted  serum  had  been  positive  in  the 
competitive  ELISA,  dilutions  of  1:2,  1:4  and  1:8 were  also  tested  for  virus 
neutralisation. Neutralising doses given for samples (ND50) are the reciprocal of 
the  serum dilution  that  caused  virus  neutralisation  in  50%  of  the  replicates 
tested, as calculated by the method of Spearman and Kärber[32]. As controls, we 
used dilutions of sera whose titres had been determined by the OIE reference  
laboratory for BT at the Istituto Zooprofilattico Sperimentale dell'Abruzzo e del 
Molise 'G. Caporale', Teramo, Italy.
Results
Serology
Before  challenge  infection,  all  but  one  vaccinated  sheep  had  BTV-specific 
antibodies; one sheep in group C (no. 12) and all sheep in the control group 
were  negative  in  all  serological  assays.  Serial  dilutions  of  sera  taken 
immediately before challenge infection showed the highest antibody titres for 
group F (two-shot vaccination). In the competitive ELISA, sera from all sheep 
were negative at a dilution of 1:16. The more sensitive sandwich ELISA scored 
positive in dilutions of up to 1:256 (figure 1a). 
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Figure 1a. VP7 antibody titres of pre-challenge sera. Serial two-fold dilutions 
were evaluated with two different commercial ELISA kits.
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On  average,  VP7  antibody  levels  (i.e.  optical  densities  measured  in  the 
sandwich ELISA) in undiluted pre-challenge sera were lowest for the sheep in 
group C (figure 1b), even when the negative result for sheep 12 was not taken 
into account. 
0.00 0.50 1.00 1.50 2.00
Group M
Group F
Group C
Controls
Optical density
Figure 1b. Average antibody levels of animals grouped by vaccine; in undiluted 
pre-challenge sera as measured by the sandwich ELISA. The group C average 
does not include sheep 12.
On day 7 after challenge infection, all vaccinated animals except sheep 12 
showed a marked boost in antibody levels in the competitive ELISA, and all 
controls and sheep 12 had seroconverted by day 14 at the latest (data not 
shown).
The ELISA results were corroborated by the BTV-8 neutralisation assay. Before 
challenge, the controls and sheep 12 had no neutralising antibodies, neither did 
one  sheep  in  group M (sheep  21) that  had been  positive  in  the  competitive 
ELISA. On average, pre-challenge neutralising titres were highest in group F, 
neutralising antibody levels of all vaccinated animals except sheep 12 increased 
markedly in the first week after challenge, and all sheep displayed neutralising 
antibodies not later than two weeks after challenge (table 2). 
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Sheep Vaccine
no. group 0 dpi 7 dpi 14 dpi 21 dpi
1 controls <10 <10 40 80
2 controls <10 2 240 320
3 controls <10 2 120 120
4 controls <10 <10 60 120
5 controls <10 <10 10 10
6 controls <10 <10 60 60
7 C 4 320 480 480
8 C 3 160 640 960
9 C 2 160 480 480
10 C 2 240 480 640
11 C 8 320 480 640
12 C <2 <2 120 160
13 F 15 160 1280 640
14 F 2 120 640 480
15 F 80 120 1280 960
16 F 40 320 320 480
17 F 15 80 320 240
18 M 2 160 120 160
19 M 4 120 240 160
20 M 15 320 320 960
21 M <2 640 240 240
22 M 6 160 320 480
23 M 15 480 1280 960
Neutralising dose 50%
Table 2. Results of the BTV-8 neutralisation assay. Neutralising doses given for 
samples (ND50) are the reciprocal of the serum dilution that caused virus 
neutralisation in 50% of the replicates tested.
RNA detection
In five of six sheep in the control group (all but sheep 5), viral genome copies 
were  first  detected  on  day  3 using real-time RT-PCR assays.  Genome copy 
numbers peaked on day 10 and viral genome remained present until the end of 
the sampling period (figure 2). 
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Figure 2. Threshold cycle (Ct) values of a BTV-8-specific real-time RT-PCR, 
results for the sheep of the control group. The BTV-specific assay gave similar 
results (data not shown). Negative results are shown as a Ct of 45.
Sheep 12 (group C) demonstrated viral replication at similar levels to the non-
vaccinated animals in both the BTV-8 specific and the BTV-specific assays. On 
day 10, sheep 9 in group C was tested positive in the BTV-8 specific real-time 
RT-PCR, albeit at a threshold cycle of 36 which is close to the detection limit. 
No BTV genome was detected in any other vaccinated animal (table 3).
Sheep no. Vaccine group
0 3 4 5 6 7 10 12 14 17 21
7 C No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
8 C No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
9 C No Ct No Ct No Ct No Ct No Ct No Ct 36.27 No Ct No Ct No Ct No Ct
10 C No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
11 C No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
12 C No Ct 32.17 27.58 24.35 21.49 22.47 23.92 27.50 29.39 27.24 29.46
13 F No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
14 F No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
15 F No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
16 F No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
17 F No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
18 M No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
19 M No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
20 M No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
21 M No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
22 M No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
23 M No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
Days after infection
Table 3. Threshold cycle (Ct) values of a BTV-8 specific real-time RT-PCR, 
results for vaccinated sheep.
Clinical observations
Sheep in the control group showed mild clinical symptoms of disease, including 
an elevated body temperature between days 5 and 12 after challenge infection as 
compared to vaccinated animals (figure 3). One animal in the control group (no. 
2) had a marked facial oedema and increased nasal discharge on days 7 to 9; 
another animal (no. 4) displayed forced breathing in the same time period. No 
symptoms  of  bluetongue  disease[33] were  evident  in  any  of  the  vaccinated 
animals.
Post-mortem examinations
At post-mortem examination at the end of the study (25 days post infection), 
sheep  2 of  the control  group showed a focal,  5 mm in diameter,  intramural 
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haemorrhage of the pulmonary artery, 1.5 cm above the origin. The medulla of 
the  right  superficial  cervical  lymph  node  showed  multifocal  to  coalescent 
hyperaemia and haemorrhage in sheep 4 of the control group. Several sheep of 
different groups had intimal melanosis of the pulmonal artery which had to be 
differentiated  from  haemorrhage  (data  not  shown).  There  were  no  lesions 
consistent with bluetongue disease[33] in any vaccinated animal. 
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Figure 3. Rectal temperatures of controls and vaccinated animals (group 
averages with standard deviation) after challenge infection with BTV-8.
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Discussion
Good efficacy results for bluetongue vaccination in sheep have been reported 
for monovalent inactivated vaccines directed against serotypes 2, 4, 11 and 16 
and a bivalent vaccine directed against serotypes 2 and 4[12,34]. In these studies, 
two-shot  vaccination  evoked  neutralising  antibodies  in  most  cases  and 
consistently  prevented  both  viraemia  and  clinical  disease.  Two doses  of  an 
experimental  inactivated  vaccine  directed  against  serotype  18,  on  the  other 
hand, reportedly failed to protect sheep from viraemia after challenge[35]. There 
is  little  precedent  for  challenge experiments  with sheep that  received  only a 
single dose of an inactivated vaccine. Experimental inactivated vaccines against 
serotypes 3, 4, 11 and 17 have been successfully tested for their immunogenicity 
when  applied  once,  but  no  challenge  infections  were  carried  out[36,37].  An 
inactivated  vaccine  against  BTV-2  led  to  100%  seroconversion  in  sheep 
following the first injection, and full protection against challenge infection has 
been  reported[38].  Nevertheless,  up  to  now  there  are  no  published  data  for 
inactivated vaccines against BTV-8. 
Within the scope of the present study, all three vaccines protected sheep against  
challenge infection with a German BTV-8 isolate, two of the vaccines even after 
a  single-shot  application  as  recommended  by  the  manufacturers.  Immunity 
against BT provided by inactivated vaccines is suspected to be only transient, 
especially after a single injection[1]. Cattle usually require a booster vaccination 
for  durable  immunity[12].  For  inactivated  vaccines  against  other  serotypes, 
protection was shown to last at least six months for sheep inoculated once, and 
up  to  twelve  months  after  two doses[12].  Since  a  decline  of  vaccine-induced 
antibody levels  can  be  expected  over  time,  and at  the same time no further 
vaccinations took place in Germany in 2008, it  is  unclear  whether  sufficient 
immunity to BTV infection will remain in single-vaccinated sheep herds over a 
period of 12 months until revaccination in 2009. This is being addressed in an 
ongoing study.
Presently, serological analyses of samples collected before challenge infection 
showed a positive effect of two-shot vaccination on antibody levels. Antibody 
levels  measured  in  the  ELISA  do  not  necessarily  correspond  to  levels  of 
neutralising  antibodies.  The  latter  are  serotype-specific  antibodies  directed 
against structural proteins of the outer capsid (mostly VP2), while according to 
information provided by the manufacturers both ELISA kits used here detect 
BTV group-specific antibodies against an inner capsid protein (VP7). This is the 
case for most commercially available BT ELISA kits[22]. The precise relationship 
between  VP7 and VP2 antibody levels  induced  by inactivated  vaccines  still 
needs  to  be  determined.  In  sheep  that  had  been  vaccinated  twice  (as 
recommended by the manufacturer of vaccine F), antibodies were detectable by 
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the sandwich  ELISA at  dilutions of up to 1:256, while  sheep that  had been 
vaccinated only once turned negative in the 1:64 dilution at the latest. Results 
obtained with the less sensitive competitive ELISA show a similar trend, and the 
neutralisation  assay  also  detected  the  highest  titres  in  group  F.  However, 
animals of the two other  vaccinated groups that  initially had lower antibody 
titres were also protected against challenge infection, including sheep 21 (group 
M) that  did not have any detectable neutralising antibodies at  all.  Protection 
against  challenge  infection  in  the  absence  of  neutralising  antibodies  has 
previously been reported for other inactivated vaccines[34,39]. In the present study, 
antibody levels before infection as well as the dynamics of seroconversion after 
challenge infection differed between diagnostic assays. Overall, the sandwich 
ELISA exhibited the greatest sensitivity and should therefore be used to verify 
the vaccination status of animals. 
Still, one sheep in group C (no. 12) turned out completely seronegative for BTV 
at  day  0  in  all  serological  assays.  The  existence  of  non-responders,  i.e. 
immunocompetent  individuals  that  fail  to  mount  an  antibody  response  after 
vaccination  with  certain  vaccines,  is  well  established  in  humans [40].  For 
ruminants,  individual  differences  in  immune  responsiveness  have  been 
shown[41]. Still, it seems more likely that sheep 12 had not received a correct 
dose  of  the  vaccine,  particularly  because  sheep  in  that  group  were  only 
vaccinated once, increasing the possible influence of human error. The animal 
was  not  protected  against  challenge  infection  as  shown  by  the  high-level 
viraemia  after  challenge  infection.  There  was  no  booster  effect  on  antibody 
levels  after  challenge.  Similar  to  sheep  in  the  control  group,  sheep  12 
seroconverted  two  weeks  after  challenge.  Conversely,  sheep  21  that  was 
positive  in  the  ELISA  but  initially  did  not  have  detectable  neutralising 
antibodies displayed a marked increase of antibody levels as early as 7 days 
after challenge infection.
In one vaccinated animal, sheep 9 in group C, BTV genome was detected with a 
threshold cycle of 36 in the highly sensitive BTV-8 specific real-time RT-PCR 
on day 10, but the animal was negative in subsequent samplings. The sheep had 
BTV-specific antibodies prior to infection, and did not show any clinical signs 
of BT at any time. Monitoring the level of viraemia in vaccinated animals after 
challenge infection is  considered  the most effective  way to evaluate  vaccine 
efficacy[12,26]. However, in the light of the low amount of viral genome detected 
on  only  one  day  and  the  absence  of  clinical  disease,  the  potential 
epidemiological relevance of this finding is questionable. At this low level of 
circulating viral  genome, the presence of infectious virus can usually not be 
demonstrated.  An  insect  vector  would  be  highly  unlikely  to  become 
infected[19,42,43]. 
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Unexpectedly,  one  unvaccinated  sheep  in  the  control  group  (no.  5)  did  not 
display  detectable  virus  amplification  after  challenge  infection,  but 
seroconverted by day 14 as measured in the competitive ELISA. Interlaboratory 
proficiency  tests  have  proved  that  the  real-time  RT-PCR  is  adequately 
sensitive[30]. The animal first displayed neutralising antibodies on day 14, but at 
a lower level than the other sheep in its group. The emergence of BTV-specific 
antibodies  substantiates  that  the  animal  had  in  fact  been  inoculated  with 
challenge virus. It appears unlikely that the failed infection was caused by an 
insufficient dose of infectious virus, as shown by the reisolation of virus from 
the inoculum. BTV isolation in cell culture is less sensitive than inoculation of 
sheep[29,44], but the injected dose was found to be over 1000-fold higher than the 
minimum  culture  infectious  dose  determined  by  end-point  titration.  Breed-
related  differences  in  susceptibility  to  BTV,  including  the  development  of 
viraemia, have been documented[33,35], so the absence of detectable viraemia in 
this  animal  as  well  as  the  generally  mild  symptoms  displayed  by  viraemic 
animals in the control group could be due to individual differences in innate 
immune response together with a generally reduced susceptibility of the used 
breed. This probably could have been avoided by choosing a more susceptible 
breed such as Poll Dorset[45]. However, this was pre-empted by the design of the 
precursive safety study, which required a large number of animals. Thus, the 
availability of the breed serves as an indicator of its importance to the German  
livestock industry, justifying its selection for the study. 
In  conclusion,  all  inactivated  vaccines  against  BTV-8 included in this  study 
showed good efficacy in a challenge experiment. Their safety has already been 
demonstrated[28,46]. Both findings are in line with results reported for inactivated 
vaccines directed against other serotypes, namely 2, 4, 11 and 16. Unique in the 
present study, however, is the use of animals vaccinated against BTV-8 in the 
field, as opposed to conducting both vaccination and challenge experimentally. 
Mass vaccinations in the field are logistically challenging, and deficiencies in 
their  implementation  can  impair  both  individual  and  herd  immunity,  while 
experimental  vaccinations  provide  unrealistically  ideal  conditions.  Thus,  our 
study presents a more realistic assessment of the efficacy of the selected BTV-8 
vaccines under field conditions.
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Abstract
The  long-term efficacy  of  three  commercially  available  inactivated  vaccines 
against bluetongue virus serotype 8 (BTV-8) (BLUEVAC® 8, Zulvac® 8, and 
BTVPUR® AlSap 8) was evaluated in a seroprevalence study and challenge 
experiments.  Seroprevalences one year  after vaccination ranged from 75% to 
100%.  In  two  infection  experiments,  groups  of  vaccinated  sheep  and  cattle 
selected  either  randomly or  for  low antibody levels  were  challenged  with a 
European BTV-8 strain twelve months after vaccination. With two exceptions, 
all animals, including those with low antibody levels prior to challenge, were 
protected from viral replication and clinical disease even at low initial antibody 
levels.  Vaccination  of  susceptible  ruminants  in  yearly  intervals  is  thus 
considered an adequate scheme for BTV-8 control in Europe. 
Introduction
Bluetongue disease (BT) is a notifiable animal disease transmitted to ruminants 
and camelids by Culicoides spp. midges. The disease is caused by a virus of the 
genus  Orbivirus,  family  Reoviridae.  Bluetongue virus (BTV) had  previously 
been considered exotic to central  Europe; however,  first cases in commercial 
livestock  caused  by  viruses  of  serotype  8 were  reported  in  the  Netherlands, 
Belgium and  Germany  in  2006.  The  successive  spread  of  the  virus  was  of 
epizootic character[1-2].
On account of the high economic losses caused by disease outbreaks and by 
transport restrictions imposed thereafter, a large-scale vaccination scheme was 
introduced to European Union member countries and Switzerland [3]. Modified-
live vaccines (MLV) have been used extensively in areas such as South Africa 
and Italy[4-5] where multiple BTV serotypes circulate. However, a live attenuated 
BTV-2  vaccine  strain  has  been  spread  to  naïve  populations  by  infectious 
vectors[6].  Furthermore,  vaccination with a  live BTV-16 vaccine in Italy was 
discontinued  due  to  unpredictable  clinical  effects  attributed  to  insufficient 
attenuation  of  the  strain[7].  Therefore,  for  safety  reasons,  it  was  decided  to 
employ only inactivated monovalent vaccines for the mass vaccination schemes 
against serotype 8.
In order to evaluate the safety of the used vaccines in sheep and cattle, a large-
scale field study on three of the inactivated commercial vaccines was conducted 
by  the  State  Office  for  Agriculture,  Food Safety  and  Fisheries  (LALLF)  of 
Mecklenburg-Vorpommern, Germany and the Friedrich-Loeffler-Institut (FLI)
[8],  showing only minor adverse effects of vaccination. Furthermore,  all three 
vaccines  induced  good  seroconversion  rates  as  well  as  good  protective 
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immunity,  as  shown by a  challenge  experiment  in  sheep  three  months  after 
vaccination[9].
The aim of the present study was to evaluate the protective immunity in sheep 
and  cattle  one  year  after  vaccination.  In  addition,  protective  immunity  in 
animals with a low remaining antibody response to vaccination was examined.
Materials and methods
Animals
Animals  used  for  the  study were  Holstein-Friesian  dairy  cattle  and  German 
Black-headed Mutton sheep. All animals included in the challenge experiments 
originated from farms that had participated in the BTV-8 vaccine field study in 
Mecklenburg-Vorpommern in 2008[8]. 
The controls were between six and ten months old at the time of challenge, and 
vaccinated  animals  were  between  seventeen  months  and  four  years  of  age. 
Vaccination  had  been  conducted  according  to  the  manufacturers’ 
recommendations  with  three  commercially  available  inactivated  monovalent 
vaccines  one  year  previously.  The  vaccine  preparations  used  (Table  1)  are 
labelled A, B and C in the text. Cattle had been vaccinated twice in three-week 
intervals, sheep had been vaccinated either with a single dose (vaccines A and 
B) or revaccinated after three weeks (vaccine C). 
Group Vaccine Manufacturer
A BLUEVAC® 8 CZ Veterinaria S.A.
Porriño, Spain
B BTVPUR® AlSap 8 Merial S.A.S.
Lyon, France
C Zulvac® 8 Bovis Fort Dodge Animal Health
Zulvac® 8 Ovis Naarden, The Netherlands
Table 1
Vaccines used in the study.
The participating farms were situated in a region in the east of Germany where 
no significant BTV activity has been recorded. After the 2008 vector season, all 
animals on the farms, including unvaccinated young stock, were screened by 
real-time  RT-PCR  to  verify  that  no  vector-borne  introduction  of  BTV  had 
occurred.  Due  to  the  passive  association  of  BTV  with  erythrocytes,  viral 
57
Long-term efficacy of inactivated BTV-8 vaccines in sheep and cattle
genome is detectable for several months after infection[10]. A single screening of 
the whole farm was therefore considered appropriate.
One year  after  vaccination, 623 cattle and 223 sheep from the 2008 vaccine 
safety study remained on the three participating farms. In the safety field study, 
the animals had been separated into two age groups, juveniles (aged three to 
twelve months at the time of vaccination) and adults (older than twelve months). 
Animals in these groups now were between fifteen months and two years or 
over two years old, respectively. The animals were evaluated for BTV-specific 
antibodies  (cELISA,  Bluetongue  Antibody  Test  Kit,  VMRD,  Pullman,  WA, 
USA)  in  an  ISO  17025-accredited  laboratory  (LALLF,  Rostock,  Germany) 
using the 50% cut-off value prescribed by the manufacturer. From these data, 
the  seroprevalence  one  year  after  vaccination  (the  percentage  of  vaccinated 
animals positive in the competitive ELISA) was calculated. 
The variance of antibody levels within groups twelve months after vaccination 
was evaluated for 57 bovines and 55 ovines in vaccine group A, 55 bovines and 
98 ovines in vaccine group B and 57 bovines and 70 ovines in vaccine group C.  
Variances were compared by one-sided F tests. P-values of less than 0.01 were 
considered significant.
At  the  conclusion  of  this  study,  all  animals  remaining  on  the  farms  were 
revaccinated and are not available for further experiments.
Challenge virus
The virus used for challenge was obtained from the reference virus collection of 
the German National Reference Laboratory for Bluetongue and was consistent 
with experiments conducted previously[9].  Briefly,  a BTV-8 strain isolated in 
Germany in 2007 was passaged once in cattle, whole blood was obtained and 
blood cells were washed three times with phosphate buffered saline. Blood cells 
were stored at 4 °C until further use and ultrasonically disrupted on the day of 
challenge.  Characterization  of  the challenge  blood included  determination of 
tissue culture infectious doses 50% (TCID50) by assessment of cytopathic effect 
5 days after infection of Vero cells and calculation of the number of genome 
copies by quantitative RT-PCR using a dilution series of in vitro transcribed 
RNA as  a  standard.  Additionally,  the  challenge  inoculum was  screened  for 
bacterial contaminants. 
A volume of 4 ml of infectious blood containing 2.0 x 105 TCID50 and 1.2 x 107 
BTV genome copies was used per  animal in the first  experiment.  Challenge 
virus was subcutaneously injected in four portions (two on each side)  in the 
shoulder region of cattle and the hairless axillary and inguinal regions of sheep 
in order to target multiple lymph nodes. Virus was retitrated after infection to 
guarantee consistent titres.
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Challenge experiments
Animals were screened prior to infection for serum antibodies by a competitive 
enzyme-linked  immunosorbent  assay  (cELISA,  VMRD)  and  a  serum 
neutralization test (SNT)[11]. They were confirmed to be free of circulating BTV 
genome by real-time RT-PCR and were then challenged with a German BTV-8 
isolate as specified above. A clinical evaluation was conducted daily and rectal 
temperatures were measured for 28 days post infection. With the exception of 
the euthanized  cow (see  below),  the animals did not  undergo a pathological 
examination at the end of the experiment.
EDTA-treated blood samples  for  real-time RT-PCR and virus isolation were 
taken immediately before challenge and at days 3, 5, 7, 10, 12, 14, 18, 21, 25 
and 28 after infection. Serum samples for evaluation of BTV-specific antibodies 
by competitive ELISA were taken in weekly intervals. The level of neutralizing 
antibodies to BTV-8 was determined by SNT for samples taken immediately 
before infection and 28 days later.
 Experiment #1
In the first experiment, randomized groups of six bovines and ovines from each 
vaccine group (A, B and C) as well as six unvaccinated control animals of both 
species were selected. Since the challenge experiments were conducted in the 
BSL-3 facility of the FLI on Insel Riems, all animals had to be transported from 
their  farms  of  origin.  Control  sheep  came  down  with  increased  body 
temperatures  after  transport  and  were  treated  with  antibiotics  (25  mg/kg 
Enrofloxacin, Baytril®, Bayer HealthCare, Leverkusen, Germany) over a four-
day period. 
Experiment #2
In a successive experiment, groups of five bovines and three to five ovines from 
each vaccine group were chosen for challenge based on their cELISA results. 
Animals with low levels of antibodies prior to challenge were selected. Apart 
from that, the experimental design was kept in concordance with experiment #1. 
One  bovine  was  treated  with  antibiotics  due  to  transport-related  injuries 
(Florfenicol,  Nuflor®,  Intervet,  Unterschleißheim,  Germany;  Enrofloxacin, 
Baytril®)  but  did  not  recover  and  was  euthanized  on  day  thirteen  of  the 
experiment. 
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Real-time RT-PCR and virus isolation
All  EDTA blood samples  were  evaluated  by  real-time  quantitative  RT-PCR 
targeting a BTV-8 specific sequence on the VP2 gene[12]. As internal control, a 
β-actin  specific  sequence  was  amplified  in  the  same  reaction  tube[13]. 
Furthermore, to screen for other BTV serotypes, samples taken on day 10 post 
infection  were  evaluated  by  a  “pan-BTV”  real-time  quantitative  RT-PCR 
targeting a conserved segment 5 (S5) sequence[13]. 
All  RT-PCR protocols  were  conducted  on Agilent-Stratagene  (La Jolla,  CA, 
USA) real-time cyclers (Mx3000P® and Mx3005P®) using a commercial RT-
PCR kit  (iScript® One Step RT-PCR Kit,  Bio-Rad,  Hercules,  CA, USA) as 
previously described[12].  Virus isolation was attempted from RT-PCR positive 
EDTA-treated  blood  samples  from  the  beginning  (days  three  to  ten  post 
infection)  and  the  end  (days  25  to  28  post  infection)  of  the  experiments. 
Isolation was performed on African green monkey kidney cells (Vero, RIE15, 
Collection of Cell Lines in Veterinary Medicine, FLI, Insel Riems, Germany) 
from 1 ml of whole blood in two passages as described by Clavijo et al.[14].
Representation of serological results
In  the  competitive  ELISA,  samples  are  scored  by  comparing  their  optical 
density (OD) to the OD of the negative control. Samples with an OD higher than 
50% of the negative control are considered negative. For the sake of the reader,  
this  counterintuitive  representation  is  reversed   in  this  report.  OD ratios  are 
subtracted from 100%. Thus, the negative control is assigned a value of 0%, and 
samples  with  an  OD ratio  of  over  50% are  positive.  This  is  referred  to  as 
“%inhibition”.
Results
Seroprevalence study
Animals  vaccinated  with  vaccine  A displayed  a  seroprevalence  of  91.2% in 
juvenile and 76.2% in adult  sheep one year  after  a single application, while 
100% of the juvenile and 89.8% of the adult sheep vaccinated once with vaccine 
B were positive in the competitive ELISA. All sheep vaccinated with two doses 
of vaccine C were seropositive after a one-year period. Bovines, which had all 
been vaccinated twice, showed seroprevalences well over 90% (Table 2).
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Bluetongue virus antibody levels in sheep before and after vaccination as well 
as  twelve  months  later  are  summarized  in  Figure  1.  Twelve  months  after 
vaccination,  the  variance  of  BTV antibody  levels  in  sheep  vaccinated  with 
vaccine C (two doses) was significantly lower than in all other groups. At the 
same time, variance in sheep vaccinated once with vaccine A (one dose) was 
significantly higher than in all other groups, even when compared to other sheep 
that received only one dose of vaccine (group B). 
Vaccine
A positive negative total seroprevalence positive negative total seroprevalence
juvenile 85 2 87 97.70% juvenile 31 3 34 91.18%
adult 131 2 133 98.50% adult 16 5 21 76.19%
total 216 4 220 98.18% total 47 8 55 85.45%
B positive negative total seroprevalence positive negative total seroprevalence
juvenile 92 2 94 97.87% juvenile 39 0 39 100.00%
adult 122 5 127 96.06% adult 53 6 59 89.83%
total 214 7 221 96.83% total 92 6 98 93.88%
C positive negative total seroprevalence positive negative total seroprevalence
juvenile 90 0 90 100.00% juvenile 46 0 46 100.00%
adult 85 7 92 92.39% adult 24 0 24 100.00%
total 175 7 182 96.15% total 70 0 70 100.00%
SheepCattle
Table 2 
Seroprevalence in vaccinated sheep and cattle one year after vaccination.
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Figure 1A-C
Serological  development  in  sheep  over  a  one-year  period  as  measured  by 
competitive ELISA. The box denotes the median as well as the 25th and 75th 
percentile. The whiskers denote the 10th and 90th percentile. The circles mark 
any outliers (individual values outside of that range). The dotted line represents 
the 50% positive cut-off of the cELISA.
Real time RT-PCR and virus isolation after challenge
Vaccinated animals in experiment #1
In the group of randomly selected vaccinated animals from experiment #1, all of 
the bovines and all but one of the ovines were protected from viral replication. 
However, one of the sheep from vaccine group B became RT-PCR positive by 
day three post infection and continued to show positive results until the end of 
the experiment (Figure 2).
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Figure 2A-D
Quantitative RT-PCR results in vaccinated (closed symbols; triangles: group A, 
boxes: group B, circles:  group C) and control  animals (open diamonds) after 
experimental BTV-8 challenge infection. 
Vaccinated animals in experiment #2
Results  were  similar  in  experiment  #2,  where  selection  had  been  made  for 
individuals  with  low serum  antibody  levels.  The  only  vaccinated  animal  to 
become positive in the RT-PCR was one bovine from vaccine group A (Figure 
2).  This  animal  was  in  bad  general  health  due  to  non-BTV  related  causes 
(transport  injuries;  confirmed  by  a  post-mortem  examination)  and  was 
euthanized on day thirteen of the experiment. 
Both the sheep in experiment #1 and the cow in experiment #2 that were RT-
PCR positive were the individuals with the lowest serum antibody levels before 
challenge (17% and 20% inhibition, respectively; see also Figure 3).
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Controls 
The  unvaccinated,  seronegative  animals  from  the  control  groups  of  both 
experiments continuously became positive in the RT-PCR between three and 
five days post infection and remained so until the end of the experiment at 28 
days post  infection.  An exception was made by one of  the control  sheep in 
experiment  #1,  which  never  turned  RT-PCR positive  during  the  entire  time 
period of the experiment. Similarly, one of the control sheep in experiment #2 
tested positive only intermittently and displayed much lower quantities of BTV-
8  RNA  than  the  other  controls  (Figure  2);  however  both  these  animals 
seroconverted.
Virus could be isolated from the blood of all RT-PCR positive animals both in 
the beginning and in the end of the experimental  period, but never from the 
weakly  positive  control  sheep  or  the  euthanized  cow  (both  experiment  #2). 
Retrieval of infectious virus roughly correlated with C t values. In general, it was 
not  possible  to  isolate  BTV from blood with  C t values  above  30  (data  not 
shown).
After  challenge,  vaccinated  animals did not  develop clinical  signs consistent 
with bluetongue disease at any time. Mean body temperatures were higher in the 
control animals for approximately five days during the phase of highest virus 
load in the blood from seven to ten days post infection. This difference was not 
as marked in the sheep from experiment #1, where mean body temperatures of 
the control animals were slightly higher than those of the vaccinated animals 
from  before  challenge  infection  throughout  the  whole  experiment  (data  not 
shown).
No BTV serotypes other than BTV-8 were detected in any animal.
Serology before and after challenge infection
In experiment #1, two of the randomly selected animals (one bovine in group C, 
one ovine in group B) displayed serum antibody levels below the 50% cut-off 
value of the competitive ELISA. All other animals were positive. 
64
Long-term efficacy of inactivated BTV-8 vaccines in sheep and cattle
In experiment #2, animals showed considerably lower initial antibody levels. In 
ten of fifteen bovines (three in group A, two in group B and five in group C) and 
four of thirteen ovines (three in group A, one in group C), BTV antibody levels 
before  challenge  did  not  reach  the  cut-off  value  of  the  competitive  ELISA. 
Antibodies  detectable  by  competitive  ELISA were  present  in  all  vaccinated 
animals  by seven  days post  infection,  albeit  still  at  lower  levels  than in  the 
serum of animals from experiment #1 at the same time point. By day fourteen 
post infection, an increase in serum antibodies close to the levels reached by 
animals from experiment #1 was visible in the ELISA (Figure 3).
Figure 3A-D
Serological results (cELISA) before and after challenge infection (A-C: vaccine 
groups,  D:  controls).  The  dotted  line  marks  the  positive  cut-off  (50%). 
Serological data of the sheep from experiment #1 and the cow from experiment 
#2 that were positive in the real-time RT-PCR are shown as striped bars.
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In  contrast  to  this,  naïve  animals  of  the  control  groups  all  showed 
seroconversion in the competitive ELISA by fourteen days post infection. 
A marked boost  in neutralising antibody titres  was seen at  four weeks after  
challenge (Figure 4). There was no pronounced difference between the vaccine 
groups; however, SNT titres in the control animals were two- to four-fold lower 
than  those  of  vaccinated  animals  at  four  weeks.  The  euthanized  cow  from 
vaccine group A (experiment #2) had detectable neutralizing antibodies before 
challenge, while the RT-PCR positive sheep from vaccine group B (experiment 
#1) did not.
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Figure 4A-B 
Neutralizing antibodies in vaccinated cattle (circles) and sheep (squares) before 
(open symbols) and after challenge infection (closed symbols) with a German 
BTV-8 strain (A: experiment #1, B: experiment #2).
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Discussion
The seroprevalence study shows a high degree of seroconversion in vaccinated 
sheep and cattle one year  after  vaccination.  No marked differences  could be 
observed between the three vaccines in cattle, where all vaccines were applied 
twice.  In contrast,  seroprevalence was higher in sheep vaccinated twice with 
vaccine C as compared to animals vaccinated only once with either one of the 
other two vaccines. Also, vaccinating sheep twice reduced the heterogeneity of 
antibody levels within the group. Nonetheless, seroprevalences even after single 
vaccination  with  vaccines  A  or  B  appear  sufficient  for  protection  of  sheep. 
Single-shot efficacy in sheep is important because compliance with double-shot 
vaccination schedules can be unsatisfactory. 
For inactivated vaccines, repeated application is generally considered necessary 
for  the  induction  of  long-term  protection,  at  least  in  cattle [10,15].  A  single 
application  of  an  inactivated  BTV-4  vaccine  did  not  protect  cattle  from 
developing  viraemia  when  challenged  seven  months  after  vaccination[16]. 
However, in an experiment in sheep conducted by Hamers et al.[17], a single dose 
of a commercial BTV-2 vaccine has proven to induce protection from challenge 
for  a  minimum  of  12  months.  Recently,  a  commercial  inactivated  BTV-8 
vaccine  that  is  not  included  in  the  present  study  (Bovilis® BTV8,  Intervet 
International  b.v.,  Boxmeer,  The  Netherlands)  was  shown  to  protect  sheep 
against virulent challenge ten months after vaccination[18]. 
Given the results of the seroprevalence study, vaccination schemes with yearly 
intervals between vaccinations are sufficient to maintain stable humoral immune 
response with the tested batches of inactivated vaccines. This is also supported 
by  the  results  of  the  challenge  experiments.  Nevertheless,  batch-to-batch 
variations could influence efficacy in the field, and consistent quality needs to 
be confirmed by continuous batch release testing.
In this study, the challenge experiments show a good protective efficacy of all 
three vaccines in both species tested. Virus replication was virtually eliminated 
by vaccination  in  all  three  vaccine  groups.  The challenge  strain  induced  no 
pronounced clinical signs in any of the groups. This is not unexpected for the 
breed used in the experiment[9].  Still,  peak body temperatures  after challenge 
infection were  higher  in controls  than in vaccinated  animals.  At the time of 
challenge in experiment #1, the control sheep were recovering from a fever due 
to  transport-related  stress  and  the  close  contact  between  animals  originating 
from different  holdings.  Throughout  the  experiment,  they  had  a  mean body 
temperature about 0.5 °C higher than the vaccinated sheep and displayed only a 
slight  peak at  day seven.  The age of  the controls might help to explain this  
observation. Younger sheep generally have a higher body temperature [19], and 
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often are clinically less affected by BTV-8[20].  Unfortunately,  no older  BTV-
naïve sheep were available for use as controls.
In  the  challenge  experiments,  even  antibody levels  below the  cut-off  of  the 
competitive ELISA were able to protect  most vaccinated animals from virus 
replication.  However,  the  two  cases  where  virus  replication  was  detectable 
despite vaccination were both individuals with the lowest serum antibody level 
in  their  respective  groups.  While  this  does  suggest  a  correlation  between 
serological  response  and  protective  efficacy,  no  definite  conclusions  can  be 
drawn from observations in only two animals. Furthermore, in the case of the 
bovine from experiment #2, an additional underlying health problem most likely 
facilitated  the  breakthrough  of  the virus.  This  suggests  that  susceptibility  to 
bluetongue virus  infection  is multifactorial  and it  is  enhanced  by underlying 
general health conditions of non-infectious origin. In the case of the vaccinated 
sheep  that  showed  low  antibody  titres  and  virus  replication  there  are  two 
interpretations: The vaccine was not administered correctly or at an insufficient 
part of the dose, or the vaccine did not induce a sufficient immune response in 
this sheep. This could be due to a general non-responsiveness to vaccination or 
underlying  health  problems  at  the  time  of  vaccination  which  negatively 
impacted the immune response. Generally speaking, no vaccine can offer 100% 
of protection in 100% of individuals.
One curious finding that warrants further investigation is the occurrence of less 
susceptible animals within the same breed, as seen in the control animals that 
displayed low or no virus replication but eventually seroconverted. Differences 
in susceptibility based on breed have been described previously[21].  However, 
our  results  imply  variations  within  the  same  breed  that  co-determine 
susceptibility to BTV infection. A marked variation in susceptibility within the 
same breed has also been described by Erasmus[22] without offering a coherent 
explanation for this phenomenon. It has been postulated that susceptibility to 
orbiviruses is influenced by intra-species differences in the expression of toll-
like receptors[23]. Further research is needed to adequately address this question.
The  virus  used  for  challenge  is  closely  related  to  the  vaccine  seed  strains. 
Therefore,  this  study  cannot  provide  information  on  cross-protection  against 
heterologous BTV-8 strains or other serotypes of BTV. Further research into 
safe polyvalent vaccines is advisable, since several other serotypes are already 
present in Europe, and the introduction of new BTV serotypes remains likely[24].
Nevertheless, all three vaccines included in this study protect both cattle and 
sheep from BTV-8 infection for up to twelve months after vaccination, reliably 
serving their intended purpose.
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Abstract
The World Organisation for Animal Health (OIE) currently recommends using 
infectious  ruminant  blood as  challenge  inoculum in  bluetongue virus  (BTV) 
vaccination and challenge experiments. The use of virus grown in cultured cells 
is discouraged because culture passages can lead to changes in virus phenotype, 
including reduced replication efficiency and virulence in the host, while the OIE 
considers  clinical  disease  in  control  animals  indispensable  evidence  of 
successful infection. 
In  the  present  study,  two  groups  of  five  sheep  were  inoculated  with  either 
infectious  calf  blood lysate  or  culture-grown bluetongue virus  of  serotype  8 
(BTV-8) (2 x 104 TCID50 and 5 x 105 TCID50, respectively). No pronounced 
difference in the induction and progression of viraemia as determined by real-
time  RT-PCR,  which  is  the  most  objective  parameter  in  the  evaluation  of 
vaccine efficacy, was observed. In a second experiment, the virulence of both 
inocula was confirmed by fatal infection of interferon receptor-deficient mice.
The recent availability of highly sensitive molecular methods for the detection 
of BTV can finally shift the focus away from clinical disease. For the sake of 
objective and repeatable BTV challenge experiments, the OIE should reconsider 
its policy on culture-grown virus.
Introduction
Bluetongue disease  (BT) is a  non-contagious infectious disease of  ruminants 
and camelids mainly spread by haematophagous Culicoides spp. vector insects. 
There  are  24  established  serotypes  of  its  causative  agent,  Bluetongue  virus 
(BTV; Orbivirus, Reoviridae). After its introduction in 2006, serotype 8 (BTV-
8) has caused a major epizootic in Europe. Starting in 2008, mass vaccinations  
using  monovalent  inactivated  vaccines  together  with  natural  immunity  after 
infection led to a dramatic reduction in the spread of BTV-8 (Conraths et al., 
2009). The virus however has not been eradicated from Europe and vaccinations 
will have to continue to effectively control the disease. From a regulatory point 
of view, the inter-batch variance in potency of licensed vaccines needs to be 
closely monitored in a sustained vaccination campaign. This calls for repeatable, 
highly standardised vaccination and challenge experiments. 
The  present  study  compares  the  experimental  induction  and  progression  of 
BTV-8 viraemia in BTV-naïve sheep for two different inocula to assess their 
suitability  for  these  experiments.  Both  inocula  were  also  evaluated  in  the 
recently published IFNAR-/- mouse model for BTV (Calvo-Pinilla et al., 2009).
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Materials and methods
A BTV-naïve Holstein calf was inoculated with a blood sample submitted to the 
German national reference laboratory for BT in 2008 (Hoffmann et al., 2008). A 
week later, blood was collected in tubes containing potassium EDTA and stored 
at 4 °C. On the day of infection of the sheep, an aliquot of the blood was diluted 
with sterile phosphate-buffered saline solution (PBS) and centrifuged. Packed 
blood cells were washed twice with PBS and sonically disrupted on ice. The 
lysate contained 2 x 104 TCID50/ml as  determined by end-point  titration on 
Vero cells (RIE15, Collection of Cell Lines in Veterinary Medicine, Friedrich-
Loeffler-Institut [FLI], Insel Riems, Germany). 
In parallel, BTV-8 isolated directly from the originally submitted sample was 
propagated in cell culture. Supernatant from the second passage on Vero cells 
had a virus titre of 5 x 105 TCID50/ml. Both inocula were tested free of bacterial 
contamination.  After  inoculation  of  BTV-8  vaccinated  sheep,  no  BTV 
replication  was  detected  with  a  “pan-BTV”  assay  (Toussaint  et  al.,  2007), 
confirming the absence of other BTV serotypes in the inocula (data not shown).
All animal experiments were conducted in the BSL-3 facility of the FLI on Insel 
Riems.  Ten  BTV-naïve  yearling  German  Black-headed  Mutton  sheep  were 
assigned  to  two  groups  of  five  animals  each.  Sheep  in  group  A  were 
subcutaneously injected with 4 ml of freshly prepared lysate of infectious calf 
blood,  while  sheep  in  group  B  similarly  received  1  ml  of  cell  culture 
supernatant. 
The  animals  were  monitored  for  clinical  signs  every  day,  rectal  body 
temperatures were measured daily and whole blood and serum samples were 
taken at days 3, 5, 7, 10, 12, 14, 18, 21, 25 and 28 after infection. Differences in  
mean body temperature between the groups were examined with Welch’s t-test 
using the R statistical package (version 2.9, http://www.r-project.org). A p-value 
of less than 0.05 for the null hypothesis was considered significant. 
Viral RNA was extracted from whole sheep blood samples using a commercial 
kit (NucleoSpin 96 Virus, Macherey-Nagel, Düren, Germany) in an automated 
liquid  handling  workstation  (MICROLAB®  STAR,  Hamilton,  Bonaduz, 
Switzerland). BTV-8 genome load in the samples was determined by serotype-
specific  real-time  quantitative  reverse  transcription  PCR  (RT-qPCR)  as 
described  previously  (Hoffmann  et  al.,  2009).  Again,  virus  isolation  was 
performed on Vero cells (Clavijo et al., 2000). At weekly intervals, serological 
data  was  collected  using  a  commercially  available  double  recognition 
(sandwich) ELISA kit (PrioCHECK® BTV DR, Prionics Deutschland GmbH, 
Planegg-Martinsried,  Germany)  and  serum  neutralisation  assay  using 
homologous virus.
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In  a  second  experiment,  calf  blood lysate  and  cell  culture  supernatant  were 
intraperitoneally injected into adult interferon receptor-deficient IFNAR-/- mice 
(Calvo-Pinilla et al., 2009) and C57BL/6 wild type mice (500 µl per animal). 
Groups  of  four  IFNAR-/-  mice  were  given  either  one  of  the  undiluted 
preparations or dilutions of  1:100 in sterile  PBS. Only three IFNAR-/- mice 
received the diluted culture supernatant, and C57BL/6 mice were only given the 
undiluted  preparations.  IFNAR-/-  control  groups  were  injected  with  BTV-
negative cattle blood or cell culture supernatant.
Results
In the first sample taken three days after challenge, two out of six sheep in the  
group inoculated with infectious blood (group A) and all sheep in the culture-
grown virus group (B) scored positive in the RT-qPCR. All sheep had detectable 
viral  RNA  in  the  next  sample  taken  on  day  five.  Viral  genome  remained 
detectable in all animals until the end of the study at day 28 (see figure 1).
Figure 1: RT-qPCR data for sheep infected with BTV-8.
 
Virus was reisolated from samples from all sheep in group B starting on day 
three. In group A, virus isolation was successful in one sample from day three, 
and in all samples from day five post infection. All sheep remained viraemic for 
at least 18 days after challenge (data not shown).
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The average rectal body temperature in group B peaked at day seven at 0.9 °C 
over  the  pre-challenge  mean  (standard  deviation  [S.D.]  0.8).  The  group  A 
average  continued  to  rise,  peaking  nine  days  after  inoculation  with  a  group 
average 1.7 °C higher than the pre-challenge mean (S.D. 0.6, see figure 2). 
Figure 2: Average body temperatures of sheep after BTV-8 infection. The body 
temperatures of individual animals are available as supplemental material.
Overall, there was a total of 30 febrile days (individual body temperature over 
40 °C) in group A and 26 days in group B. Mild clinical symptoms (increased  
nasal  discharge,  forced  breathing,  transient  facial  oedema)  were  recorded  in 
both groups with no pronounced difference between the groups.
All sheep in group B and one sheep in group A were positive in the sandwich 
ELISA one week after infection. All sheep displayed BTV-specific antibodies in 
the  next  sample  taken  one  week  later  (data  not  shown).  One  month  after  
infection, virus neutralisation titres in group B (average [-log2] 6.6, S.D. 0.7) 
were higher than in group A (average [-log2] 5.6, S.D. 1.1) (data not shown).
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All IFNAR-/- mice died within five days of injection of either culture-grown 
BTV or BTV in calf blood lysate. Survival times were similar for both inocula. 
All  IFNAR-/-  controls  and  C57BL/6  mice  stayed  healthy  throughout  the 
experiment (see table 1). 
Group Days post infection
0 1 2 3 4 5 6 7
Controls 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
BTV-8 in blood 100% 100% 100% 100% 100% 75% 0% 0% 0% 0% 0% 0% 0% 0%
BTV-8 supernatant 100% 100% 100% 100% 100% 0% 0% 0% 0% 0% 0% 0% 0% 0%
BTV-8 in blood 1:100 100% 100% 100% 100% 100% 100% 100% 50% 50% 0% 0% 0% 0% 0%
BTV-8 supernatant 1:100 100% 100% 100% 100% 100% 100% 100% 33% 33% 0% 0% 0% 0% 0%
Table  1:  Survival  times  of  mice  after  BTV-8  injection.  Controls  include 
C57BL/6 wild type mice injected with BTV and IFNAR-/- mice injected with 
BTV-negative blood or cell culture supernatant. The number of surviving mice 
at each time point is given as a percentage of the total number of inoculated 
mice in that group.
Discussion
Both  the  infectious  blood  lysate  and  culture-grown  virus  caused  high-level 
viraemia  in  all  sheep.  The  RT-qPCR  results  suggest  a  steadier  course  of 
infection  in  group  B,  but  owing  to  the  limited  number  of  animals  in  the 
experiment, no robust statement can presently be made. Differences in the initial 
progression of viraemia can probably be attributed to the higher infectious dose 
in group B (culture-grown virus). Sheep in this group also seroconverted earlier 
and  eventually  reached  higher  titres  of  neutralising  antibodies.  Since  the 
infectivity  of  freshly  prepared  blood  lysate  can  only  be  determined 
retrospectively, it was not possible to use exactly matched challenge doses for 
both groups. 
Conversely, sheep in group A (blood) displayed moderate pyrexia about a week 
after  challenge,  fulfilling the requirement  of +1.7 °C laid out for controls in 
BTV challenge experiments by the World Organisation for Animal Health (OIE, 
2009) while body temperatures of sheep in group B only rose mildly. An acute 
reaction  to  the  bovine  blood  itself  is  unlikely  due  to  the  late  onset  of  the 
temperature rise. This cannot be verified, however, because no control group of 
sheep  injected  with  BTV-negative  blood or  supernatant  was  included  in the 
experiment. 
In any case, even the most prominent difference in average temperature between 
the  groups  (on  day  9)  was  not  statistically  significant  (p  =  0.0667).  The 
presumed low susceptibility of the breed (Eschbaumer et al.,  2009) probably 
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contributed to the faint clinical manifestation in both groups. The environmental  
conditions in high-containment animal housing also play a role in the relatively 
mild  BT  symptoms  often  observed  in  experimentally  infected  ruminants 
(Verwoerd and Erasmus, 2004). On the other hand, both infectious blood and 
culture-grown BTV-8 invariably led to fatal infection in all IFNAR-/- mice. The 
limited number of mice available for the experiment, however, did not allow the 
determination of 50% lethal doses for the inocula.
To our knowledge, this is the first study directly comparing a BTV field strain 
that  was  only  passaged  in  ruminants  (as  per  OIE  recommendations)  to  the 
homologous strain passaged in vitro. In other experiments that used both kinds 
of inoculum, infectious blood had merely been obtained by an animal passage of 
a virus isolate that had already been propagated in cell culture (MacLachlan et 
al., 1994; Martinelle et al., 2009).
In a challenge experiment, the most objective and reliable benchmark of BTV 
vaccine  efficacy  is the protection against  viraemia (Savini  et  al.,  2008),  and 
regulating  authorities  consider  it  to  be  the  main  parameter  (EMEA,  2008). 
Sterile  immunity  of  vaccinated  animals  prevents  vector-borne  spread  of  the 
disease,  and clinical BT in the absence of viraemia has never been reported. 
Accordingly, the reliable induction of viraemia in control animals is the most 
important feature of a suitable challenge model. The highly sensitive detection 
of BTV in blood samples by RT-qPCR is a well established, reproducible and 
reliable tool for monitoring BTV viraemia (Hoffmann et al., 2009). With less 
emphasis  on  clinical  scoring,  the  use  of  culture-grown  virus  in  challenge 
experiments  should  be  reconsidered.  The  objective  comparison  of  vaccine 
efficacy between different experiments depends on a well-defined inoculum of 
known infectivity, which is impractical with blood-derived inocula. 
What  is  more,  RT-PCR  amplification  of  BTV  genome  fragments  and 
sequencing using viral  RNA from culture-grown virus is  considerably  easier 
than with viral RNA isolated from blood. This provides an additional means of 
ensuring the integrity of the inoculum and the absence of contamination with 
other serotypes.
But even though cell culture derived inocula have been used successfully in a 
number of recent challenge experiments (Boone et al., 2007; Di Emidio et al., 
2004; Savini et al., 2009; Savini et al., 2007), the OIE currently discourages the 
use of virus isolates passaged in cell culture or embryonated chicken eggs (OIE, 
2009).
In vitro and in ovo passages positively select  for spontaneous mutations that 
promote replication in the heterologous culture system. This can lead to changes 
in virus phenotype, including reduced replication efficiency and virulence in the 
host (exploited in the production of live vaccines) as well as changes in tissue 
tropism (Alpar  et  al.,  2009;  Kirkland  and  Hawkes,  2004).  But  even  highly 
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passaged,  “attenuated”  strains  can  cause  viraemia  sufficient  for  vector-borne 
spread (Batten et al., 2008; Ferrari et al., 2005; Listes et al., 2009) and disease 
(Veronesi et al., 2010). Interestingly, the ability to cross the placenta, the most 
prominent property acquired in culture passages of BTV, has repeatedly been 
reported for the European BTV-8 field strain (De Clercq et al., 2008; Worwa et  
al.,  2009),  suggesting  that  this  strain  might  already  have  undergone  culture 
adaptation (MacLachlan, 2009).
 
Conclusion
Culture-grown virus is easier to produce and standardise than infectious blood 
and less prone to deteriorate when stored for longer periods, and no additional 
animals are required for the production of challenge inoculum. In light of the 
similar  outcome  between  the  two  different  inocula  this  study  found  no 
compelling need for the use of blood in BTV-8 challenge experiments. A low 
number of cell culture passages of BTV-8 did not lead to attenuation compared 
to the field strain after a cattle passage. Both BTV-8 (Dal Pozzo et al., 2009; 
Darpel et al., 2007; Dungu et al., 2008) and other serotypes (Boone et al., 2007; 
Di Emidio et al.,  2004; Savini  et  al.,  2009; Savini et al.,  2007) amplified in  
heterologous  culture  systems  have  been  used  successfully  in  many  recent 
experiments.  Furthermore,  the  protective  efficacy  of  BTV  vaccines  can  be 
adequately evaluated without recourse to clinical observations, which renders a 
challenge  model  that  involves  unnecessary  suffering  for  the  control  animals 
ethically questionable. While the experimental induction of clinical disease is 
indispensable for pathogenesis studies, it is incidental in BTV vaccine efficacy 
trials. In general, the use of culture-grown virus allows a more standardised and 
rapid  implementation  of  challenge  studies,  which  is  especially  important 
considering  the  need  for  a  swift  response  to  the  introduction  of  new  BTV 
serotypes.
Conflict of interest
None of the authors has any financial or personal relationships with other people 
or organisations that could inappropriately influence this work.
 
82
Comparison of BTV challenge models
Acknowledgements 
The authors thank Karin Lissek and Christian Korthase of the German national 
reference  laboratory  for  BT  at  the  Friedrich-Loeffler-Institut  for  excellent 
technical assistance. Help with the statistical analysis by Dr. Mario Ziller and 
Dr. Dirk Höper is greatly appreciated. Dedicated animal care was provided by 
the staff  of the BSL-3 facility  on Insel  Riems. This work was supported by 
EPIZONE, the EU Network of Excellence for Epizootic Disease Diagnosis and 
Control (Contract No. FOOD-CT-2006-016236).
References
Alpar, H.O., Bramwell, V., Veronesi, E., Darpel, K., Pastoret, P.P., Mertens, P., 
2009, Bluetongue virus vaccines past and present, In:  Mellor, P., Baylis, 
M.,  Mertens,  P. (Eds.) Bluetongue. Elsevier  Academic Press, London, 
United Kingdom.
Batten,  C.A.,  Maan,  S.,  Shaw,  A.E.,  Maan,  N.S.,  Mertens,  P.P.,  2008,  A 
European  field  strain  of  bluetongue  virus  derived  from  two  parental 
vaccine strains by genome segment reassortment. Virus Res 137, 56-63.
Boone,  J.D.,  Balasuriya,  U.B.,  Karaca,  K.,  Audonnet,  J.C.,  Yao,  J.,  He,  L., 
Nordgren, R., Monaco, F., Savini, G., Gardner, I.A., Maclachlan, N.J., 
2007,  Recombinant  canarypox  virus  vaccine  co-expressing  genes 
encoding the VP2 and VP5 outer  capsid proteins of  bluetongue virus 
induces high level protection in sheep. Vaccine 25, 672-678.
Calvo-Pinilla, E., Rodríguez-Calvo, T., Anguita, J., Sevilla, N., Ortego, J., 2009, 
Establishment  of  a  bluetongue virus  infection  model  in  mice  that  are 
deficient in the alpha/beta interferon receptor. PLoS One 4, e5171.
Clavijo,  A.,  Heckert,  R.A.,  Dulac,  G.C.,  Afshar,  A.,  2000,  Isolation  and 
identification of bluetongue virus. J Virol Methods 87, 13-23.
Conraths,  F.J.,  Gethmann,  J.M.,  Staubach,  C.,  Mettenleiter,  T.C.,  Beer,  M., 
Hoffmann,  B.,  2009,  Epidemiology  of  bluetongue  virus  serotype  8, 
Germany. Emerg Infect Dis 15, 433-435.
Dal Pozzo, F., De Clercq, K., Guyot, H., Vandemeulebroucke, E., Sarradin, P., 
Vandenbussche,  F.,  Thiry,  E.,  Saegerman,  C.,  2009,  Experimental 
reproduction of bluetongue virus serotype 8 clinical  disease in calves. 
Vet Microbiol 136, 352-358.
Darpel, K.E., Batten, C.A., Veronesi, E., Shaw, A.E., Anthony, S., Bachanek-
Bankowska,  K.,  Kgosana,  L.,  bin-Tarif,  A.,  Carpenter,  S.,  Müller-
Doblies, U.U., Takamatsu, H.H., Mellor, P.S., Mertens, P.P., Oura, C.A., 
2007, Clinical  signs and pathology shown by British sheep and cattle 
83
Comparison of BTV challenge models
infected  with  bluetongue  virus  serotype  8  derived  from  the  2006 
outbreak in northern Europe. Vet Rec 161, 253-261.
De Clercq, K., Vandenbussche, F., Vandemeulebroucke, E., Vanbinst, T., De 
Leeuw, I., Verheyden, B., Goris, N., Mintiens, K., Meroc, E., Herr, C., 
Hooybergs,  J.,  Houdart,  P., Sustronck, B., De Deken,  R.,  Maquet,  G., 
Bughin,  J.,  Saulmont,  M.,  Lebrun,  M.,  Bertels,  G.,  Miry,  C.,  2008, 
Transplacental bluetongue infection in cattle. Vet Rec 162, 564.
Di Emidio, B., Nicolussi, P., Patta, C., Ronchi, G.F., Monaco, F., Savini, G., 
Ciarelli,  A.,  Caporale,  V.,  2004,  Efficacy  and  safety  studies  on  an 
inactivated vaccine against bluetongue virus serotype 2. Vet Ital 40, 640-
644.
Dungu,  B.K.,  Louw, I.,  Potgieter,  C.,  von Teichman,  B.F.,  2008, Attenuated 
Live Bluetongue Virus 8 Vaccine Protects Sheep from Challenge with 
the European BTV-8. The Open Veterinary Science Journal 2, 130-133.
EMEA 2008. Guideline on requirements for an authorisation under exceptional 
circumstances  for  vaccines  for  emergency  use  against  bluetongue 
(EMEA/CVMP/IWP/220193/2008)  (London,  United  Kingdom, 
European  Medicines  Agency  Committee  for  Medicinal  Products  for 
Veterinary Use).
Eschbaumer,  M.,  Hoffmann,  B.,  König,  P.,  Teifke,  J.P.,  Gethmann,  J.M., 
Conraths, F.J., Probst, C., Mettenleiter, T.C., Beer, M., 2009, Efficacy of 
three inactivated vaccines against bluetongue virus serotype 8 in sheep. 
Vaccine 27, 4169-4175.
Ferrari,  G.,  De Liberato,  C.,  Scavia,  G.,  Lorenzetti,  R.,  Zini,  M.,  Farina,  F., 
Magliano,  A.,  Cardeti,  G.,  Scholl,  F.,  Guidoni,  M.,  Scicluna,  M.T., 
Amaddeo, D., Scaramozzino, P., Autorino, G.L., 2005, Active circulation 
of  bluetongue  vaccine  virus  serotype-2  among  unvaccinated  cattle  in 
central Italy. Prev Vet Med 68, 103-113.
Hoffmann, B., Eschbaumer, M., Beer, M., 2009, Real-time quantitative reverse 
transcription-PCR  assays  specifically  detecting  bluetongue  virus 
serotypes 1, 6, and 8. J Clin Microbiol 47, 2992-2994.
Hoffmann, B., Sasserath, M., Thalheim, S., Bunzenthal, C., Strebelow, G., Beer, 
M., 2008, Bluetongue virus serotype 8 reemergence in Germany, 2007 
and 2008. Emerg Infect Dis 14, 1421-1423.
Kirkland,  P.D.,  Hawkes,  R.A.,  2004,  A comparison  of  laboratory  and  'wild' 
strains of bluetongue virus - is there a difference and does it matter? Vet  
Ital 40, 448-455.
Listes, E., Monaco, F., Labrović, A., Paladini, C., Leone, A., Di Gialleonardo, 
L.,  Cammá,  C.,  Savini,  G.,  2009,  First  evidence  of  bluetongue  virus 
serotype 16 in Croatia. Vet Microbiol 138, 92-97.
84
Comparison of BTV challenge models
MacLachlan,  N.J.,  2009. Bluetongue Virus Vaccines:  Solution or  Part  of the 
Problem? In:   Proceedings  of  the  International  Meeting  on  Emerging 
Diseases and Surveillance, 13-16 February 2009, Vienna, Austria.
MacLachlan,  N.J., Nunamaker,  R.A., Katz,  J.B., Sawyer,  M.M., Akita,  G.Y., 
Osburn, B.I., Tabachnick, W.J., 1994, Detection of bluetongue virus in 
the blood of inoculated calves: comparison of virus isolation, PCR assay, 
and in vitro feeding of Culicoides variipennis. Arch Virol 136, 1-8.
Martinelle, L., dal Pozzo, F., Sarradin, P., de Leeuw, I., de Clercq, K., Ziant, D., 
Thiry, E., Saegerman, C., 2009. Experimental  infection of calves with 
BTV-8  using  two  different  inocula.  In:   Proceedings  of  the  8th 
International  Congress  of  Veterinary  Virology,  August  23-26,  2009, 
Budapest, Hungary.
OIE 2009. Manual of Diagnostic Tests and Vaccines  for Terrestrial  Animals 
(Paris, France, Office International des Epizooties).
Savini, G., Hamers, C., Conte, A., Migliaccio, P., Bonfini, B., Teodori, L., Di 
Ventura,  M.,  Hudelet,  P.,  Schumacher,  C.,  Caporale,  V.,  2009, 
Assessment  of  efficacy  of  a  bivalent  BTV-2  and  BTV-4  inactivated 
vaccine by vaccination and challenge in cattle. Vet Microbiol 133, 1-8.
Savini,  G.,  MacLachlan,  N.J.,  Sánchez-Vizcaíno,  J.M.,  Zientara,  S.,  2008, 
Vaccines against bluetongue in Europe. Comp Immunol Microbiol Infect 
Dis 31, 101-120.
Savini,  G.,  Ronchi,  G.F., Leone,  A., Ciarelli,  A., Migliaccio,  P., Franchi,  P., 
Mercante, M.T., Pini, A., 2007, An inactivated vaccine for the control of 
bluetongue virus serotype 16 infection in sheep in Italy. Vet Microbiol 
124, 140-146.
Toussaint,  J.F.,  Sailleau,  C.,  Bréard,  E.,  Zientara,  S.,  De  Clercq,  K.,  2007, 
Bluetongue virus  detection  by two real-time RT-qPCRs targeting  two 
different genomic segments. J Virol Methods 140, 115-123.
Veronesi,  E.,  Darpel,  K.E.,  Hamblin,  C.,  Carpenter,  S.,  Takamatsu,  H.H., 
Anthony, S.J.,  Elliott,  H.,  Mertens,  P.P.,  Mellor,  P.S.,  2010, Viraemia 
and clinical disease in Dorset Poll sheep following vaccination with live 
attenuated  bluetongue virus  vaccines  serotypes 16 and 4.  Vaccine  28, 
1397-1403.
Verwoerd, D.W., Erasmus, B.J., 2004, Bluetongue, In:  Coetzer, J.A.W., Tustin, 
R.C.  (Eds.)  Infectious  diseases  of  livestock.  Oxford  University  Press, 
Cape Town, South Africa.
Worwa, G., Hilbe, M., Ehrensperger, F., Chaignat, V., Hofmann, M.A., Griot, 
C.,  Maclachlan,  N.J.,  Thuer,  B.,  2009,  Experimental  transplacental 
infection of sheep with bluetongue virus serotype 8. Vet Rec 164, 499-
500.
85
86
4.4 Genome detection after vaccination with an inactivated BTV-8 vac-
cine
Re: Detection of bluetongue virus genome after vaccination with 
an inactivated vaccine
Michael Eschbaumer1, Regula Wäckerlin1,2, Bernd Hoffmann, Martin Beer
Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Federal Research 
Institute for Animal Health, Südufer 10, 17493 Greifswald-Insel Riems, 
Germany
1 Both authors contributed equally to this work.
2 Present address: Department of Ecosystem and Public Health, Faculty of 
Veterinary Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, 
AB T2N 4N1, Canada
Vaccine 2010
28(4):881-882
87
Genome detection after vaccination with an inactivated BTV-8 vaccine
Dear Editor:
In their recent article “Seroconversion, neutralising antibodies and protection in 
bluetongue serotype 8 vaccinated sheep”[1], C.A.L. Oura and colleagues mention 
in passing that they could not detect bluetongue virus (BTV) genome by real-
time  RT-PCR in  blood  samples  taken  after  vaccination  with  an  inactivated 
vaccine. Conversely, A. Steinrigl of the Austrian Agency for Health and Food 
Safety has reported in a presentation given at the 2009 annual meeting of the 
German Society for Virology[2] that his group found BTV genome in vaccinated 
sheep up to 61 days after vaccination.
Prompted  by this  presentation,  the  German  national  reference  laboratory  for 
bluetongue  attempted  to  reproduce  the  results  of  the  Austrian  study.  Four 
German Blackheaded Mutton yearling sheep were injected with a commercially 
available  inactivated  BTV serotype  8  vaccine  (BTVPUR® AlSap  8,  Merial 
S.A.S.,  Lyon, France;  batch no. L242032) and ten EDTA blood samples for 
real-time RT-PCR analysis were taken over a period of seven days. In two sheep 
(nos. 1 and 2), the vaccine was applied subcutaneously into the lateral thoracic 
wall (as per manufacturer’s instructions), while the other two sheep (nos. 3 and 
4) were given the same amount of vaccine (1 ml) intravenously, diluted in 9 ml 
of  sterile phosphate buffered  saline (PBS) solution. The blood samples were 
analysed  for  BTV  genome  content  using  two  different  real-time  RT-PCR 
assays[3,4]. 
RNA was extracted from 100 µl of each sample. Of a total of 100 µl of eluate, 5 
µl  were  used  for  RT-PCR.  BTV  genome  was  never  detected  in  the 
subcutaneously vaccinated sheep, but minute amounts were detectable for three 
days after intravenous injection of the vaccine (see table 1). At the low genome 
copy numbers encountered here, the generally excellent agreement of threshold 
cycle  (Ct)  values  between  the  used  assays  breaks  down due  to  the  random 
distribution  of  individual  RNA  molecules  among  aliquots  of  the  extracted 
sample. All samples were analysed in one real-time RT-PCR run, where both 
“no template” controls and all negative extraction controls gave no Ct.
Due to PCR inhibitors in the vaccine, we were unable to define a C t value for 
RNA extracted directly from the injected vaccine preparation. However, linear 
real-time RT-PCR results were obtained for extractions from ten-fold dilutions 
of the inoculum, starting at 10-2 (Ct 25.13) down to 10-5 (Ct 35.15). Based on 
this, a Ct value of approximately 19 for the original vaccine could be deduced.
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Assay Route Animal
-1 min 15 min 30 min 6 hrs 24 hrs 2 days 3 days 4 days 5 days 7 days
pan-BTV S5[3] s.c. Sheep 1 No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
s.c. Sheep 2 No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
i.v. Sheep 3 No Ct 35.39 35.40 34.87 38.45 No Ct 38.96 No Ct No Ct No Ct
i.v. Sheep 4 No Ct 39.00 35.29 40.40 37.75 39.21 No Ct No Ct No Ct No Ct
BTV-8 VP2[4] s.c. Sheep 1 No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
s.c. Sheep 2 No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct No Ct
i.v. Sheep 3 No Ct 37.52 36.53 36.09 No Ct 38.23 No Ct No Ct No Ct No Ct
i.v. Sheep 4 No Ct 36.32 37.30 No Ct No Ct No Ct 37.54 No Ct No Ct No Ct
Time after injection
Table  1.  Real-time  RT-PCR  results  after  vaccination  of  sheep  with  an 
inactivated BTV-8 vaccine.
Assuming a plasma volume of 2 litres[5] for a yearling sheep of 50 kg, the full 
dose  of  vaccine  (1  ml)  given  intravenously  will  be  diluted  2000-fold, 
hypothetically resulting in a Ct value of approximately 30 if distributed evenly. 
In our experiment, the Ct values were even higher than that, probably owing to 
inhomogenous distribution of the inoculum in the blood, and positive results 
were only obtained for a very limited time. In any case, intravenous injection of 
the full dose is an unlikely “worst-case” scenario. Poor vaccination technique 
could conceivably result in the introduction of small amounts of vaccine into 
blood vessels, but given the results of our experiment, it is doubtful whether this  
would be sufficient for detection by real-time RT-PCR.
Properly vaccinated sheep, on the other hand, where the vaccine is deposited 
under the skin, are not expected to score positive for BTV genome in peripheral  
blood at all, as is also confirmed by the results presented by Oura et al.[1].
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Abstract
Bluetongue virus (BTV) is a major pathogen of ruminants. Especially serotypes 
1, 6 and 8 are of concern to veterinary authorities in Central Europe. This article 
describes highly sensitive real-time RT-PCR assays directed to BTV genome 
segment 2, for specific detection of BTV-1, -6 or -8 in animal samples. 
Note
Bluetongue virus (BTV), an arthropod-borne Orbivirus in the family Reoviridae 
is  a  major  pathogen of  ruminants,  and  there  are  24 established serotypes (18). 
Until the end of the 20th century, bluetongue disease (BT) had been considered 
exotic to Europe. Since 1998, strains of at least five serotypes (BTV-1, -2, -4, -9 
and -16) have been present along the Mediterranean coast(5,14). In 2006, BTV-8 
was first detected in the Netherlands without any previous notion of its presence 
in Europe(3). Clinical disease in sheep was severe and, unusual for BTV, it was 
also seen in a wide range of non-ovine species including cattle, exacerbating the 
economic impact(5,13). By the end of 2008, BTV-8 was present in all of Central 
Europe and beyond, and vaccination campaigns are ongoing(4,6,17). At the same 
time,  BTV-1 of  Algerian  origin has  expanded northwards  across  the Iberian 
Peninsula and France(5), and in October 2008, BTV-6 was found in cattle in the 
Netherlands  and  later  also  in  Germany(8,9).  Finally,  in  2009,  BTV-11  was 
reported in Flanders(10). European Union monitoring requirements and the need 
for fast, reliable and sensitive detection of BTV RNA in animal samples led to 
the  development  of  several  real-time  quantitative  reverse  transcription 
polymerase  chain  reaction  (RT-qPCR)  assays(7).  This  article  describes  new 
assays  specifically  detecting  either  BTV-1,  -6  or  -8,  to  be  used  for  further 
characterization of a BTV-positive sample.
For maximum specificity, our assays are directed to BTV genome segment 2 
encoding  the  highly  variable  outer  shell  protein  VP2(18).  VP2 sequences  are 
available  for  at  least  one  isolate  of  every  established  serotype(11) (NCBI 
GenBank). Several independent VP2 sequences have been published for BTV-1 
and -8(12). Among these, we gave priority to sequences of European isolates. The 
sequence  of  segment  2 of  “NET2006/04”,  the European  reference  isolate  of 
BTV-8, was found to have higher similarity to a 1982 isolate from Nigeria than 
to the South African BTV-8 reference strain(12). On the other hand, segments 2 
of North African and French isolates of BTV-1 are close to the reference strain 
“RSArrrr/01”, all belonging to the “western group”(16). For BTV-6, VP2 of the 
recently  emerged  strain  is  over  99%  identical  to  the  South  African  BTV-6 
reference  strain  “RSArrrr/06”(15),  the  only  published  sequence.  Accordingly, 
primers  and  hydrolysis  probes  (see  table  1)  were  selected  using  “Beacon 
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Designer” (PremierBiosoft International, USA), and “primer3” design software 
(http://frodo.wi.mit.edu/).  The probes were  labeled  with 6-carboxyfluorescein 
(6-FAM) at the 5' end, and “black hole quencher-1” carboxylic acid (BHQ-1) 
was attached to the 3' end. Oligonucleotides were synthesized by a commercial  
supplier (Eurogentec Deutschland GmbH, Germany).
BTV1-VP2-Mix1-FAM (product size 123 bp)
Type Name Sequence
Forward primer BTV1-VP2-186F 5' CGG ACC GCA TTA TGG TAT AAC C 3'
Reverse primer BTV1-VP2-308R 5' ACT CTT GTG TCT CGT ACT TTC AAC 3'
Probe BTV1-VP2-203FAM 5' ACC GCC CGT CTT TCA TCG TAA CCC 3'
BTV1-VP2-Mix2-FAM (product size 120 bp)
Type Name Sequence
Forward primer BTV1-VP2-2407F 5' CCT CAA AGG CGA TTC GAT TTA GC 3'
Reverse primer BTV1-VP2-2526R 5' TCA CGA CGT TGT AGT TGA CTC C 3'
Probe BTV1-VP2-2438FAM 5' TGA AGC GCA GCC CAA GAT TGC ACG 3'
BTV6-VP2-Mix1-FAM (product size 97 bp)
Type Name Sequence
Forward primer BTV6-VP2-785F 5' GAT ACG TGA TGC GTG GAT TG 3'
Reverse primer BTV6-VP2-881R 5' TAC CAC CTT CCT TCC GAC AC 3'
Probe BTV6-VP2-817FAM 5' ATC CGA GGC ATA TTC GCT CGC TGG 3'
BTV6-VP2-Mix2-FAM (product size 89 bp)
Type Name Sequence
Forward primer BTV6-VP2-1056F 5' TAT AAT GGC AGA ATA TGG TGG AC 3'
Reverse primer BTV6-VP2-1144R 5' CAG TAA ACA TCG CCC AAC CT 3'
Probe BTV6-VP2-1081FAM 5' ATC CGT ACC CTT GCT TGC GTG GAG 3'
BTV8-VP2-Mix1-FAM (product size 86 bp)
Type Name Sequence
Forward primer BTV8-VP2-1604F 5' GTT ACG CAT TAC CGA GGT TGT G 3'
Reverse primer BTV8-VP2-1689R 5' GAT CAT GTG TGA ACG CCT TCG 3'
Probe BTV8-VP2-1631FAM 5' AAC GGC TCA CAC CGA CGA TCC AGC 3'
Table 1. Primers and probes.
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Before one-step RT-PCR could be performed, double-stranded RNA extracted 
from samples needed to be denatured.  Briefly,  template RNA was dispensed 
onto PCR plates; these were sealed, heated for 5 minutes at 95 °C, snap-frozen 
in liquid nitrogen and placed in a cooling rack at -20 °C. RT-PCR master mix 
was added to the plate,  the plate was resealed and centrifuged briefly before 
placement in the thermal cycler.
Two commercially available kits were used for amplification, iScript One-Step 
RT-PCR Kit for Probes (Bio-Rad Laboratories,  USA), and QuantiTect Probe 
RT-PCR Kit (QIAGEN, Germany). For the iScript kit the RT-PCR master mix 
consists of 5 µl of nuclease-free water, 12.5 µl of 2-fold reaction mix, 0.5 µl of  
reverse  transcriptase  and  2  µl  of  custom  primer/probe  mix  per  reaction. 
Primer/probe mixes contain forward and reverse primers at a concentration of 
10 pmol per µl and labeled probe at 1.25 pmol per µl in 0.1-fold TE buffer. 20 
µl of chilled master mix are added to 5 µl of snap-frozen denatured template 
RNA  for  one-step  RT-PCR.  Validation  data  presented  herein  was  collected 
using the iScript kit (see figure 1). The QuantiTect kit produced very similar 
results  (data  not  shown).  A  reference  sample  containing  BTV  RNA of  the 
appropriate serotype was serially diluted ten-fold in RNA-safe buffer containing 
50 ng per µl poly-A carrier RNA, 0.05% Tween 20 and 0.05% sodium azide in 
nuclease-free water. One-step RT-PCR was carried out for 10 minutes at 50 °C 
and 5 min at 95 °C followed by 42 cycles of 15 seconds at 95 °C, 20 sec at 56 
°C and 30 sec at 72 °C in an Mx3005P QPCR system (Stratagene, USA).
There  was  no  cross-reactivity  with  BTV  field  isolates  or  reference  strains 
(obtained from the European community reference laboratory for  BT) of the 
heterologous  serotypes  for  all  three  serotype-specific  RT-qPCR  assays, 
demonstrating  an  analytical  specificity(2) of  100%.  No  cross-reaction  was 
observed  with  isolates  of  epizootic  hemorrhagic  disease  virus  of  different 
serotypes (data not shown). 
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Figure 1. Real-time RT-PCR results for serial dilutions of RNA of BTV-1, -6 
and -8 using the appropriate primer/probe mixes. For BTV-1 and BTV-6, the 
alternative mixes produced similar results (BTV1-VP2-Mix2-FAM: y = 
-3.4471x + 17.383, R2 = 0.9983 and BTV6-VP2-Mix2-FAM: y = -3.2771x + 
8.5275, R2 = 0.999; data not shown).
For  clinical  samples  submitted  to  the  German  national  reference  laboratory 
(NRL) for BT and for samples from in-house animal experiments, the assays 
proved to be as sensitive as the highly sensitive “pan-BTV” assay currently used 
at our laboratory(1,19) (see table S1 in the supplemental material). For selected 
samples, serotype identification was confirmed by sequencing of the amplicons 
(data not shown). The equivalent analytical  sensitivity of the used RT-qPCR 
assays leads to highly similar results between them. In routine diagnostics at the 
NRL, the serotype-specific assays generally had a clinical sensitivity(2) of 100% 
for samples that had a threshold cycle (Ct) value of less than 36 in the “pan-
BTV”  assay  (data  not  shown).  Very  low  viral  genome  loads  can  lead  to 
inconsistencies between assays or between replicates of the same assay, owing 
to the random distribution of individual molecules of viral RNA among aliquots 
of total RNA extracted from a sample.
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Sample pan-BTV S5 BTV-8 VP2 BTV-6 VP2 mix 1 BTV-6 VP2 mix 2 BTV-1 VP2 mix 1 BTV-1 VP2 mix 2
Ct value Ct value Ct value Ct value Ct value Ct value
subm. #308-00, 2008 27.82 No Ct No Ct No Ct 27.54 27.40
subm. #008-01, 2009 28.69 No Ct No Ct No Ct 29.10 28.60
subm. #060-01, 2009 28.04 No Ct No Ct No Ct 29.52 28.80
exp. 3/08 anim. 503, 03 dpi 34.92 No Ct No Ct No Ct 35.12 33.82
exp. 3/08 anim. 503, 09 dpi 29.93 No Ct No Ct No Ct 29.69 29.51
exp. 3/08 anim. 503, 18 dpi 33.49 No Ct No Ct No Ct 34.64 33.88
exp. 3/08 anim. 764, 03 dpi 36.34 No Ct No Ct No Ct 37.10 35.80
exp. 3/08 anim. 764, 09 dpi 24.43 No Ct No Ct No Ct 24.78 24.71
exp. 3/08 anim. 764, 18 dpi 29.25 No Ct No Ct No Ct 29.50 30.02
supernatant BTV-1 FR/07 22.89 No Ct No Ct No Ct 25.83 25.48
subm. #201-04, 2008 29.76 No Ct 27.60 28.85 No Ct No Ct
subm. #268-04, 2008 29.26 No Ct 27.90 28.29 No Ct No Ct
subm. #290-01, 2008 32.24 No Ct 30.18 30.72 No Ct No Ct
subm. #295-03, 2008 32.27 No Ct 33.90 31.10 No Ct No Ct
subm. #295-06, 2008 31.31 No Ct 33.31 30.93 No Ct No Ct
subm. #300-01, 2008 29.01 No Ct 27.12 28.35 No Ct No Ct
subm. #300-02, 2008 28.78 No Ct 26.35 26.52 No Ct No Ct
subm. #077-00, 2009 28.52 No Ct 27.80 28.19 No Ct No Ct
supernatant BTV-6 DE/08 25.33 No Ct 27.43 26.71 No Ct No Ct
subm. #161-01, 2008 29.86 28.48 No Ct No Ct No Ct No Ct
subm. #196-01, 2008 28.43 27.00 No Ct No Ct No Ct No Ct
subm. #282-02, 2008 29.71 28.99 No Ct No Ct No Ct No Ct
subm. #284-11, 2008 26.75 25.23 No Ct No Ct No Ct No Ct
subm. #311-02, 2008 30.38 29.88 No Ct No Ct No Ct No Ct
subm. #097-01, 2008 22.07 23.57 No Ct No Ct No Ct No Ct
subm. #023-00, 2009 39.12 40.43 No Ct No Ct No Ct No Ct
supernatant BTV-8 DE/08 23.69 24.77 No Ct No Ct No Ct No Ct
Table S1. Real-time qRT-PCR results for clinical samples submitted to the NRL 
and samples from animal experiments.
The  serotype-8-specific  assay  does  not  detect  the  South  African  BTV-8 
reference  strain  “RSArrrr/08”.  This  is  intentional  and  a  consequence  of  the 
tailoring of  the  assay  to  the  European  isolates.  The sudden appearance  of  a 
genetically different strain of BTV-8 would signify a new introduction event. 
Detecting this in routine diagnostics requires an assay with strict specificity for 
the local strain. At the same time, this also allows the detection of emerging 
nucleotide variations (antigen drift) in the local strain. In any case, the initial  
evaluation of a sample should be done with at least one robust group-specific 
“pan-BTV” assay,  and  if  the  serotype  cannot  be  readily  identified  with  the 
described assays, the sample must be further analyzed by an alternative method.
In conclusion, all  RT-qPCR assays presented here reliably detect  bluetongue 
virus  with  high  sensitivity  and  serotype  specificity.  Each  assay  specifically 
detects one serotype with no cross-reactivity. With two independent assays each 
for serotypes 1 and 6, it is possible to cross-confirm positive results. All assays 
are used successfully for routine diagnostics at the German NRL for BT. From 
January 2008 to March 2009, over 10,000 submitted samples were tested for the 
presence  of  BTV  genome.  Of  these,  1,303  were  screened  for  BTV-8  (880 
positives),  937  also  for  BTV-6  (88  positives)  and  142  for  BTV-1  (four 
positives). To our knowledge, no false positives have ever been identified, and 
all  tested assays  had a diagnostic  specificity  of  100%. The serotype-specific 
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assays had already been made available to regional veterinary laboratories in 
Germany,  and  both  the  BTV-6  and  BTV-8-specific  assays  have  since  been 
evaluated successfully in ring trials. 
Studies  assessing  the  feasibility  of  multiplex  assays  directly  differentiating 
between BTV serotypes are underway.
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Abstract
In late  2008, bluetongue virus  (BTV) serotype 6 (BTV-6),  which had never 
occurred in Europe before, was first detected in the Netherlands and Germany. 
While the origin of the virus remains unknown, the prevalence of infections in 
cattle was investigated in a virological (N= 28,658) and serological (N= 2,075) 
field survey in Lower Saxony, where 45 cases confined to the district Grafschaft 
Bentheim  were  found.  Blood  from  affected  animals  was  used  for  the 
experimental  infection  of  three  cattle  with  different  BTV  antibody  status, 
leading to sustained viraemia in one animal naïve for BTV. Of two animals that  
had  detectable  antibodies  against  BTV  serotype  8,  one  became  transiently 
infected  and  seroconverted  for  BTV-6  while  the  other  did  not  react.  In 
conclusion, while only a very limited spread of BTV-6 could be observed in the 
field, experimental infection of cattle did not show substantial differences of the 
course of infection in comparison to other BTV serotypes.
Introduction
Bluetongue in Europe
Bluetongue  (BT)  is  an  arthropod-borne  disease  of  ruminants  and  camelids 
caused  by  any  of  24  established  serotypes  of  Bluetongue  virus  (BTV),  an 
Orbivirus  of  the  family  Reoviridae.  It  is  principally  transmitted  by 
haematophagous Culicoides midges (Schwartz-Cornil et al., 2008). Bluetongue 
virus  did  not  regularly  occur  in  mainland  Europe  before  1998.  Since  then, 
serotypes  1,  2,  4,  9  and  16  have  been  circulating  in  Southern  Europe 
(Saegerman et al., 2008). In recent years, a BTV-1 strain of Algerian origin has  
expanded northwards across the Iberian Peninsula and France and its intrusion 
into the Benelux and Germany appears imminent  (Hateley, 2009). After its first 
detection in the Netherlands in 2006, BTV-8 has spread across Central Europe 
and beyond in three seasons, eventually reaching as far as Norway and Israel. 
Vaccination campaigns against BTV-1 and -8 are ongoing. In the beginning of 
2008, a putative new BTV serotype, “Toggenburg orbivirus”, has been detected 
in  goats  in  Switzerland  (Hofmann  et  al.,  2008)  and  later  that  year,  BTV 
serotypes  6  and  11  (ISID  ProMED-mail,  2008b;  ISID ProMED-mail,  2009) 
appeared in Europe for the first time.
102
Emergence of BTV-6 in Germany
BTV-6 in the Netherlands and Germany
In October 2008, BTV was detected in the Netherlands in animals previously 
vaccinated against BTV-8. Routine sequencing of real-time RT-PCR amplicons 
yielded only 95% nucleotide identity of genome segment 10 to the European 
strain of BTV-8, and the introduction of a new strain or serotype was suspected 
by the Dutch  national  reference  laboratory  for  bluetongue (NRL BT) at  the 
Central  Veterinary  Institute  of  Wageningen  UR  (CVI),  Lelystad  (ISID 
ProMED-mail, 2008a). 
The  European  Community  reference  laboratory  (CRL)  at  the  Institute  for 
Animal Health, Pirbright, UK, was able to isolate the virus from a Dutch sample 
and identified it as BTV-6, with over 99.9% segment 2 (VP2) sequence identity 
to the South African modified-live virus (MLV) vaccine strain (ISID ProMED-
mail, 2008b-c). Vector-borne spread of vaccine viruses has been reported before 
(Savini et al., 2008; Listeš et al., 2009). A BTV-6 restriction zone was created, 
entailing a mandatory screening of all animals to be moved outside the zone.
The eastern part of the restriction zone covered German territory. Here, the first 
case of BTV-6 was confirmed by the NRL BT at the Friedrich-Loeffler-Institut 
(FLI), Insel Riems, on November 5, 2008. 
Subsequently, a field survey was undertaken to determine the virological and 
serological  prevalence  of  BTV-6  in  the  affected  area.  At  the  NRL,  initial 
attempts  to  isolate  BTV-6  from  submitted  samples  in  cell  culture  and 
embryonated  chicken  eggs  did  not  succeed.  Since  inoculation of  susceptible 
animals is considered the most sensitive method (Clavijo et al., 1999), an animal 
experiment was conducted to obtain a virus isolate and investigate the virulence 
of BTV-6 in cattle.
Materials and Methods
Field survey
Initially, infection with BTV-6 was detected in four cattle in three holdings in 
the  district  Grafschaft  Bentheim,  Lower  Saxony,  Germany.  Further  samples 
were  taken  from  these  animals  in  December  2008  and  January  2009  and 
epidemiological inquiries were performed in the holdings by epidemiologists of 
the FLI. 
Regional laboratories in Lower Saxony conducted a survey to study the spatial 
distribution  of  the  infection.  The  majority  of  samples  were  taken  along  the 
Dutch  border  and  around  the  initially  affected  holdings,  where  the  risk  of 
exposure to BTV-6 infected midges was highest. In total, 28,658 animals were 
investigated using the “pan-BTV” group-specific  real-time RT-PCR assay by 
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Toussaint et al. (2007). Initially, samples from BTV-positive animals were then 
evaluated at the NRL with real-time RT-PCR assays specific for BTV-6 and -8 
(Hoffmann  et  al.,  2009b).  For  ongoing  surveillance,  these  assays  were 
outsourced to the regional laboratories in late November.
Serum  samples  (N=  2,075)  from  all  susceptible  animals  in  the  first  three 
affected holdings and all holdings within a radius of 1 kilometre were sent to the 
bluetongue reference laboratory of the World Organisation for Animal Health 
(OIE) at the Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise “G. 
Caporale” (IZSAM),  Teramo, Italy,  for BTV neutralisation assays (Gard and 
Kirkland, 1999).
Animal experiment
Animals and experimental design
Three male Holstein Frisian calves were obtained locally and transferred to the 
BSL-3 facility of the FLI on Insel Riems, where they were confirmed to be free 
of  circulating BTV genome by real-time RT-PCR analysis of blood samples 
(Toussaint et al., 2007). They came from a region where BTV has never been 
reported. They were purchased as immunised against BTV-8 with two doses of 
an inactivated vaccine (BTVPUR® AlSap 8, Merial S.A.S., Lyon, France) but 
displayed different levels of BTV-specific antibodies (Table I). The calves had 
been vaccinated with a gE-deleted BHV-1 marker vaccine. They had detectable 
antibodies against BVDV, and were negative for BVDV antigen.
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Animal Assay Day 0 Day 7 Day 14 Day 21 Day 60
Calf 588 DR ELISA 8 8 16 2048 1024
NA BTV-6 0 0 0 10 100
NA BTV-8 4 3 3 2 0
Calf 605 DR ELISA 0 0 32 128 64
NA BTV-6 0 0 3 40 320
NA BTV-8 0 0 0 0 0
Calf 607 DR ELISA 64 64 64 64 32
NA BTV-6 0 0 0 0 0
NA BTV-8 8 6 4 4 3
Table I: Serological data from the animal experiment. Values given for virus 
neutralisation assays (NA) are 50% neutralising doses against the indicated 
serotype, double-recognition (DR) ELISA values denote the reciprocal of the 
last serum dilution that gave a positive result.
On  day  0  of  the  study,  the  animals  were  inoculated  intravenously  and 
subcutaneously  (multiple  sites  in  the  shoulder  region)  with  BTV-6  positive 
blood  pooled  from  samples  submitted  to  the  NRL.  None  of  the  samples 
contained detectable BTV-8 RNA (data not shown). Packed blood cells of the 
inoculum had been repeatedly washed with phosphate-buffered saline solution 
(PBS) and then ultrasonically disrupted. The blood preparation was tested free 
of bacterial contamination and it had a threshold cycle (Ct) value of 26.87 in the 
BTV-6 specific real-time RT-PCR (Hoffmann et al., 2009b).
After  inoculation,  blood samples  were  taken  at  regular  intervals.  Blood was 
drawn by jugular puncture and collected in tubes containing potassium EDTA or 
clot  activator,  respectively  (Monovette,  Sarstedt,  Nümbrecht,  Germany). 
Samples were stored at 4 °C until analysis. During the entire study, rectal body 
temperatures were taken daily, and the calves were monitored for clinical signs.
Serology
Serological data were collected from samples taken on days 0, 7, 14, 21 and 60 
after infection, using a commercially available double-recognition (DR) ELISA 
(PrioCHECK® BTV DR, Prionics  Deutschland  GmbH,  Planegg-Martinsried, 
Germany) to detect BTV group-specific antibodies against the highly conserved 
core protein VP7. Virus neutralisation assays against German isolates of BTV-8 
and -6 were performed as described previously (Eschbaumer et al., 2009). The 
BTV-6 isolate was obtained by cell culture inoculation with blood taken from 
calf 605 on day 7 post-infection (dpi) and subsequently passaged on Vero cells 
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(RIE15, Collection of Cell Lines in Veterinary Medicine [CCLV], FLI,  Insel 
Riems, Germany).
Detection of viral RNA and virus isolation
Total  RNA  from  whole  blood  samples  was  extracted  manually  using  a 
commercial  kit (QIAamp Viral  RNA Mini Kit, QIAGEN, Hilden, Germany). 
The amount of BTV genome in the samples was determined using the “pan-
BTV” assay by Toussaint  et  al.  (2007) and the in-house BTV-6 and BTV-8 
assays that had also been used for the field samples (Hoffmann et al., 2009b). 
The “pan-BTV” assay amplifies a highly conserved sequence at the 5' end of 
BTV  genome  segment  5,  while  the  serotype-specific  assays  are  directed  to 
genome segment 2,  encoding the outer shell  protein VP2. One-step RT-PCR 
was  carried  out  using  a  commercial  kit  (iScript  One-Step  RT-PCR  Kit  for 
Probes,  Bio-Rad  Laboratories,  Hercules,  CA,  USA)  in  an  Mx3005P  QPCR 
system (Stratagene, La Jolla, CA, USA). 
For  RT-PCR-positive  samples,  virus  isolation  was  performed  by  a  method 
adapted from Clavijo et al. (1999), using embryonated chicken eggs as well as 
Vero  (RIE15,  CCLV)  and  baby  hamster  kidney  (BHK)  21  clone  13  cells 
(RIE179,  CCLV).  Briefly,  blood cells  were  packed,  washed  repeatedly  with 
PBS and ultrasonically disrupted on ice. Intravenous inoculation of 10-day-old 
chicken embryos and adsorption onto 75% confluent cell layers was performed 
in parallel.  After  5 days of incubation,  embryo organ lysate and cell  culture 
supernatants  were  blindly passaged in cell  culture.  When a cytopathic effect 
developed in the second passage, BTV-6 replication was confirmed by serotype-
specific real-time RT-PCR.
Results
Epidemiological investigations and field survey
All three initially affected holdings were dairy farms whose animals had not 
been in contact with other cattle or sheep either on the farm or on pasture. Two 
farms had their own breeding stock, and the third had only bought animals from 
Lower  Saxony  in  2008.  Animals  on  the  farms  were  healthy  and  well  kept. 
Record-keeping was complete and consistent, and there was no indication of the 
illegal  use of  modified-live bluetongue vaccines.  The distance  to  the  closest 
affected holding in the Netherlands was found to be only 17 kilometres, while 
the farthest was 52 kilometres away. No direct epidemiological link between the 
farms could be established.
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Of  the  28,658  animals  in  Lower  Saxony  that  were  tested  by  regional 
laboratories,  3,753 (12.71-13.49%, 95% confidence interval)  were positive in 
the  group-specific  “pan-BTV”  real-time  RT-PCR.  Among  them,  45  BTV-6 
positive animals (overall prevalence 0.11-0.21%) in 23 holdings (Figure 1) were 
found. In at  least two cases,  BTV-6 and BTV-8 genome was detected in the 
same animal by serotype-specific real-time RT-PCR analysis (data not shown).
For 36 BTV-6 positive animals identified by the NRL in November 2008, C t 
values ranged from 25.56 to 34.72 (average 30.38). Table II shows the results of 
the  longitudinal  virological  monitoring  of  the  first  four  cases  together  with 
serological  data  from the  first  sampling  in  November.  The  amount  of  viral 
genome detected in these animals slowly decreased within the survey period of 
10 weeks. All four animals were negative in the BTV-8 specific real-time RT-
PCR.
Animal
BTV-6 BTV-8 5 Nov 08 8 Dec 08 22 Jan 09
1328 40 0 Ct 26.86 Ct 26.83 Ct 29.00
1338 40 0 Ct 26.82 Ct 27.00 Ct 30.46
2635 40 160 Ct 30.66 Ct 29.36 Ct 30.14
9707 40 40 Ct 29.85 Ct 27.65 Ct 29.23
BTV-6 real-time RT-PCRVirus neutralisation
Table II: Two-month follow-up on the first four BTV-6 positive animals. 
Threshold cycle (Ct) values given were obtained with a real-time RT-PCR assay 
specific for BTV-6. Values for neutralisation assays (NA) are 50% neutralising 
doses for the indicated serotype.
Based on data from the German animal identification and registration system 
(HI-Tier;  Kroschewski  et  al.,  2006),  BTV-8 vaccine  coverage  in  the district 
Grafschaft Bentheim was 96% for female cattle, 69% for sheep and 47% for 
goats. In the 2,075 sera tested at IZSAM, only antibodies against BTV-8 and -6 
were found (Table III), while all samples were negative for serotypes 1, 2, 4, 9, 
15  and  16.  Neutralising  antibodies  against  BTV-8  were  detected  in  1,218 
(56.55-60.83%)  cases  and  BTV-6-specific  antibodies  in  39  animals  (1.34-
2.56%),  27  of  which  also  had  neutralising  antibodies  against  BTV-8  (0.86-
1.89%).  Neutralising  titres  against  BTV-8 ranged from 1:10 to  over  1:1280, 
BTV-6 titres were between 1:10 and 1:640.
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Sample origin No. of samples BTV-8 pos. BTV-6 pos. Both
First 3 holdings 858 574 23 15
1 km zone 1217 644 16 12
Total: 2075 1218 39 27
(56.55-60.83%) (1.34-2.56%) (0.86-1.89%)
Table III: Results of BTV neutralisation assays for field samples. No 
neutralising antibodies against serotypes 1, 2, 4, 9, 15 or 16 were detected in any 
sample. Percentages are given as a 95% confidence interval.
Figure 1. Cattle herds with BTV-6 infections in 
Germany. Dots (blue) mark the locations of affected 
holdings. The thick line (red) is the Dutch-German 
border.
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Animal experiment
While the calves had reportedly been vaccinated against BTV-8 in mid-2008 
with two doses of an inactivated vaccine,  their serological status was diverse 
(Table  I).  After  inoculation  with  BTV-6,  two animals  (calves  605 and  588) 
displayed measurable virus replication (as detected by real-time RT-PCR, Table 
IV)  and  subsequently  seroconverted  for  BTV-6  after  two  and  three  weeks, 
respectively,  together  with  a  marked  increase  in  group-specific  antibodies 
(Table  I).  Calf  607  failed  to  react  both  in  the  real-time  RT-PCR (data  not 
shown) and by serology.
Calf 588 was only transiently infected and had already fully cleared the virus 
four weeks after infection, but the viraemia in calf 605 lasted over six weeks 
(Table IV). The animal remained BTV-6-positive in the real-time RT-PCR for 
over 100 days until the end of the study period. BTV-8 was not detected in any 
animal (data not shown).
Day
pan-BTV real-time BTV-6 real-time virus isolation pan-BTV real-time BTV-6 real-time virus isolation
0 No Ct No Ct ND No Ct No Ct ND
5 No Ct No Ct ND No Ct No Ct ND
7 No Ct No Ct ND 29.41 28.26 positive
8 No Ct No Ct ND 27.44 26.86 ND
9 35.62 32.23 negative 27.03 26.43 ND
10 32.81 31.14 negative 26.03 25.29 ND
12 No Ct 34.35 negative 26.53 28.02 positive
13 33.28 32.22 negative 23.66 21.36 ND
14 32.75 31.94 negative 22.79 22.00 ND
17 32.95 32.56 positive 26.39 23.95 ND
19 33.76 34.04 negative 26.04 24.81 positive
21 35.78 No Ct negative 27.85 26.93 positive
24 No Ct No Ct ND 29.06 27.94 positive
27 38.23 No Ct ND 30.11 29.35 positive
31 No Ct No Ct ND 29.92 29.35 positive
34 No Ct No Ct ND 30.97 29.03 positive
38 No Ct No Ct ND 31.10 29.90 positive
45 No Ct No Ct ND 30.29 29.40 positive
52 No Ct No Ct ND 32.74 29.93 negative
60 No Ct No Ct ND 30.82 27.84 negative
69 No Ct No Ct ND 29.55 27.88 negative
77 No Ct No Ct ND 30.66 29.90 ND
84 No Ct No Ct ND 31.30 30.69 ND
91 32.06 32.15 ND
98 31.32 30.56 ND
105 31.83 31.18 ND
Calf 588 Calf 605
Table IV: Real-time RT-PCR and virus isolation from samples from the animal 
experiment
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Threshold  cycle  (Ct)  values  and  results  of  the  second  passage  of  the  virus 
isolation are given where applicable, ND = not determined. No BTV-8 genome 
was detected in any animal and no BTV-6 genome was detected in calf 607 
(data not shown).
Between days 5 and 9 after  infection,  calf  605 had a slightly elevated body 
temperature and calf 588 showed a similar increase in temperature from day 10 
to 12 (data not shown), while no other clinical signs could be observed.
Discussion
Among tens of thousands of animals that were screened in the field survey, only 
a small number was found to be positive for BTV-6 RNA or antibodies. These 
were mostly isolated cases in holdings scattered throughout a single district in 
the  German  federal  state  of  Lower  Saxony,  close  to  the  border  with  the 
Netherlands,  where similar findings were made (MinLNV, 2009a). Given the 
BTV screening measures that were in place in 2008, BTV-6 most likely was 
detected much earlier after its introduction than BTV-8 had been, suggesting an 
entry late in the season. Apparently it has only been able to propagate to a very  
limited extent, while BTV-8 had spread rapidly after its introduction in 2006 
(Hateley, 2009). Together with the reported genetic similarities, this gave rise to 
the theory that BTV-6 was an attenuated strain introduced either by the illegal 
local  use  of  a  modified  live  vaccine  (ISID  ProMED-mail,  2008d)  or  the 
unrecognized import of animals that had been vaccinated with a modified live 
vaccine in a third country and were still viraemic for BTV-6 when they arrived 
in Europe (MinLNV, 2009a).
Serological evidence from areas affected by BTV-6 provided no indication of a 
recent  use  of  the  commercially  available  multivalent  MLV  vaccine.  No 
antibodies against serotypes other than BTV-6 and -8 were detected in either the 
Netherlands (MinLNV, 2009a) or Germany (this study). Specifically, there were 
no traces of other serotypes from bottle A of the multivalent vaccine package (1, 
4,  12 and 14) (Dungu et  al.,  2004),  which would have been the most likely 
source of the BTV-6 vaccine strain. This however has no bearing on another 
possible explanation, the accidental introduction of vectors already infected with 
BTV-6 as stowaways in global trade (Mintiens et al., 2008).
According to the CRL, genome segment 2 of the Netherlands isolate is almost 
identical  to  the  South  African  BTV-6  vaccine  strain  (ISID  ProMED-mail, 
2008d). Whether this isolated finding is particularly meaningful remains open to 
debate.  The manufacturer  of  the vaccine (Onderstepoort  Biological  Products, 
Onderstepoort,  South  Africa)  maintains  that  based  on  segment  2  alone,  all 
African  strains  of  BTV-6,  including  the  vaccine,  are  closely  related  (ISID 
110
Emergence of BTV-6 in Germany
ProMED-mail,  2008e).  Such  a  high  degree  of  homology  was  not  seen  in 
European BTV-8, however, which shares 93% of nucleotides of segment 2 with 
the South African BTV-8 vaccine strain, and 97% with a Nigerian isolate (Maan 
et al., 2008). For other segments of European BTV-6, a high similarity to the 
South  African  reference  strain  is  claimed,  but  the  origin  of  segment  10  is 
unknown (MinLNV, 2009b) and reassortment has been suspected (Saegerman 
and  Pastoret,  2009).  Only  four  isolated  sequences  of  individual  genome 
segments of BTV-6 are presently available online, and no sequence of either the 
BTV-6 vaccine  strain  or  the recent  European  isolates  has  been  made public 
(U.S.  National  Center  for  Biotechnology  Information,  GenBank, 
http://www.ncbi.nlm.nih.gov/ Genbank/).
But regardless of its origin, the question remains if the very limited spread of 
BTV-6 that has been observed in 2008 is due to attenuation of the virus itself.  
Judging from our data,  other factors could have contributed to that  outcome. 
Our experiment suggests that the susceptibility to BTV-6 infection of cattle is 
influenced by previous exposure to BTV-8, but this needs to be investigated in a
broader  study  using  a  deﬁned  challenge  dose  of  BTV-6.  In  the  present 
experiment,  it  is  difficult  to  estimate  the  infectious  dose  contained  in  the 
inoculum. The dates of infection of the donor animals remain unknown, but the 
low amount of BTV-6 genome in the pooled samples (no Ct value lower than 
25, data not shown) and the failure to isolate virus by other means suggest that 
the blood had been collected at  a late stage of infection,  resulting in limited 
infectivity. While BTV-infected ruminants can remain positive in the RT-PCR 
and even viraemic for weeks or months, the concentration of infectious particles 
in the blood decreases over time (Singer et al., 2001; MacLachlan et al., 2009; 
Hoffmann et  al.,  2009a).  In a related animal experiment at the CVI, using a 
BTV-6 field sample from a Dutch cow, at first only one of six animals could be 
infected, which also suggests a low infectious dose.  When fresh blood taken 
from  the  latter  animal  at  10  dpi  was  inoculated  in  a  second  experiment, 
however, 11 out of 11 animals displayed virus replication (Van Rijn, 2009).
Nevertheless, within the scope of our experiment, the course of BTV-6 infection 
once established in the naïve calf was similar to BTV-8. No data are available  
for  the  BTV-6  MLV  vaccine  strain,  but  the  longest  duration  of  viraemia 
reported  after  vaccination  of  cattle  with  other  MLV  vaccines  was  28  days 
(Monaco et al., 2004) – less than two thirds of the viraemic period in calf 605. 
Long-lasting viraemia has been observed with an insufficiently attenuated strain 
of  BTV-16 (Savini  et  al.,  2008),  and  up  to  63  days  of  viraemia  have  been 
described  after  experimental  infection  of  cattle  with  virulent  BTV  strains 
(Singer et al., 2001; Dal Pozzo et al., 2009). On the other hand, the high number 
of culture passages commonly used in the production of MLV vaccines (Savini 
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et  al.,  2008)  might  actually  facilitate  the  subsequent  reisolation  of  vaccine 
viruses in vitro.
At its peak, the amount of BTV-6 genome detected in calf 605 did not notably 
differ from viral genome levels observed in BTV-8 animal experiments (Darpel  
et al., 2007). This similarity also extends to the persistence of detectable viral  
RNA in peripheral blood of calf 605 and the only gradual decrease of circulating 
BTV-6 genome in the presence of neutralising antibodies that was observed in 
field-infected animals (Table II) (Dal Pozzo et al., 2009). Viral RNA remains 
detectable in the blood for extended periods of time because BTV persists in 
invaginations  in  the  cell  membrane  of  erythrocytes  (Schwartz-Cornil  et  al., 
2008), a trait probably shared by both field and vaccine strains. 
With regard to the absence of any clinical symptoms other than elevated body 
temperature, it has to be noted that in our experience and based on experimental 
data reported by other groups (Darpel et al., 2007), clinical bluetongue disease 
in  cattle  does  occur,  but  it  is  not  a  regular  finding  in  Holstein  Frisians 
experimentally infected with BTV-8 either. Conversely, it has been shown that 
even vaccine strains can cause disease (Savini et al.,  2008), if only in sheep 
(Veronesi et al.,  2005). Exposure to sunlight might play a role in bluetongue 
pathogenesis, which could contribute to the reduced severity of disease observed 
after experimental infection in high-containment animal housing (Verwoerd and 
Erasmus, 2004). The initial detection of BTV-6 in the Netherlands, on the other 
hand,  had  been  precipitated  by  clinical  disease  observed  in  the  field  (ISID 
ProMED-mail, 2008d; Hateley, 2009).
There is no doubt that after two years of the BTV-8 epidemic and with mass 
vaccinations  beginning  in  mid-2008,  BTV-6  faced  by  no  means  an  animal 
population naïve to BTV (Saegerman and Pastoret, 2009). To the contrary, the 
western  North  European  Plain  shared  by  Belgium,  the  Netherlands  and 
Germany  arguably  was  the  region  with  the  highest  cumulative  incidence  of 
BTV-8 in Europe. In the field survey presented here, over half of the animals 
had  neutralising  antibodies  to  BTV-8,  and  more  than  one  tenth  were  still 
positive  in  the  real-time  RT-PCR.  Even  if  cross-neutralisation  between 
serotypes  is  low,  there  is  evidence  of  group-specific  cell-mediated immunity 
after  infection  (Schwartz-Cornil  et  al.,  2008).  Given  these  unfavourable 
conditions,  the  fact  that  BTV-6  was  able  to  spread  at  all  does  not  suggest 
attenuation.
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Conclusion
The final evaluation as well as the measures taken by animal health authorities 
concerning the emergence of BTV-6 (SCoFCAH, 2009) are debatable from a 
scientific  point  of  view (Saegerman and Pastoret,  2009).  If  BTV-6 does not 
return in 2009, it will be difficult to say with any certainty whether this was 
because of its vaccine origin or simply because BTV-8 had come first. 
In either case, one troubling fact remains: since 2006, three different serotypes 
of BTV have first been detected in the same geographical region, without any 
previous notion of  their  presence  on European  soil  and without any definite 
explanation  for  their  introduction  (Mintiens  et  al.,  2008;  MacLachlan  et  al., 
2009). Finding and closing that loophole is crucial for animal health in Europe, 
particularly with regard to the looming threat of other, more lethal, orbivirus 
diseases of domestic animals like African horse sickness.
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5 Discussion
5.1 Bluetongue vaccination
5.1.1 Short- and long-term efficacy of inactivated vaccines
When the inactivated BTV-8 vaccines  were first delivered in 2008, no peer-
reviewed data on their safety and efficacy were available. The study presented 
here was the first independent assessment of the efficacy of the vaccines used in 
Germany  and  elsewhere  (Eschbaumer et  al.,  2009a).  Complementing  these 
results,  a  study  demonstrating  the  safety  and  efficacy  of  their  company’s 
vaccine was later published by researchers from Merial (Hamers et al., 2009a). 
Four manufacturers had offered inactivated vaccines against BTV-8, but only 
three were available in Germany in 2008. In a recent  publication, the fourth 
product  (Bovilis®  BTV8,  Intervet  International  b.v.,  Boxmeer,  The 
Netherlands) was shown to protect sheep against virulent challenge ten months 
after  vaccination  (Oura et  al.,  2009),  the  first  published  study  of  long-term 
efficacy  of  any  inactivated  vaccine  against  BTV-8.  The  12-month  study 
presented here is the first to provide data on the long-term efficacy in cattle. It 
further  confirmed the findings of  Oura  et  al. for  the three  other  vaccines  in 
sheep. Two of the vaccines (by Merial and Fort Dodge) have since been issued 
marketing authorizations valid throughout the EU (EMEA, 2010a; b; c).
The excellent  experimental  efficacy  is overwhelmingly corroborated  by field 
data. After the safety of the vaccines had been demonstrated (Gethmann et al., 
2009),  they were  temporarily  exempted from German licensing requirements 
(BlZSchutzImpfuaÄndV, 2008). Vaccinations began in mid-May, and over 80% 
coverage had been achieved by the end of 2008 (Gethmann et al., 2010). This is 
generally  regarded  as  the critical  threshold for  a  BTV vaccination  campaign 
(Giovannini et al., 2004). From 22,700 cases in the previous year, the number of 
new  BTV  cases  notified  in  Germany  between  May  2008  and  April  2009 
dropped to 3,200 and the virus did not spread further east (see maps in Conraths 
et  al.,  2009).  Apart  from  vaccination,  natural  immunity  after  infection 
contributed  to  the  reduction  of  new  cases  in  areas  that  had  been  severely 
affected in 2007 (Conraths et al., 2009). 
Vaccinations in Germany continued in 2009, and between May and October 
2009, less than 10 new cases had been reported (Gethmann et al., 2010), while 
there is no compelling evidence that any of those actually was a productive BTV 
infection1. See figure 6 for a timeline of BTV-8 cases in Germany.
1 Bernd Hoffmann, German NRL BT, personal communication.
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Figure 6: BTV-8 cases (infected animal holdings) in Germany from 2006 to 
2009 (Anonymous, 2007; 2008; 2009a; b).
Conversely, in France, where vaccination was not compulsory and coverage was 
low, the number of new cases increased from 21,000 in 2007/2008 to 29,000 in 
2008/2009.  Gethmann et  al. (2010)  give  an  exhaustive  overview  of  case 
numbers and vaccination coverage in Europe. Overall, the BTV-8 vaccination 
campaign is a remarkable success story. This success, however, is now put in 
jeopardy  by  the  hasty  decision  to  abandon  compulsory  vaccination 
(Mettenleiter, 2009).
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5.1.2 Vaccination and impact on diagnostic capability
The commonly used commercial  ELISA systems for BTV antibody detection 
are based on VP7 (Batten et al., 2008a). This is a structural protein, and both 
BTV infection and vaccination with inactivated whole virus vaccines will create 
a  VP7  antibody  response.  Therefore,  these  systems  do  not  allow  the 
differentiation  of  infected  from vaccinated  animals  (DIVA)  for  the  currently 
available BTV-8 vaccines, and meaningful serological surveillance is rendered 
impossible by the vaccination campaigns (Mertens et al., 2009a).
On the other hand, since inactivated vaccines  do not cause virus replication, 
there is no perceived risk of them interfering with molecular diagnostics, but 
this  has  not  been  studied  in  depth.  In  one  published  study,  the  community 
reference laboratory found no BTV genome in 33 sheep at one day or one week 
after  vaccination (Oura et  al.,  2009).  This was confirmed by the experiment 
presented here (Eschbaumer et al., 2010). Another study in sheep, however, had 
detected BTV RNA in recently vaccinated animals (Steinrigl et al., 2009).
In any case, the practical relevance of this matter is limited. Even in the latter  
study, vaccine-derived RNA was only frequently detectable within the first two 
weeks after vaccination. In this time frame, however, vaccinated animals will 
not routinely be examined with real-time RT-PCR. For animal movement in the 
European  Union,  the  relevant  guidelines  are  given  in  regulation  289/2008 
(European Commission, 2008). When no testing is done, vaccinated animals are 
not be moved until  60 days after  vaccination.  If  alternatively they are to be 
tested for virus in order to be moved earlier, this can first be done 14 days after  
the onset of immunity as laid out in the vaccine specifications (15 to 25 days, 
depending on the manufacturer). The OIE Terrestrial Animal Health Code, on 
the other hand, does not grant any exemption from the 60-day rule at all (OIE, 
2009a).
5.1.3 Challenge experiments
The breeding of  Culicoides midges in captivity is very demanding, and only a 
small  number of  colonies have  been established worldwide (Veronesi  et  al., 
2009). Accordingly, most experimental infections with BTV are carried out by 
needle inoculation (reviewed by Darpel et al.,  2009a) of blood from viremic 
ruminants or culture-grown virus. 
In  nature,  BTV  is  maintained  by  an  endless  series  of  alternating  cycles  of 
replication  in  Culicoides midges  and  various  mammalian  ruminant  species 
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(Mellor, 1990) and the virus has evolved to maximum efficiency in this context. 
Other means of propagation, including repeated passages in ruminants alone, 
change  the  selective  pressure  on  the  virus  quasispecies.  Point  mutations 
introduced  during  viral  replication  lead  to  initially  subtle  differences  in 
replication efficiency of virus progeny, and repeated passages will favor strains 
that replicate efficiently in the heterologous culture system (Dungu et al., 2004). 
While the phenotypic changes induced by frequent passaging in heterologous 
culture systems (Kirkland and Hawkes, 2004) are long known and have been 
used for the production of attenuated vaccines for decades (Dungu et al., 2004), 
they are  only now being investigated  on a molecular  basis  (Caporale  et  al., 
2009).  Even  though  dramatic  changes  in  fitness  resulting  from single  point 
mutations  have  been  described  (Le  Blois  and  Roy,  1993;  Tsetsarkin et  al., 
2007), virus attenuation often is a gradual process and the number of passages 
required  for  a  noticeable  reduction  in  virulence  is  variable  (Kirkland  and 
Hawkes, 2004).
Presently, given the dubious history of the European BTV-8 field strain, it is 
doubtful  whether  a  small  number of  culture passages will  result  in  dramatic 
changes to its phenotype. A case can be made that for this strain the benefits of 
virus maintenance in culture – easier preparation, standardization, handling and 
storage of inocula – outweigh the risk of further  misadaptation of the virus. 
Accordingly, the study presented here found no difference in virulence between 
a native BTV isolate passaged only in ruminants and culture-grown virus at a 
low passage level, making the latter a viable choice for challenge experiments.
The reduction of  suffering in control  animals in a challenge experiment  is  a 
welfare issue.  The OIE requirement  of clinical  disease in control  animals as 
proof  of  successful  challenge  infection  is  rendered  obsolete  by  advances  in 
molecular  detection  techniques.  Conversely,  the replacement  of  ruminants  in 
BTV animal experiments  by rodents  only offers  economical  advantages.  But 
these can be considerable, in terms of both purchase and maintenance. It has 
recently  been  shown  that  interferon-α/β  receptor-deficient  mice  are  fully 
susceptible  to  BTV  infection  (Calvo-Pinilla et  al.,  2009a;  independently 
confirmed in the study presented  here),  but  can  be  protected  by vaccination 
(Calvo-Pinilla et al., 2009b). This makes them a very promising tool for vaccine 
research and evaluation, and possibly even pathogenesis studies. Nevertheless, 
they  are  not  the  natural  host,  and  conclusions  based  on  observations  in  the 
mouse model will eventually require confirmation in sheep or cattle.
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5.2 Bluetongue diagnosis and epizootiology
5.2.1 Highly sensitive detection and serotyping by real-time RT-PCR
In the past, the identification of BTV in a field sample was a labor-intensive and 
time-consuming process. Goldsmit and Barzilai (1968) put the time required at 
five to nine weeks. Some forty years later, twenty years after the first adaptation 
of the PCR method to BTV detection (Dangler et al., 1990), real-time RT-PCR 
can detect and type BTV in any sample in a matter of hours. Its combination of  
speed,  sensitivity,  and specificity  (Bustin et  al.,  2009) has transformed BTV 
diagnostics.  Molecular  methods  (real-time RT-PCR as  well  as  RT-PCR and 
sequencing)  are  now  the  standard  for  BTV  antigen  detection  and 
characterization. Traditional methods retain an important role as confirmatory 
tests, however. Due to the very high sensitivity of the real-time RT-PCR, the 
clinical  and  epidemiological  significance  of  weakly  positive  results  must  be 
carefully evaluated, especially if no virus can be isolated (Eschbaumer et al., 
2009a).
The assays presented here were the first published assays to specifically detect 
BTV-1, 6 and 8 (Hoffmann et al.,  2009c).  An earlier assay developed at the 
Friedrich-Loeffler-Institut (first published in Conraths et al., 2009, but actually 
developed in 2006) was highly sensitive but not strictly specific  for  BTV-8. 
Previously, only one type-specific BTV real-time RT-PCR assay had been made 
public, detecting and differentiating BTV-2 field and vaccine strains (Orrù  et  
al.,  2004).  The  new  assays  are  used  in  routine  diagnostics  in  the  national 
reference  laboratory  and  regional  laboratories  and  have  proven  to  be  very 
reliable.
Meanwhile, another set of assays specific for BTV serotypes 1, 6, 8 and 11 has 
been presented (Vandenbussche et  al.,  2009),  and a commercial  kit  that  can 
differentiate  between  BTV-1,  2,  6,  8,  9,  11  and  16  is  now  available 
(Anonymous, 2009i). 
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5.2.2 BTV-6 and -11 in Europe
After the initial detection of BTV-6 and BTV-11, extensive field surveys found 
only very low prevalences for both viruses (De Clercq et al., 2009; Eschbaumer 
et al., 2009b). Neither virus reappeared in 2009, confirming the passive stance 
taken by the veterinary authorities (SCFCAH, 2008). 
The  very  high  level  of  genetic  identity  between  their  segments  2  and  the 
respective modified-live vaccine strains had been noted very early on (ProMED-
mail, 2008; 2009). With the detection of segment 10 from the BTV-2 vaccine 
strain  in  the  European  isolates  of  BTV-6 (Maan et  al.,  2010),  evidence  for 
vaccine strains from all three bottles of the Onderstepoort Biological Products 
vaccine package has now been found in Northern Europe. It is possible that the 
reassortment  occurred  during  co-infection  by  BTV-2  and  BTV-6  vaccine 
strains, which would corroborate the theory that the illegal use of live vaccines 
lies at the heart of the recent emergence of two new BTV serotypes in Europe.  
The manufacturer  of the vaccine package states that  no vaccine has recently 
been delivered to Europe. It is freely available in agricultural stores in South 
Africa, however, and the importation of small amounts in tourist travel cannot 
be ruled out (Anonymous, 2009g).
The level of variation observed in segment 10 (from BTV-2) in Dutch BTV-6, 
on the other hand, suggests that the exchange had happened several cycles of 
replication  before  the  virus  arrived  in  Europe  (Maan et  al.,  2010). 
Unfortunately, no isolate of Belgian BTV-11 could be obtained. Therefore, only 
its segment 2 was partially sequenced, and no data on its other segments are  
available (De Clercq et al., 2009).
In any case, a vaccine origin alone cannot fully explain the failure of BTV-6 to 
spread  after  its  introduction into the Netherlands  and Germany.  Other  MLV 
strains  had  been  shown  to  be  pathogenic  for  European  breeds  of  sheep 
(Veronesi et al., 2005; Veronesi et al., 2010), and have been widely spread by 
vectors (Ferrari et al., 2005; Listes et al., 2009). The influence of a previous 
exposure  to  BTV-8  observed  in  the  study  presented  here  and  the  reduced 
replication efficiency of BTV-6 in naïve animals offer a possible explanation for 
its failure to spread in the wake of the BTV-8 epizootic. A similar hypothesis 
was put forward for BTV-11 (De Clercq et al., 2009).
While the recent emergence of BTV-6 and BTV-11 in the same geographical 
region  might  be  attributable  to  the  illegal  use  of  live  vaccines,  there  is 
contradictory  molecular  evidence.  More  data  on  the  time  and  place  of  the 
introduction  of  BTV-8  have  recently  become  available  (Saegerman et  al., 
2010b),  but  its  origin and particularly the agent  and method of  introduction 
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remain mysterious as ever. These, however, are the key issues with regard to 
future introduction events of BTV, other arboviruses, or non-viral vector-borne 
diseases. A particularly alarming scenario is the introduction of African horse 
sickness. It is caused by a closely related orbivirus that is regularly spread by the 
same vectors (Mellor and Hamblin, 2004), so it could conceivably be introduced 
in the same way as BTV. Its impact on the naïve horse population in Europe 
would  be  tremendous,  with  expected  mortalities  of  up  to  95%  (recently 
reviewed by Zimmerli et al., 2010). 
Vector-borne pathogens pose exceptional  challenges to biosafety and disease 
control.  Further research into the means and ways of introduction of foreign 
animal  diseases  into  the  European  Union  is  absolutely  vital,  as  is  the 
establishment of suitable vaccine reserves.
5.3 Conclusions and outlook
Vaccination with inactivated vaccines  proved to be a highly effective tool in 
BTV-8 control. Data collected in the initial safety study and during the German 
vaccination  campaign  showed  very  good  safety  for  all  vaccines.  This  was 
confirmed by data from several other EU member countries (EMEA, 2009) and 
by a field study in Switzerland (Bruckner et al., 2009). In 2008, the incidence of 
adverse reactions notified to the competent authority in Germany (Paul-Ehrlich-
Institut) was only 0.003% (Hoffmann and Cußler,  2009).  Individual farmers, 
however,  reported massive damage to their stock. Studies in Switzerland and 
Germany  followed  up  on  these  reports,  and  found  no  causal  link  to  BTV 
vaccination. To the contrary, it was felt that farmers often used BTV vaccination 
as a simple explanation for complex management problems (Probst et al., 2010). 
Interestingly, some farmers who had publicly decried vaccination subsequently 
declined the offered on-site investigations (Tschuor et al., 2009). 
Public perception, however,  was different.  A campaign of disinformation and 
fearmongering  mounted  by  a  vocal  minority  (see  Englhart,  2009  for  an 
example) received wide media coverage. Despite its excellent success in 2008 
and 2009, the compulsory vaccination campaign in Germany was discontinued 
following a majority vote by the states, contrary to unanimous recommendations 
by the Federal Ministry, veterinary associations, farming bodies and the Federal 
Research Institute for Animal Health (Anonymous, 2009j). The original goal of 
the campaign, the eradication of BTV-8, was summarily abandoned.
There is  a high presumed risk for the reoccurrence and spread  of BTV-8 in 
Germany  in  2011  if  there  is  a  large  decrease  in  vaccine  coverage  in  2010 
(Mettenleiter,  2009).  Licensed  vaccines  are  now  available  in  the  market, 
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however, and the future development will depend on the farmers’ willingness to 
vaccinate  their  stock  and  the  duration  of  immunity  afforded  by  previous 
infections  and  vaccinations,  not  only  in  Germany  but  in  all  of  Europe 
(Gethmann et al., 2010). As an incentive, several federal states will continue to 
cover the costs for BTV vaccines in 2010 (Anonymous, 2009c; f; 2010a; b). 
Another important factor in the recrudescence is the possible virus reservoir in 
wild ruminants, but the available data currently bear out no definite conclusion 
in this regard (Mettenleiter, 2009).
In any case, this pertains only to BTV-8. If a virulent strain of a new serotype of 
BTV is introduced to Germany, vaccination will again become the only option. 
Recent events have shown that introductions can happen at any time with no 
warning at all, and further research on possible routes and ways of introduction 
of vector-borne diseases is critical.
The recent development of reverse genetic systems for BTV (Boyce et al., 2008; 
Attoui et  al.,  2009) has opened up tremendous possibilities for research into 
BTV replication (Matsuo and Roy, 2009), pathogenesis (Caporale et al., 2009) 
and  novel  vaccines  (Roy et  al.,  2009).  The BTV-8 epizootic  in  Europe  has 
sparked interest and brought about funding for BTV research like no outbreak of 
this  disease  before.  Concerted  efforts  of  scientists  all  over  the  world  have 
provided new insights that will directly benefit global animal health.
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6 Summary
Compulsory  vaccination  with  inactivated  vaccines  against  BTV-8  had  been 
introduced in Germany in mid-2008. The used vaccines were shown to be very 
efficacious,  and immunity was found to persist for at least one year,  even in 
sheep that had been given only one dose of vaccine. It is considered unlikely 
that  vaccination  with  inactivated  BTV-8  vaccines  interferes  with  routine 
diagnostics  by  real-time  RT-PCR.  In  preparation  of  future  challenge 
experiments, culture-grown BTV-8 and virus passaged only in ruminants were 
compared. There was no pronounced difference in the induction and progression 
of viremia in sheep. Both inocula were also shown to fatally infect interferon-
α/β receptor-deficient mice, confirming the utility value of the knock-out mouse 
model for BTV research.
After the introduction of BTV-6 to northwestern Germany in 2008, an extensive 
field survey was carried out. The prevalence of BTV-6 in Lower Saxony was 
found to be very low, and it did not spread any further in 2009. The virus was  
shown to be derived from a modified-live vaccine strain. Based on experimental 
findings,  its  failure to spread is probably attributable to the previous BTV-8 
epizootic in the region. This and other studies were only made possible by the 
development and validation of serotype-specific real-time RT-PCR assays for 
the highly sensitive detection of BTV-1, -6 and -8. They have been transferred 
to regional veterinary laboratories and can be used in routine diagnostics.
This work reproduces major recent contributions to BTV research. Experimental 
findings fully  supported  the decision to  use inactivated  vaccines  for  the EU 
campaign. Studies of BTV virulence and challenge models provided vital data 
for  future  experiments.  The  implications  of  the  introduction  of  BTV-6  into 
Germany were evaluated in detail, and the newly developed real-time RT-PCR 
assays  considerably  extended  the  possibilities  of  BTV  diagnostics  in  the 
European context.
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7 Zusammenfassung
Mitte  2008 wurde  die  verpflichtende  Impfung gegen BTV-8 in Deutschland 
eingeführt. Die hohe Wirksamkeit der verwendeten Impfstoffe konnte gezeigt 
werden. Nach Anwendung der Vakzine hielt der Impfschutz mindestens ein Jahr 
an,  sogar  bei  Schafen  die  nur  eine  Impfdosis  erhalten  hatten.  Es  erscheint 
unwahrscheinlich, dass sich eine Impfung mit inaktivierten BTV-8-Impfstoffen 
störend  auf  die  Routinediagnostik  mittels  Real-time  RT-PCR  auswirkt.  Zur 
Vorbereitung  weiterer  Impfstoffversuche  wurde  BTV-8  aus  Zellkultur  mit 
einem nur in Wiederkäuern passagierten Isolat verglichen. Bei Schafen konnte 
kein Unterschied im Infektionsverlauf festgestellt werden. Außerdem konnte mit 
beiden Isolaten eine tödliche Infektion in Mäusen ohne Interferon-α/β-Rezeptor 
hervorgerufen werden, was den Nutzwert des Knock-out-Mausmodells für die 
BTV-Forschung bestätigt.
Nach der Einschleppung von BTV-6 nach Niedersachsen im Jahr 2008 wurde 
eine umfassende Feldstudie durchgeführt. Dabei wurde nur eine sehr niedrige 
Prävalenz  festgestellt  und das  Virus  breitete  sich 2009 nicht  weiter  aus.  Die 
Ergebnisse  weitergehender  Untersuchungen  lassen  vermuten,  dass  die 
Verbreitung  des  als  Impfstamm  identifizierten  Virus  durch  die  hohe 
Durchseuchung mit BTV-8 in der Region verhindert wurde. Diese und andere 
Studien waren nur möglich, nachdem serotyp-spezifische Real-time RT-PCR-
Verfahren für die hochsensitive Erkennung von BTV-1, -6 und -8 entwickelt 
und erfolgreich getestet worden waren. Die Verfahren wurden an die regionalen 
Untersuchungsämter  gegeben und können in der Routinediagnostik eingesetzt 
werden.
Diese Arbeit  fasst wichtige aktuelle Beiträge zur BTV-Forschung zusammen. 
Die  Impfstoffversuche  bestätigten  umfassend  die  Entscheidung,  inaktivierte 
Impfstoffe  für  die  EU-Kampagne  einzusetzen.  Die  Untersuchungen  zu 
Challengemodellen  und  Virulenz  von  BTV  lieferten  wertvolle  Daten  für 
zukünftige Versuche. Die Auswirkungen der Einschleppung von BTV-6 nach 
Deutschland wurden ausführlich untersucht, und die neu entwickelten Real-time 
RT-PCR-Verfahren erweiterten die diagnostischen Möglichkeiten für BTV in 
Europa erheblich.
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9 Abbreviations
aa Amino acids
AHSV African Horse Sickness virus
BHK Baby hamster kidney
BMELV Bundesministerium für Ernährung, Landwirtschaft und 
Verbraucherschutz
BT Bluetongue disease
BTV Bluetongue virus
cDNA Complementary desoxyribonucleic acid
CLP Core-like particle
CTL Cytotoxic T-lymphocyte
DIVA Differentiating infected from vaccinated animals
DNA Deoxyribonucleic acid
EC Endothelial cells
EHDV Epizootic Hemorrhagic Disease virus
ELISA Enzyme-linked immunosorbent assay
EMEA European Medicines Agency
EU European Union
(m)RNA (Messenger) ribonucleic acid
MLV Modified-live virus
NS Non-structural protein
OIE World Organisation for Animal Health
PBMC Peripheral blood mononuclear cells 
RBC Red blood cells
RT-PCR Reverse transcription polymerase chain reaction
SA South African
SCAHAW Scientific Committee on Animal Health and Animal Welfare
SCFCAH Standing Committee on the Food Chain and Animal Health
SNT Serum neutralization test
spp. Species pluralis, several species
TOV Toggenburg orbivirus
US, U.S. United States
VLP Virus-like particle
VP Virion protein
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